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Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the 
gastrointestinal tract that includes Crohn’s disease (CD) and ulcerative colitis (UC). Over 
6.8 million individuals are affected by this condition worldwide.1 In The Netherlands, 
approximately 90.000 people suffer from IBD, and the incidence is still rising.2 The 
condition may present at any time and at all ages, but there is a peak in disease 
onset between the age of 15 and 30 years.3 The disease follows a relapsing course, 
characterized by a variety of symptoms such as abdominal pain, (hemorrhagic) diarrhea, 
weight loss, and anemia. The goal of treatment is to induce clinical remission as well 
as endoscopic remission. The treatment strategy is based upon disease severity and 
extent, and includes anti-inflammatory medication or, if needed, colorectal surgery. In 
the last decade, the number of anti-inflammatory drugs is rapidly growing and currently 
includes corticosteroids, 5-aminosalicylic acid, thiopurines, methotrexate, anti-TNF, 
anti-IL12/IL23), anti-integrines, and JAK- inhibitors.
Despite the upcoming therapeutic arsenal, long-term complications may still occur. 
Up to 50% of patients with IBD experience extra-intestinal symptoms during their 
disease course4, that can involve nearly any organ system including the musculoskeletal 
(articular, periarticular and muscular involvement, osteoporosis), dermatologic 
(erythema nodosum, pyoderma gangrenosum) and hepatopancreatobiliary (primary 
sclerosing cholangitis) systems. Moreover, patients are at risk of intestinal complications 
like fistulae, abscesses, stenosis, toxic megacolon, and colon perforation. However, one 
of the most detrimental complications of IBD is colorectal cancer (CRC).
COLORECTAL CANCER
Incidence
The incidence of CRC in patients with UC is reported 2.4 times greater than that 
in the general population.5 In patients with CD the excess CRC risk for has been 
estimated 1.9 times greater.6 The CRC risk varies between patients, depending on their 
individual risk profile.
Pathogenesis
Colitis-associated cancers develop in chronically inflamed mucosa through an 
inflammation-dysplasia-carcinoma sequence. Chronic inflammation of the colon 
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General Introduction
causes oxidative stress resulting in DNA damage with subsequent activation of pro-
carcinogenic genes and silencing of tumor-suppressor pathways. This may result in the 
development of a dysplastic precursor lesion that arises in the historically inflamed 
mucosa. If left untreated, this lesion may progress to CRC through various grades of 
dysplasia, including indefinite for dysplasia (IND), low-grade dysplasia (LGD) and high-
grade dysplasia (HGD) (Figure 1).
Figure 1. Pathogenesis of colorectal cancer in patients with inflammatory bowel disease
Reproduced with permission from Beaugerie L, Itzkowitz SH. N Engl J Med 2015;372:1441-14527, 
Copyright Massachusetts Medical Society.
Current colorectal cancer surveillance guidelines
Endoscopic surveillance may allow early detection and removal of precancerous 
lesions such as IND, LGD, and HGD, and may subsequently prevent CRC development. 
Therefore, both European guidelines (British Society of Gastroenterology (BSG), 
European Crohn’s and Colitis Organization8, 9) and American guidelines (American 
Gastroenterology Association10, American College Of Gastroenterology3, American Society 
of Gastrointestinal Endoscopy11) recommend regular CRC surveillance in IBD patients. This 
may improve clinical outcomes in the case of CRC by early detection. This is supported 
by better CRC-related survival rates in IBD patients undergoing regular surveillance, but 
still needs confirmation in large prospective studies with long-term follow-up.12, 13
Table 1 summarizes the different CRC surveillance recommendations per guideline. 
European guidelines recommend a surveillance strategy that is tailored to the individual 
patient’s risk profile. This risk profile is based upon several clinicopathological risk 
factors. The recommended surveillance interval is 1, 3, or 5 years in respectively high-
,intermediate-, and low-risk patients. However, the evidence for several of these risk 




American guidelines recommend a surveillance interval of either 1-2 or 1-3 years.10 3, 11 
The exact interval is based on the degree of endoscopic and histologic inflammation 
at the previous colonoscopy, combined with the risk profile of the individual patient. 
However, there are no strict risk categories in these guidelines based upon well-defined 
clinicopathologic patient characteristics.
Table 1. Summary of current guidelines for IBD-associated colorectal cancer surveillance
IBD= inflammatory bowel disease; CRC= colorectal cancer
Guideline Surveillance interval Risk categories
BSG 20109 • High risk: 1 year
• Intermediate risk: 3 years
• Low risk: 5 years
High-risk: Stricture, dysplasia detected within 
the past 5 years, concomitant primary sclerosing 
cholangitis, extensive colitis with moderate/severe 
active inflammation, a family history of CRC in a first-
degree relative diagnosis at age 49 years or younger.
Intermediate risk: Extensive colitis with mild 
active inflammation, post-inflammatory polyps, 
a family history of CRC in a first-degree relative 
diagnosis at age 50 years and above.
Low risk: Quiescent extensive colitis, left-sided 
colitis or Crohn’s disease with colitis < 50 %.
ECCO 20138 • High risk: 1 year
• Intermediate risk: 3 years
• Low risk: 5 years
High risk: similar to BSG except extensive colitis 
with severe active inflammation.
Intermediate risk: similar to BSG except extensive 
colitis with mild-moderate inflammation.
Low risk: no intermediate or high-risk features.
AGA 201010 1-2 years / 1-3 years 1 year: primary sclerosing cholangitis
1-2 years: all other patients (not specified).
1-3 years: 2 negative surveillance colonoscopies 
until 20 years IBD duration (then 1-2 years).
No surveillance: proctosigmoiditis.
ASGE 201411 1-3 years 1 year: primar y sclerosing cholangitis, 
active inflammation, stricture, multiple post-
inflammatory polyps, history of dysplasia, a family 
history of CRC in a first-degree relative.
1-3 years: other IBD patients.
ACG 20193 1-3 years 1 year: primary sclerosing cholangitis.
1-3 years: other patients (not specified), interval 
should be based on number of risk factors for CRC 




More data on the long-term risk of dysplasia and CRC in IBD patients with certain 
risk factors are needed. Prospective studies are generally regarded as the optimal 
study design since it allows to overcome issues of confounding and selection bias. 
However, this study design is not feasible when studying CRC risk given the large 
numbers of patients that are required in combination with the long-term follow-up 
that is needed. Consequently, large retrospective studies are of great value and should 
contribute to the optimization of current surveillance strategies. Potential factors that 
may impact CRC risk include LGD, post-inflammatory polyps, serrated polyps, and 
colectomy. I will describe both the evidence and the current gaps of knowledge for 
these specific risk factors.
CRC risk factors in IBD
a) Low-grade dysplasia
One of the main risk factors for advanced colorectal neoplasia (aCRN, including HGD 
and CRC) development are precancerous lesions like LGD. LGD is a frequent finding 
that occurs in 11-21% of IBD patients.14-16 Current rates of aCRN after LGD vary widely 
between 0% and 54%.17-22 These risk estimates are mainly derived from cohorts from 
tertiary referral centers incorporating selection bias. In addition, the follow-up period 
is generally short and thus the long-term aCRN risk in the general IBD population 
after LGD detection is uncertain. Current guidelines recommend annual surveillance 
colonoscopies for a period of 5 years after detection of LGD.9 However, the need for 
these annual surveillance colonoscopies after detection of LGD, as well as the length 
of this intensified surveillance strategy, is debated. The relatively high prevalence of 
LGD underlines the importance of gaining more knowledge regarding the aCRN risk 
after LGD. We aimed to study the long-term risk of aCRN after LGD, and to assess the 
impact of several potential risk factors, including gender, and age. In addition, we aimed 
to establish the aCRN risk in patients with recurrent/persistent LGD and to assess the 
prognostic impact of a neoplasia-free period after LGD.
b) Post-inflammatory polyps
Patients with long-standing inflammation might develop post-inflammatory polyps 
(PIPs, or ‘pseudopolyps’). PIPs are non-neoplastic lesions that originate from the colonic 
mucosa as a result of an excessive healing process after inflammation and ulceration. 
It is considered unlikely that PIPs by itself have a direct malignant potential.23 However, 
PIPs indicate longstanding severe inflammation which is associated with an increased 




dysplasia. The presence of post-inflammatory polyps is regarded as an ‘intermediate’ 
risk factor in current guidelines.8, 9 However, data on the neoplasia risk in patients 
with PIPs are conflicting, and thus the need for an intensified surveillance strategy is 
debated. We aimed to study which factors are associated with the presence of PIPs, 
and to determine whether PIPs are a risk factor for aCRN development.
c) Serrated polyps
In addition to the adenoma-carcinoma sequence, colorectal carcinogenesis may also 
develop via the serrated pathway. Serrated polyps are histologically characterized 
by serration of the colonic crypts (saw-tooth appearance) and contain KRAS or BRAF 
mutations.24 Serrated polyps can be categorized into hyperplastic polyps, sessile 
serrated lesions, and traditional serrated adenomas. In general, the majority of serrated 
polyps are hyperplastic. Serrated polyps might have been misclassified in the past as 
all serrated polyps were regarded as ‘harmless’ hyperplastic polyps. However, in the 
last decades, the impact of serrated polyps on the CRC risk has been acknowledged 
in the general population and classification systems of serrated polyps have been 
revised by the World Health Organisation.25 Since then, several studies reported that 
individuals with serrated polyps have a 2- to 4- fold increased risk of synchronous 
and metachronous aCRN.26, 27 In contrast to surveillance guidelines in the general 
population, IBD surveillance guidelines do not report on serrated polyps as a risk factor 
for aCRN. Given the paucity of data, the impact of serrated polyps on the CRN risk in 
IBD has not been clarified yet. Only few small studies are available and the majority of 
reported serrated polyps were hyperplastic polyps.24, 28, 29 We aimed to characterize the 
serrated polyps in IBD patients, and to determine if serrated polyps are a risk factor 
for aCRN development.
d) IBD patients with a history of colectomy
Although a colectomy results in a substantially decreased aCRN risk, IBD patients are 
still at risk to develop aCRN in the residual colon.30 Although surveillance guidelines 
propose a surveillance strategy in IBD patients with an intact colon, guidance for the 
surveillance strategy in patients with an ileal pouch-anal anastomosis is less clear. 
Several recent studies reported on the risk of aCRN in IBD patients with an ileal pouch-
anal anastomosis. These studies showed that there are important risk factors for aCRN 
development in this subgroup of IBD patients. We aimed to establish an overview of 
available literature to guide a proposal of an up-to-date surveillance strategy in this 
specific subgroup of IBD patients.
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EFFECTIVENESS OF THE CURRENT SURVEILLANCE PROGRAM
The current surveillance strategy might improve CRC-related survival rates in IBD 
patients undergoing regular surveillance.12, 13 In addition, the CRC incidence and CRC-
related mortality are higher in IBD patients not undergoing regular surveillance.12 
Nevertheless, CRC still develops in 10-14% of IBD patients after 30-40 years of disease 
duration.14 Therefore, optimization of the current surveillance guidelines is warranted. 
It can be expected that aggressive surveillance will lead to increased CRC detection. 
By contrast, frequent surveillance colonoscopies put a high burden on IBD patients 
due to the bowel preparation, invasive procedures, biopsies, and potential but rare 
complications. Moreover, it has a major impact on the endoscopy capacity and healthcare 
costs. Therefore, there is a need for further optimization of the current surveillance 
program. This includes risk stratification and selection of a subgroup of patients who are 
at increased CRC risk and therefore require frequent surveillance. Moreover, one may 
identify IBD patients who may benefit from a less intensive surveillance strategy which 
could reduce the burden for patients and the health care system.
AIM
The long-term goal of my thesis is to optimize evidence-based CRC surveillance strategies 
in IBD patients. For this purpose, I have formulated two main aims, including:
1. To determine the long-term risk of dysplasia and CRC in IBD patients stratified 
by risk profile
2. To translate our findings into recommendations for an improved CRC surveillance 
strategy in IBD patients
OUTLINE
Part 1 of this thesis describes the prognostic impact of LGD in IBD patients. In chapter 
2, we aimed to establish the long-term risk of aCRN after detection of LGD. In addition, 
we identified risk factors for aCRN in these IBD patients with LGD. To this end, we 
established a nationwide cohort using the Dutch national histo-and cytopathology 
database (PALGA). We identified all patients with a concomitant diagnosis of IBD and 
LGD. We collected all histological follow-up reports to determine the cumulative risk 




chapter 3, we used this IBD cohort with LGD to determine whether recurrent LGD 
further increased the aCRN. Moreover, since the need of a 5-year period with annual 
surveillance colonoscopy after LGD is not evidence-based, we aimed to determine how 
long a patient should undergo annual surveillance after LGD detection. Therefore, we 
first assessed the prognostic impact of a neoplasia-free period after LGD detection. 
Next, we determined the optimal neoplasia-free period after which the surveillance 
interval can be safely extended.
In Part II, we assessed several factors that may impact aCRN risk and subsequently may 
aid risk stratification in colorectal surveillance. One potential risk factor is the presence 
of PIPs. In chapter 4, we compared the risk of dysplasia and CRC in patients with and 
without PIPs. We established a large cohort at the Radboudumc Nijmegen including all 
IBD patients undergoing surveillance.
In chapter 5, we described the risk of synchronous and metachronous neoplasia in 
IBD patients with serrated polyps. We identified all IBD patients who had a serrated 
polyp in our center since 1996. We determined the characteristics of patients who 
developed serrated polyps, and compared the risk of neoplasia in IBD patients with 
and without serrated polyps.
The aim of chapter 6 was to provide an overview of the available literature of all 
potential CRC risk factors in IBD. We performed a systematic review and meta-analysis 
to provide an up-to-date overview of all factors that might impact the risk of aCRN. The 
goal was to pool all available data to determine the magnitude of the impact of the 
individual risk factors. These findings may guide the development of an evidence-based 
risk-stratification model in future studies. In addition, it may identify knowledge gaps 
that should be addressed in future studies.
While several factors increase the aCRN risk, a (sub)total colectomy decreases the 
subsequent aCRN risk. However, aCRN may still develop in the residual colon and 
surveillance is still warranted. Given the recently expanding evidence regarding the risk 
of aCRN in IBD patients with an ileal pouch-anal anastomosis, there is an unmet need 
for updated colorectal surveillance recommendations. Therefore, the aim of chapter 
7 was to summarize the current available literature on this subject, and to propose a 
surveillance strategy in this particular group of patients.
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In chapter 8 I will discuss the results of the studies in this thesis. In addition, I will reflect 
on the implications for clinical practice.
Table 1. Summary of aims and methodology of this thesis
PART I THE RISK OF ADVANCED NEOPLASIA AFTER LOW-GRADE DYSPLASIA IN IBD
Chapter Aim(s) Study design Methodology
2 • What is the long-term risk 
of advanced neoplasia after 
detection of low-grade 
dysplasia?
• What are risk factors for 




• Validation of search strategy
• Cumulative incidence 
advanced neoplasia
• Hazard ratios for risk factors
3 • Is recurrent low-grade dysplasia 
a risk factor for advanced 
neoplasia?
• Does a neoplasia-free period 
after low-grade dysplasia impact 
the subsequent risk of advanced 
neoplasia?
• What is the optimal duration of 




• Cumulative incidence 
advanced neoplasia
• Hazard ratios for recurrent 
and non-recurrent low-grade 
dysplasia
• Area under the curve 
neoplasia-free time period
PART II RISK FACTORS FOR ADVANCED NEOPLASIA IN IBD
4 • Are post-inflammatory polyps a 




• Cumulative incidence 
advanced neoplasia
• Hazard ratios for post-
inflammatory polyps
5 • Are serrated polyps a risk 





• Cumulative incidence HGD/
CRC
6 • What are risk factors for 









• Univariable and multivariable 
odds ratios/hazard ratios for 
separate risk factors
7 • What is the risk of colorectal 
cancer in IBD patients with a 
pouch or ileorectal anastomosis?
• What surveillance strategy 
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Background and aims: The long-term risk of high-grade dysplasia (HGD) and colorectal 
cancer (CRC) following low-grade dysplasia (LGD) in inflammatory bowel disease (IBD) 
patients is relatively unknown. We aimed to determine the long-term cumulative 
advanced neoplasia (HGD and/or CRC) incidence, and to identify risk factors for HGD 
and CRC in a nationwide IBD cohort with a history of LGD.
Methods: This is a nationwide cohort study using data from the Dutch National 
Pathology Registry (PALGA) to identify all IBD patients with LGD between 1991 and 2010 
in the Netherlands. Follow-up data were collected until January 2016. We determined the 
cumulative advanced neoplasia incidence and identified risk factors with multivariable 
Cox regression analysis.
Results: We identified 4,284 patients with colonic LGD with a median follow-up of 
6.4 years after initial LGD diagnosis. Cumulative incidence of subsequent advanced 
neoplasia was 3.6, 8.5, 14.4 and 21.7%, after 1, 5, 10 and 15 years, respectively. 
Median time to develop advanced neoplasia after LGD was 3.6 years. Older age (> 
55 years) at moment of LGD (hazard ratio (HR) 1.73, 95% CI 1.44-2.06), male gender 
(HR 1.33, 95% CI 1.10-1.60), and follow-up at an academic (versus non-academic) 
medical centre (HR 1.37, 95% CI 1.07-1.76) were independent risk factors for advanced 
neoplasia following LGD.
Conclusions: In a large nationwide cohort with long-term follow-up of IBD patients with 
LGD, the cumulative incidence of advanced neoplasia was 21.7% after 15 years. Older 
age at LGD (>55 years), male gender, and follow-up by a tertiary IBD referral centre were 
independent risk factors for advanced neoplasia development after initial LGD.
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Long-term risk of advanced neoplasia after colonic low-grade dysplasia
INTRODUCTION
Colorectal cancer (CRC) is one of the most detrimental complications in patients with 
inflammatory bowel disease (IBD), and CRC risk is increased compared with the general 
population1. It develops through an inflammation – low-grade dysplasia (LGD) – high-grade 
dysplasia (HGD) pathway to carcinoma2. Endoscopic surveillance is advocated in order 
to detect and remove precancerous lesions before CRC develops. After removal of LGD 
lesions, patients have an increased risk for development of subsequent advanced neoplasia 
(HGD and/or CRC)3, 4. Current guidelines recommend colectomy or intensified surveillance 
following LGD detection, but the optimal surveillance strategy is still under debate5, 6.
Data regarding the advanced neoplasia risk after LGD are scarce. One recent study 
reported that 33 of 172 (19.1%) IBD patients with LGD developed HGD or CRC7. However, 
lower but also higher rates up to 54% have been reported as well8-12. A recent meta-
analysis calculated a pooled CRC rate after LGD of 0.8 per 100 patient-years follow-up4. 
Most of the included studies had limited numbers of LGD patients (range 2-172) and 
no studies including > 60 patients exceeded a median follow-up duration of 5 years. 
Moreover, most data were collected in tertiary referral centres and these cohorts are 
at risk of selection bias. As a consequence, point estimates of the long-term risk of 
advanced neoplasia following LGD remains unclear.
In order to determine the long-term advanced neoplasia risk in IBD patients with a 
history of LGD, we established a nationwide cohort of IBD patients with a history 
of LGD. In this cohort we aimed to (1) determine the cumulative incidence of 




We studied the cumulative incidence and risk factors for advanced neoplasia following 
LGD in a nationwide multicentre cohort study.
Study population
A nationwide search was conducted to identify all patients with IBD and neoplasia 




the Netherlands (PALGA)13. PALGA collects all pathology reports in the Netherlands 
since 1971 and has complete national coverage since 1991 covering both academic 
and non-academic hospitals. All reports can be tracked to an individual patient using 
a unique identifier, allowing follow-up on an individual basis even when biopsies are 
performed at different institutes. We have previously shown that a search strategy in 
the PALGA database was able to identify 95% of all IBD patients correctly as confirmed 
by individual patient files3. A PALGA-search was performed including terms for IBD 
(“ulcerative colitis”, “Crohn’s disease”, “indeterminate colitis”, and “chronic idiopathic 
inflammatory bowel disease” ), combined with terms for colorectal neoplasia (“indefinite 
for dysplasia”, “low-grade dysplasia”, “high-grade dysplasia”, “carcinoma in situ”, “colorectal 
cancer”, and “dysplasia” ) located in colon, rectum or appendix. The PALGA search was 
restricted to patients with neoplastic lesions between 1991 and 2010 allowing long-
term follow-up. Follow-up pathology reports were collected until 1st January 2016. All 
individual pathology reports were carefully evaluated to confirm inclusion or exclusion. 
The study was approved by the PALGA ethical committee (lzv-1215).
Inclusion and exclusion criteria
All patients with a diagnosis of IBD (ulcerative colitis (UC), Crohn’s disease (CD) and 
IBD-unclassified (IBD-U)) with colonic LGD (after IBD diagnosis) from January 1991 to 
December 2010 were eligible for inclusion. IBD diagnosis was based on histology from 
both biopsies and resection specimens. Exclusion criteria were defined as follows: HGD 
and/or CRC diagnosis before IBD development, HGD and/or CRC diagnosis before LGD 
development, no histological follow-up, and patients with hereditary CRC syndromes 
such as Lynch syndrome and familial adenomatous polyposis. Furthermore, patients 
who underwent (sub)total colectomy before LGD diagnosis (in the residual colon) were 
excluded since this significantly impacts CRC risk14. Subtotal colectomy was defined as 
a colon resection, only leaving the rectum in place.
Data collection
The variables extracted from the PALGA database included gender, date and type of 
neoplasia, date and type of colon resection, number of colonoscopies, origin of histology 
(academic versus non-academic centre) and type of IBD diagnosis. The diagnosis IBD-U 
was used when no clear distinction between a diagnosis of UC or CD could be made. 
Date of IBD diagnosis could not be accurately extracted from PALGA and was therefore 
not included in our analysis. The highest grade of dysplasia at baseline was considered 
the initial neoplastic lesion. Patients with a LGD diagnosis in an academic centre, and/
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or with subsequent follow-up in an academic centre were considered as ‘academic’. 
To confirm whether patients that were identified in our PALGA search indeed had a 
diagnosis of IBD, a verification cohort was compiled. The verification cohort consisted 
of all IBD patient with LGD (identified with our PALGA search) from one academic 
(Radboud university medical centre Nijmegen) and two non-academic centres ( Jeroen 
Bosch Hospital s’Hertogenbosch and Rijnstate Hospital Arnhem). All patient charts were 
reviewed to confirm IBD diagnosis.
Statistics
Cumulative incidences of HGD and CRC were counted with 1 minus Kaplan-Meier curves, 
censoring patients at the end of follow-up. End of follow-up was defined as date of 
last pathology report or, if performed, date of (sub)total colectomy given the impact 
on CRC risk14. A sensitivity analysis was performed with exclusion of patients who 
developed advanced neoplasia within a year of LGD diagnosis, as these lesions might 
represent missed advanced lesions instead of new HGD or CRC. Continuous outcomes 
are presented as means including standard deviation (SD) if normally distributed and as 
medians with interquartile range (IQR) if non-normally distributed. In order to identify 
risk factors for developing advanced neoplasia, potential risk factors were compared 
univariable with Kaplan-Meier curves and log-rank tests. Risk factors with a p-value 
<0.2 in univariable analysis were included in a multivariable Cox regression model with 
backward elimination. The proportional hazards assumption was tested for all variables 
in our model by testing time-covariate interactions and visual inspection of log-minus 
log plots. A p-value of <0.05 was considered to be statistically significant.
Data analysis was performed using the SPSS statistical software (version 22, IBM, 
Chicago ILL). Incidence rates of HGD and CRC with 95% confidence interval (CI) were 
determined using OpenEpi software15.
RESULTS
Patient selection
Our initial PALGA search yielded 8,715 patients. A total of 4,284 IBD patients with LGD 
were available for inclusion (Figure 1). The cumulative follow-up for the entire cohort 
from date of LGD diagnosis to date of last available report was 33,401 patient-years, 
with a median follow-up of 6.4 years (3.2-11.3), including 2655 patients with a follow-up 




A total of 24,796 colonoscopies were performed in our cohort (median 5 per patient). 
Overall, median time between consecutive colonoscopies after LGD was 1.4 (0.8-2.3) 
years, median time to first follow-up after LGD was 1.5 (0.7-3.2) years. The majority of 
patients was male (61.4%) and had a diagnosis of UC (71.5%), see Table 1. Mean age at 
LGD diagnosis was 55.3 (+14.8) years.
Figure 1. Patient inclusion flowchart. IBD = inflammatory bowel disease, LGD = low-grade 
dysplasia, HGD = high-grade dysplasia, CRC = colorectal cancer.
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Table 1. Baseline characteristics of included patients with low-grade dysplasia. 
IBD = inflammatory bowel disease, LGD = low-grade dysplasia, SD = standard deviation, IQR 
= interquartile range.
Characteristic
Patients with LGD  
(n=4284)
Male gender, n (%) 2630 (61.4)
Disease
 Ulcerative colitis, n (%)










Age at LGD, mean (+SD) 55.3 (14.8)
Follow-up after dysplasia in years, median (IQR) 6.4 (3.2-11.3)







Our verification cohort consisted of 235 patients. Diagnosis of IBD could be confirmed 
in 216/235 (91.9%) patients. Patients without confirmed IBD diagnosis had unspecified 
colonic inflammation, diverticulitis and/or abdominal tuberculosis. First date of 
histologically confirmed IBD as found in PALGA was mean 2.4 (+6.8) years later than 
reported in medical charts and thus IBD duration was excluded from analysis.
Cumulative CRC and HGD incidence
In our cohort 526 of 4284 LGD patients developed advanced neoplasia. Within this 
subgroup, 211/526 patients developed HGD as highest grade of dysplasia and 315/526 
patients developed CRC at a median age of 62 years (51-74). Seventy-one of 315 patients 
were diagnosed with HGD preceding CRC. Figure 2 demonstrates cumulative advanced 
neoplasia incidence and cumulative CRC incidence after LGD. The 1-, 5-, 10- and 15 years 
cumulative incidence of advanced neoplasia was 3.6, 8.5, 14.4 and 21.7%, respectively. 
The cumulative incidence of CRC was 2.1, 4.9, 8.6, 14.0%. Sensitivity analysis, excluding 
patients who developed advanced neoplasia within one year following LGD (n=146), 
had a cumulative advanced neoplasia incidence of 18.8% after 15 years (supplementary 
file Figure A). The incidence rate of advanced neoplasia was 17.4 (95% CI 16.0-19.0) per 




incidence rate of CRC 10.4 (95% CI 9.3-11.7) per 1,000 patient-years). Median time to 
develop HGD or CRC after LGD was 3.6 years (0.8-8.7).
A total of 551/4284 (12.9%) of LGD patients underwent (sub)total colectomy during follow-
up and 175 of 551 underwent (sub)total colectomy within a year after LGD. Histological 
evaluation of the 175 resection specimens revealed CRC in 28 patients (16%) and HGD in 13 
patients (7%). Twelve patients developed advanced neoplasia after (sub)total colectomy in 
the residual rectum (5 HGD, 7 CRC). Median time to develop HGD or CRC after (sub)total 
colectomy was 6.0 years (4.8-8.8). Patients with LGD before the year 2000 underwent 
colectomy more frequently than after the year 2000 (17.8% versus 10.2%, p <0.001).
Figure 2. Kaplan-Meier plot showing cumulative incidence of 1) high-grade dysplasia or col-
orectal cancer combined and 2) colorectal cancer only, both after initial low-grade dysplasia.
LGD = low-grade dysplasia, HGD = high-grade dysplasia, CRC = colorectal cancer.
Risk factors for HGD/CRC development
Table 2 displays the results of the univariable analyses. Male gender (hazard ratio (HR) 
1.38, 95% CI 1.15-1.67; p-value 0.001), and LGD at age 55 or older (HR 1.72, 95% CI 1.44-
2.05; p-value <0.001) were significant risk factors (Figure 3). A histopathology report from 
an academic centre (HR 1.26, 95% CI 0.99 – 1.62, p=0.06) and a history of indefinite for 
dysplasia before LGD (HR 1.69, 95%CI 0.84-3.40, p=0.14) were no significant risk factors in 
univariable analysis, but were included in multivariable analysis as the p-value was below 
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the prespecified threshold of p<0.2. A LGD diagnosis before the year 2000 was not identified 
as a risk factor in univariable analysis. Likewise, the type of IBD diagnosis (UC/CD/IBD-U) 
was not significantly different between patients with and without advanced neoplasia.
Figure 3. Kaplan-Meier plot showing cumulative incidence of advanced neoplasia after low-
grade dysplasia for A) age > 55 years at moment of low-grade dysplasia B) male gender and 
C) Academic centre.
LGD = low-grade dysplasia, HGD = high-grade dysplasia, CRC = colorectal cancer, IBD=inflam-
matory bowel disease.
Table 2. Univariable and multivariable analysis of potential demographic risk factors for 
high-grade dysplasia or colorectal cancer.
UC = ulcerative colitis, CD = Crohn’s disease, IBD-U = IBD-unclassified, LGD = low-grade 
dysplasia, IBD = inflammatory bowel disease, IND = indefinite for dysplasia, NS = not significant.
Baseline HR
univariable









































1.26 0.99-1.62 0.063 1.37 1.07-1.76 0.012
Age at first LGD












Multivariable analysis identified LGD at age 55 or older (HR 1.73, 95% CI 1.44-2.06), male 
gender (HR 1.33, 95% CI 1.10-1.60), and academic centre (HR 1.37, 95% CI 1.07-1.76) as 
independent risk factors for advanced neoplasia development. Multivariable analyses 
for development of CRC only identified age >55 at LGD diagnosis as single independent 
risk factor (supplementary file Table A).
The number of risk factors (including LGD age > 55, male gender and academic centre) 
corresponded with a higher cumulative advanced neoplasia risk (1 versus 0 risk factors: 
p=0.007; 2 versus 1: p<0.001; 3 versus 2: p=0.21). The 10-year cumulative advanced 
neoplasia incidences (Figure 4) were 8.3% (no risk factors), 12.9% (1 risk factor), 19.8% 
(2 risk factors) and 20.4 % (all three risk factors).
Figure 4. Kaplan-Meier plot showing cumulative incidence of advanced neoplasia in patients 
with different numbers of risk factors
Number of patients: 0 risk factors (n=724), 1 risk factor (n=1883), 2 risk factors (n=1557), 3 risk 
factors (n=120)
DISCUSSION
In this nationwide cohort study including IBD patients with long-term follow-up, the 
cumulative incidence of developing advanced neoplasia after colonic LGD was 21.7% 
after 15 years. Risk factors for developing advanced neoplasia included older age at 
LGD (>55 years), male gender, and a histologic follow-up at an academic centre.
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LGD is a frequent finding in IBD patients, with reported rates of 11-21%16-18. Given the 
high prevalence of LGD, more insight in cancer risk after LGD is desired to determine an 
optimal surveillance strategy for these patients. Previously reported incidence rates of 
advanced neoplasia after LGD showed a wide range between 0% and 54%7-12. One study 
including 172 UC patients with LGD showed a cumulative advanced neoplasia risk of 
27.1% after 10 years7. This is considerably higher than the reported 14.4% in our cohort, 
which may be explained by our nationwide study approach, better representing the 
general IBD population and avoiding selection bias. Indeed, we found a higher advanced 
neoplasia risk in LGD patients from academic centres. Similar to previous studies, this 
might be the result of a more complex IBD population in academic centres resulting 
in a higher CRC risk. In addition, a recent meta-analysis reported that the risk of CRC 
was higher when LGD was diagnosed by expert gastro-intestinal pathologists than 
by community pathologists4.
One meta-analysis including 671 UC patients reported a pooled incidence rate of advanced 
neoplasia of 18 per 1000 patient-years, which is in line with the incidence rate of 17.4 per 
1000 patient-years in our cohort. The annual CRC incidence in our cohort was 1.0%, 
compared with a previously reported annual CRC incidence of 0.3% in patients with ‘non-
dysplastic’ UC19 and 0.017% to 0.041% in a general non-IBD screening population20, 21.
We found that older age at LGD diagnosis was associated with a higher advanced 
neoplasia risk. This observation possibly reflects the overall higher CRC risk at older 
age. Previous studies reported an increased risk when dysplasia developed at older 
age22, although this was not always statistically significant7, 23. In addition, we identified 
male gender as an independent risk factor for advanced neoplasia development. 
Male gender is an established risk factor for development of metachronous high-risk 
adenoma in non-IBD CRC screening24. Moreover, a large Danish population-based study 
also reported a higher CRC risk in male IBD patients. It was suggested that hormonal 
effects such as estrogens may protect females from developing CRC25, 26.
The results of our nationwide cohort may impact IBD surveillance recommendations 
after LGD detection. The American Gastroenterological Association guidelines6 
recommend an intensified surveillance in IBD patients with LGD, but do not specify 
an interval. The British Society of Gastroenterology guidelines5 define intensified 
surveillance as performing yearly colonoscopy during the subsequent 5 years. This 




neoplasia developed within 5 years of LGD diagnosis (median time between LGD and 
advanced neoplasia: 3.6 years). Given our finding that a large proportion of advanced 
neoplasia was detected within 1 year after LGD diagnosis (146/526, 28%), we would 
recommend performing a first surveillance colonoscopy within 1 year after LGD 
detection. Moreover, 23% of IBD patients who underwent a colectomy within one year 
after LGD detection, had synchronous or metachronous HGD or CRC in the colectomy 
specimen. This illustrates the risk of missed neoplasia when LGD is detected. Similarly, 
another study reported 38.9% advanced neoplasia in colectomy specimens of patients 
who underwent colectomy for LGD7.
Furthermore, risk stratification allows tailoring of endoscopic surveillance following LGD 
in IBD patients to a more individualized approach. For example, high-risk patients may 
be recommended to undergo yearly surveillance in the 5 years following LGD diagnosis, 
while low-risk patients may be well off with a less intensified surveillance strategy. One 
study already reported an increased advanced neoplasia risk based on the number 
of risk factors7. Similarly, we observed that patients with multiple risk factors were at 
highest risk to develop advanced neoplasia. Future studies are needed to determine 
the effectiveness of such risk stratification.
Our study has several strengths, including the long-term follow-up (median 6.4 years, 
with 2655 patients with >5 years of follow-up), the nationwide population based study 
approach reducing selection bias, and the large cohort of 4284 LGD patients. In addition, 
we established a verification cohort to confirm reliability of IBD diagnosis in our 
nationwide IBD cohort. This study also comes with some limitations. First, our results 
reflect the overall long-term outcomes of LGD over more than 2 decades, representing 
a mix of colonoscopy practices and quality of endoscopes. In addition, due to the 
retrospective nature of our study no standardized surveillance strategy was followed, 
which may result in selection bias. However, overall patients received frequent follow-up 
colonoscopies (median interval 1.4 years). Second, the use of a histopathology database 
without clinical data from patient files did not allow us to evaluate known potential risk 
factors, such as LGD location and size/morphology (flat or raised LGD), concomitant 
diseases like primary sclerosing cholangitis, disease duration, extent and activity as 
well as type of IBD treatment. Moreover, it is unknown how LGD was approached (wait 
and see, polypectomy, colectomy), which subsequently may impact advanced neoplasia 
risk. Third, our results are based on data from IBD patients with LGD detected between 
1991 and 2010. As such, we could establish long-term risk with a median follow-up of 6.4 
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years, much longer than in previous studies. However, advanced neoplasia incidences 
might be overestimated since currently more advanced endoscopic techniques (such 
as high definition endoscopes and the use of chromo-endoscopy) with updated 
surveillance guidelines are available, as well as a host of new therapeutic options. 
Indeed, a meta-analysis reported a declining CRC risk in IBD over the past decades27. 
We did not find a significantly different advanced neoplasia risk between patients who 
developed LGD before 2000 and those with LGD between 2000 and 2010. One can 
hypothesize that higher colectomy rates before 2000 may contribute to these findings. 
Finally, in the past histopathology specimens were not always re-assessed by a second 
pathologist. It is well-established that there is substantial inter-observer variation in 
grading of dysplasia between pathologists24, 28 and that misclassification of LGD might 
lead to lower advanced neoplasia incidence rates29.
In conclusion, we found in a nationwide IBD cohort that the cumulative incidence of 
advanced neoplasia after LGD is 21.7% after 15 years (incidence rate 17 per 1000 patient-
years). Potential risk factors include older age (>55) at the moment of LGD, male gender, 
and follow-up at an academic centre. These findings support current guidelines that 
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Supplementary Table A. Univariable and multivariable analysis of potential demographic 
risk factors for colorectal cancer only. 
UC = ulcerative colitis, CD = Crohn’s disease, IBD-U = IBD-unclassified, LGD = low-grade 
dysplasia, IBD = inflammatory bowel disease, IND = indefinite for dysplasia.
Baseline HR 
univariable







































Academic center 1.25 0.90-1.72 0.182 - - NS
Age at first LGD
 < 55 years old
 >55 years old
1
1.48 1.17 -1.85 0.001
1
1.48 1.18-1.86 0.001
IND before LGD 2.17 0.97-4.86 0.061 - - NS
37
Long-term risk of advanced neoplasia after colonic low-grade dysplasia
Supplementary Figure A. Kaplan-Meier plot (sensitivity analysis, excluding patients with 
high-grade dysplasia or colorectal cancer within one year) showing cumulative incidence of 
1) high-grade dyplsaisa or colorectal cancer combined and 2) colorectal cancer only, both 
after initial low-grade dysplasia
LGD = low-grade dysplasia, HGD = high-grade dysplasia, CRC = colorectal cancer.
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Background and aims: This is a nationwide cohort study using data from the Dutch 
National Pathology Registry to identify all IBD patients with LGD and ≥1 follow-up 
colonoscopy between 1991 and 2010 in the Netherlands. Follow-up data were collected 
until January 2016. We compared the cumulative advanced neoplasia incidence between 
patients with and without recurrent LGD at first follow-up colonoscopy using log-rank 
analysis. We subsequently studied the impact of a neoplasia-free period after initial 
LGD on the advanced neoplasia incidence.
Methods: This is a nationwide cohort study using data from the Dutch National 
Pathology Registry (PALGA) to identify all IBD patients with LGD and ≥1 follow-up 
colonoscopy between 1991 and 2010 in the Netherlands. Follow-up data were collected 
until January 2016. We compared the cumulative advanced neoplasia incidence between 
patients with and without recurrent LGD at first follow-up colonoscopy using log-rank 
analysis. We subsequently studied the impact of a neoplasia-free period after initial 
LGD on the advanced neoplasia incidence.
Results: We identified 4,284 IBD patients with colonic LGD with a median follow-up of 
6.4 years. Recurrent low-grade dysplasia was a risk factor for advanced neoplasia (HR 
1.66, 95%CI 1.22-2.25, p=0.001). A neoplasia-free period of > 3 years after LGD protected 
against advanced neoplasia.
Conclusions: Recurrent LGD at follow-up colonoscopy after initial LGD was a risk 
factor for advanced neoplasia. A neoplasia-free period of > 3 years after initial LGD 
was associated with a reduced subsequent risk of advanced neoplasia.
41
Increased advanced neoplasia risk after recurrent dysplasia
INTRODUCTION
Patients with inflammatory bowel disease (IBD), such as Crohn’s disease (CD) and 
ulcerative colitis (UC), bear an increased colorectal cancer (CRC) risk.1 The main driver of 
CRC in IBD patients is chronic inflammation of the colonic tissue, which may lead to the 
development of a dysplastic precursor lesion. Subsequently, this lesion may eventually 
progress through different grades of dysplasia, including indefinite for dysplasia (IND), 
low-grade dysplasia (LGD), and high-grade (HGD) dysplasia, into CRC.2 In order to 
detect and remove LGD before it progresses to advanced neoplasia (HGD and/or CRC), 
surveillance colonoscopies are recommended by national and international guidelines. 
For example, the surveillance guideline of the British Society of Gastroenterology (BSG) 
sets the surveillance intervals at one, three, or five years depending on the patient’s 
risk profile (low, medium, or high).3
IBD patients with a history of colonic LGD have a high advanced neoplasia risk estimated 
at 20 to 30%, and are therefore considered high-risk patients.4-6 Consequently, the BSG 
recommends annual surveillance colonoscopies during five consecutive years after 
LGD diagnosis. The surveillance interval may be extended if no dysplasia is detected at 
these 5 follow-up colonoscopies.3 Similarly, the American Society for Gastrointestinal 
Endoscopy (ASGE) and the American Gastroenterological Association (AGA) guidelines 
recommend an intensified surveillance strategy after LGD detection, without specifying 
the duration of this strategy.7-9 The issue is that robust evidence supporting this 
intensive surveillance strategy following LGD diagnosis is absent. For example, it is 
unclear whether subsequent colonoscopies without recurrent or persistent neoplasia 
puts the patient in a lower-risk category. This is of major importance because frequent 
surveillance colonoscopies put a high burden on IBD patients, and have a major impact 
on endoscopy capacity. Moreover, the impact of recurrent dysplasia on the advanced 
neoplasia risk is unknown, and the only available studies are small and reported 
conflicting results.4, 10 As such, the optimal surveillance strategy in IBD patients with 
LGD remains under debate.
In the current study, we aimed to (1) determine the impact of recurrent/persistent 
LGD (termed as “recurrent dysplasia” going forward) on the advanced neoplasia risk 
in IBD patients with a history of LGD and to evaluate the impact of a neoplasia-free 








We studied the impact of 1) recurrent LGD and 2) a neoplasia-free period after LGD 
on the subsequent advanced neoplasia (HGD and CRC) risk in a retrospective Dutch 
nationwide IBD cohort with a history of LGD.
Study population
We used the nationwide network and registry of histopathology and cytopathology in 
the Netherlands (the Dutch National Pathology Registry [PALGA]) to identify our study 
population.11 The database was searched for IBD patients with neoplasia (indefinite for 
dysplasia, LGD, HGD, and CRC) in the Netherlands between 1991 and 2010. Follow-up 
data were collected until January 2016, allowing long-term follow-up. The search terms 
have been described in detail in our previous publication. 6
Inclusion and exclusion criteria
All patients with colonic IBD (CD, UC, and IBD unclassified) with LGD in the colon from 
January 1991 to December 2010 were included in this study. In previous studies we 
verified that PALGA is able to identify 95% of IBD patients in hospitals in the Netherlands, 
and that an IBD diagnosis in the PALGA database accurately corresponds with an IBD 
diagnosis in the patient’s medical charts.6, 12 Exclusion criteria were defined as follows: 
dysplasia before a diagnosis of IBD, HGD, or CRC diagnosis before LGD development; 
lack of ≥1 follow-up report after initial LGD; (sub)total colectomy before LGD; and 
patients with hereditary CRC syndromes.
Data collection
Both baseline demographics and data regarding colorectal neoplasia were extracted 
from PALGA. Baseline characteristics included gender, type of IBD diagnosis, date and 
type of colonic resections, and age at first LGD. In addition, we extracted the date and 
type of neoplasia and the date of colonoscopies. We did not enter age at IBD diagnosis 
as a variable in our analysis because the PALGA data set does not contain a specific 
entry allowing unambiguous extraction of this outcome.6 The first neoplastic lesion 
with LGD was defined as the index LGD. Histopathologic follow-up reports (including 
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the reports of surgical resection specimens) were evaluated for development of 
subsequent LGD, HGD or CRC. Recurrent dysplasia was defined as LGD >6 months 
after index LGD. Follow-up colonoscopies were defined as colonoscopies after the index 
LGD, irrespective of the indication. A negative follow-up colonoscopy was defined as a 
colonoscopy without LGD or advanced neoplasia.
IBD surveillance strategy in the Netherlands
In the 1990’s, surveillance colonoscopies in IBD patients were performed using standard-
definition white-light endoscopy with targeted biopsy sampling of abnormalities, in 
combination with random biopsies. Subsequently, high-definition white-light endoscopy 
became the mainstay endoscopic technique between 2005 and 2010. After updates in 
IBD surveillance guidelines in 2008, Dutch centers gradually adopted chromoendoscopy 
as a first-choice modality for IBD surveillance. 13 Chromoendoscopy involves pan-colonic 
dye-spraying using either indigo carmine or methylene blue, along with targeted biopsy 
sampling of abnormal areas. The interval between surveillance colonoscopies is based 
on the guidelines of the British Society of Gastroenterology.3
Statistics
Impact of recurrent LGD on advanced neoplasia
To determine the impact of recurrent LGD on the risk of advanced neoplasia, we selected 
patients with two or more follow-up colonoscopies and compared the cumulative 
incidence of advanced neoplasia between patients with and without recurrent LGD 
at the first follow-up colonoscopy, using Kaplan Meier curves and log-rank analysis. 
Only patients who had undergone a first follow-up colonoscopy within a maximum of 
3 years after index LGD were included in this analysis in order to reduce heterogeneity. 
The time to event was calculated from the first colonoscopy after index LGD until 
advanced neoplasia or end of follow-up. End of follow-up was defined as the last 
follow-up colonoscopy or (sub)total colectomy, given the low CRC risk after colectomy.14 
Because several risk factors may impact the advanced neoplasia risk, we performed a 
multivariable Cox analysis adjusting for these previously identified and published risk 
factors (ie, male gender, diagnosis of index LGD in an academic center, and diagnosis of 
index LGD ≥55 years).6 Moreover, improved endoscopic techniques and guidelines over 
time may impact the advanced neoplasia risk as well. Therefore, we included the year 
of dysplasia diagnosis (categorized as 1990-1994, 1994-1999, 2000-2004, 2005-2010) 





Impact of a neoplasia-free period after index LGD on advanced neoplasia
For our second aim, we assessed how a neoplasia-free period after the index LGD 
impacts the risk of advanced neoplasia. We performed the following 3 steps:
1. Evaluate whether a longer neoplasia-free period after the index LGD resulted in a 
lower subsequent risk of advanced neoplasia.
2. Determine the optimal cut-off point of the length of the neoplasia-free period
3. Verify in our cohort if patients who were neoplasia free for this period indeed had 
a low subsequent risk of advanced neoplasia.
Evaluate whether a longer neoplasia-free period after the index LGD resulted in a 
lower subsequent risk of advanced neoplasia
The area under the receiver operating characteristic (ROC) curve was applied to evaluate 
the prognostic impact of the length of the neoplasia-free time period in predicting 
advanced neoplasia development. For this analysis, we used the clinically relevant 
outcome of advanced neoplasia development within 10 years of the index LGD. Therefore, 
only patients with a minimum of 10 years of follow-up or those who developed advanced 
neoplasia within 10 years were included. To verify the prognostic impact of a longer 
neoplasia-free period, we calculated the maximum neoplasia-free time for each patient. 
The maximum neoplasia-free time is defined as the time from LGD diagnosis until the 
last negative follow-up colonoscopy within a time interval of 10 years.
Determine the optimal cut-off point of the length of the neoplasia-free period.
After confirmation of the prognostic impact of the length of the neoplasia-free time 
period, the optimal cutoff value of the neoplasia-free period for the risk of advanced 
neoplasia was determined from the ROC curve. Ideally, this cutoff point corresponds to 
a neoplasia-free time period that is followed by a low advanced neoplasia risk, whereas 
the number of unnecessary surveillance colonoscopies is limited. Therefore, we choose 
the cutoff point with the most optimal sensitivity × specificity. Because a high sensitivity 
corresponds to a low risk of missing advanced neoplasia, we choose a cutoff value 
with a sensitivity of at least 85%. A high specificity corresponds with a low number 
of unnecessary colonoscopies.
Verification of the identified cut-off point
We verified the optimal cutoff value (referred to as ‘X’ years), that was established in 
the ROC curve in the total cohort of IBD patients with LGD. We used a Kaplan-Meier 
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plot to illustrate the cumulative incidence of advanced neoplasia in the total cohort of 
IBD patients who had a neoplasia-free follow-up period of at least X years after the 
index LGD. In addition, we analyzed the cumulative incidence of any neoplasia (ie, LGD 
or advanced neoplasia). Time to event was calculated from moment of cutoff (ie, date 
of index LGD + X years) to event or to censoring. Patients with advanced neoplasia at 
the first colonoscopy that was performed more than X years after the index LGD were 
excluded because most of these patients may already have had advanced neoplasia at 
the moment of cutoff (but not yet detected because colonoscopy was performed later 
than the cutoff point). Additionally, we performed (1) a sensitivity analysis including 
these patients (‘worst-case scenario’), and (2) a sensitivity analysis including patients 
without previously identified risk factors for advanced neoplasia development (‘best-
case scenario’).
Risk of recurrent dysplasia and advanced neoplasia after sporadic adenomas
We evaluated the risk of recurrent dysplasia and advanced neoplasia after sporadic 
adenomas. In clinical practice, the distinction between colitis-associated neoplasia 
and sporadic adenoma is often not clear.15 In general, lesions are categorized as 
sporadic adenomas if they are located in historically non-inflamed colonic segments.16 
Therefore, we assessed whether there was any histologic inflammation in the colonic 
segment that harbored the dysplastic lesion simultaneously or before the moment 
of dysplasia detection. For this purpose, we analyzed all individual pathology reports 
of the subgroup of patients who developed LGD in the most recent 5 years of the 
inclusion period (2005-2010). We compared the cumulative incidence of recurrent LGD 
and advanced neoplasia using log-rank test.
General statistics
Outcomes with a normal distribution were presented as means with standard deviation 
(SD), and non-normally distributed outcomes were presented as medians with 
interquartile range (IQR). The proportional hazards assumption was tested by testing 
time-covariate interactions and visual inspection of log-minus-log plots. A p-value < 
0.05 was considered statistically significant. SPSS Statistics (IBM, version 25 , Armonk, 
NY, USA) was used for statistical analyses.
Ethics
The study was approved by the PALGA ethical committee (lzv-1215) and by the 






The PALGA search yielded 4,284 IBD patients with LGD available for inclusion. The 
results of the PALGA search has been described in detail in a prior publication Of these 
4284 patients, 1620 patients (37.8%) developed recurrent LGD after a median of 3.6 
years (IQR 1.7-6.9) after the index LGD. Baseline characteristics of all included IBD 
patients with LGD are shown in Table 1. Of 4,284 patients, 3065 (71.5%) had UC, 970 
(22.6%) CD, and 249 (5.8%) IBD unclassified. The median follow-up was 6.4 years (IQR 3.2-
11.3). During follow-up, patients underwent a median of 5 colonoscopies. The median 
time between colonoscopies was 1.4 years (IQR 0.8-2.3). Of 4284 patients, 551 (12.9%) 
underwent (sub)total colectomy.
Table 1. Baseline characteristics of included IBD patients with low-grade dysplasia.
IBD = inflammatory bowel disease, LGD = low-grade dysplasia, SD = standard deviation, 
IQR = interquartile range.
Characteristic Patients with LGD 
(n=4284)
Male gender, n (%) 2630 (61.4)
Disease
 Ulcerative colitis, n (%)





Age at LGD, mean (+SD) 55.3 (14.8)
Follow-up after dysplasia in years, median (IQR) 6.4 (3.2-11.3)
Follow-up after IBD diagnosis in years, mean (+ SD) 13.8 (8.2)
Recurrent LGD (%) 1,620 (37.8)
Two or more follow-up colonoscopies, n (%) 2,788 (65.1)
Recurrent versus no recurrent LGD
Recurrent LGD
A total of 2788 patients had 2 or more follow-up colonoscopies (2040 UC, 584 CD, and 
164 IC). Of these, 2047 patients (73%) received a follow-up colonoscopy within 3 years 
after the index LGD and were therefore included in this analysis (Figure 1). Recurrent 
LGD at this first follow-up colonoscopy was detected in 392 of 2037 patients (19.1%), 
of whom 56 patients eventually developed advanced neoplasia (14.3%, 30 CRC and 26 
HGD) during 2467 person-years of follow-up. By contrast, only 166 of 1655 patients 
without recurrent LGD at the first follow-up colonoscopy developed advanced neoplasia 
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(10.0%, 111 CRC, 55 HGD) in 11,832 person-years. The incidence rate of advanced 
neoplasia was 22.7 per 1000 patient-years in patients with recurrent LGD versus 14.0 
per 1000 patient-years in patients without recurrent LGD. Patients with recurrent LGD 
had a higher cumulative incidence rate of advanced neoplasia compared with patients 
without recurrent LGD (log-rank, hazard ratio [HR], 1.66; 95% confidence interval [CI], 
1.22-2.25; p = .001) (Figure 2). The 10-year cumulative incidence of advanced neoplasia 
was 17.4% and 12.2% in patients with recurrent and no recurrent LGD, respectively.
Our multivariable analysis showed that recurrent LGD remained an independent risk 
factor for advanced neoplasia after correction for the confounders age, academic 
centre, male gender and year of LGD diagnosis (HR 1.56, 95% CI 1.15-2.11, p=0.005).
Figure 1. Risk of advanced neoplasia in patients with and without recurrent LGD at first fol-
low-up colonoscopy (within 3 years) after index LGD.





Figure 2. Kaplan Meier plot showing the cumulative incidence of advanced neoplasia in IBD pa-
tients with recurrent and without recurrent LGD at first follow-up colonoscopy after index LGD.
IBD=inflammatory bowel disease, LGD=low-grade dysplasia, HGD=high-grade dysplasia, 
CRC=colorectal cancer
Neoplasia-free time after index LGD
In total, 1444 patients (1060 UC, 287 CD, 97 IBD unclassified) had a follow-up period of 
at least 10 years or developed advanced neoplasia within 10 years. For this subgroup, 
the association between the number of patients developing advanced neoplasia 
and maximum neoplasia-free time after the index LGD is shown in Figure 3A. The 
value 0 represents patients with new neoplasia at the first follow-up colonoscopy 
and hence a neoplasia-free follow-up period of 0 years. Based on these results a 
ROC curve was constructed that showed an area under the ROC curve of .76 (95% CI, 
.74-.79; p < .001) (Figure 3B). Therefore, neoplasia-free time can be considered a fair 
predictor for risk of advanced neoplasia development. A cutoff value of 3 years of 
neoplasia-free time after the index LGD was associated with a sensitivity and specificity 
of 89.3% (95% CI, 85.9%-92.1%) and 55.1% (95% CI, 52.0%-58.2%), respectively, for 
detecting advanced neoplasia.
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Figure 3.
A: Bar-chart of the 1,444 IBD patients with at least 10 years of follow-up or advanced neopla-
sia within 10 years, illustrating the number of patients with and without advanced neoplasia 
within 10 years of index LGD, stratified by maximum years of neoplasia-free time.
B: The corresponding receiver operating characteristics (ROC) curve. The arrow represents 
the cut-off value of 3 years.
IBD=inflammatory bowel disease, LGD=low-grade dysplasia, HGD=high-grade dysplasia, 
CRC=colorectal cancer, AUC=area under the curve
Figure 4 illustrates the cumulative incidence of advanced neoplasia in the total group 
of 2383 patients (1715 UC, 524 CD, 144 IBD unclassified) who remained neoplasia-free 
for 3 years after the index LGD. The x-intercept represents the moment the cutoff of 
a neoplasia-free period of 3 years was reached, thus the date of index LGD + 3 years. 
The subsequent 3- and 5-year cumulative incidences were, respectively, .9% and 2.2% 
for advanced neoplasia and 19.8% and 29.5% for any dysplasia (ie, LGD + advanced 
neoplasia) (Supplementary Figure 1). The incidence rate of advanced neoplasia was 
8.5 per 1000 patient-years (CRC, 5.2/1000 patient-years). Patients without risk factors 
for advanced neoplasia development (male gender, diagnosis of index LGD in an 
academic center, and diagnosis of index LGD ≥55 years; best-case scenario) who 
remained neoplasia-free 3 years after the index LGD had an even lower risk of advanced 
neoplasia (incidence rate, 5.6/1000 patient-years; 3- and 5-year cumulative incidences 
of .5% and 1.4%; p = .048). In the sensitivity analysis (worst-case scenario, 77 additional 
IBD patients with advanced neoplasia at first follow-up >3 years after the index LGD 




We then extrapolated our results to all patients who remained neoplasia-free at 3 years 
and would continue yearly surveillance until 5 years after index LGD. In that scenario, a 
total of 355 patients should be screened to find 1 additional case of advanced neoplasia 
(42 patients in the worst-case scenario).
Figure 4. Kaplan Meier plot showing the cumulative incidence of advanced neoplasia in the 
2,383 IBD patients with a neoplasia-free period of 3 years after index LGD.
The X-intercepts represents the moment that the neoplasia-free period reached the cut-off of 
3-years (index LGD date + 3 years). The ‘best-case scenario’ represents the group of patients 
with no risk factor (ie, not: male gender, index LGD ≥55 years or follow-up at an academic 
centre). In the sensitivity analysis, 77 additional IBD patients with advanced neoplasia at first 
follow-up >3 years after index LGD were included.
IBD=inflammatory bowel disease, LGD=low-grade dysplasia, HGD=high-grade dysplasia, 
CRC=colorectal cancer
Risk of recurrent neoplasia in sporadic adenomas in IBD
Based on the histopathology reports, 50.1% of patients had extensive colitis (extending 
proximal to the splenic flexure) and 40.3% had nonextensive disease. In 9.6% of patients, 
the specific colonic location of inflammation was not reported. The exact colonic location 
of the LGD was reported in 1064 of 1557 patients. We observed that 190 of 1064 patients 
(17.9%) had LGD in a colonic segment without documented inflammation, whereas 
783 of 1064 patients (73.6%) had LGD in a colonic segment with reported histologic 
inflammation (in 91 of 1064 patients [8.5%] the exact location of colonic disease activity 
was never specified). We observed no differences in the risk of recurrent LGD (HR, 1.11; 
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95% CI, .85-1.45; p = .44) or of advanced neoplasia (HR, 1.58; 95% CI, .81-3.06; p = .18) 
between LGD located in an inflamed versus a noninflamed colonic segment.
DISCUSSION
In this nationwide study we found that recurrent LGD at follow-up colonoscopy after 
LGD is a risk factor for developing advanced neoplasia in IBD patients (incidence rate 
of 22.7 per 1000 patient-years for recurrent LGD vs 14.0 per 1000 patient-years for no 
recurrent LGD). Second, we found that a neoplasia-free follow-up period of 3 years after 
the index LGD was associated with a reduced advanced neoplasia risk (incidence rate 
of 8.5/1000 patient-years). These results demonstrate the advanced neoplasia risk in 
IBD patients with LGD and may impact current surveillance guidelines.
Recurrence of LGD is a frequent finding in IBD patients with LGD. We found that 37.8% 
of patients with LGD developed recurrent LGD. This relatively high number is still lower 
than previously reported recurrence rates of LGD in a small cohort from 2002 (44/60, 
73.3%).17 Moreover, we found an increased advanced neoplasia incidence in patients 
with recurrent dysplasia. Likewise, in the general non-IBD screening population, patients 
with recurrent colorectal adenomas at first follow-up had a higher risk of developing 
advanced neoplasia at their second follow-up compared with patients with a negative 
first follow-up colonoscopy.18, 19 Robust data on advanced neoplasia risk in IBD patients 
with recurrent dysplasia are absent and the available literature reported conflicting 
results. One study identified a history of IND before LGD as a risk factor for advanced 
neoplasia in 172 UC patients with LGD.4 By contrast, a small study (n=46) found no 
increased advanced neoplasia incidence in IBD patients with recurrent LGD.10
One could hypothesize that recurrent LGD occurs in the mucosa of IBD patients who 
underwent a larger ‘field change’ of cancer-associated molecular alterations in the 
colon.20 This concept of ‘field cancerization’ assumes that there are multiple patches 
of premalignant mucosa with mutant clones close to the primary tumor. These mutant 
clones are histologically indistinguishable from the normal cell population but harbor 
the potential of tumor development.21, 22 Because these field changes are primed to 
develop multifocal (pre)cancerous changes, the presence of a larger ‘field change’ might 
result in a higher CRC risk. Recurrent LGD may be the outcome of this field cancerization, 




the design of the current study did not allow the further testing of this hypothesis, and 
future studies are required to explore this theory.
Given the concept of field cancerization, one may hypothesize that patients with colitis-
associated neoplasia bear an increased recurrent LGD and advanced neoplasia risk 
compared with IBD patients with sporadic adenomas. However, we observed a similar 
risk of recurrent LGD (HR 1.11, 95% CI 0.85-1.45, p=0.44) and advanced neoplasia (HR 
1.58, 95% CI 0.81-3.06, p=0.18) between LGD located in an inflamed versus a non-
inflamed colonic segment. This is in line with prior cohort studies that reported no 
significant difference in risk of recurrent dysplasia after removal of a sporadic adenoma 
versus a colitis-associated adenoma (HR for colitis-associated dysplasia relative to 
sporadic adenoma: 1.3; 95% CI, 0.6–2.7, p= 0.55).23-25 In addition, one recent study 
reported that there is an increased risk of advanced neoplasia in Dutch IBD patients 
with a sporadic adenoma compared with non-IBD patients with a sporadic adenoma.26 
Moreover, 43.8% of IBD patients with untreated sporadic adenomas developed 
colitis-associated neoplasia in the same colonic segment.27 These data suggest that 
the distinction between sporadic adenomas and colitis-associated dysplasia does 
not impact surveillance intervals, given the increased neoplasia risk in both IBD 
patients with a sporadic adenoma and IBD patients with colitis-associated dysplasia, 
as well as the lack of clear definitions to distinguish colitis-associated neoplasia 
and sporadic adenomas.
The observation of a decreased cancer risk in patients with negative endoscopies 
accords with results coming from other cancer screening programs.28 Recently, a 
multicenter retrospective analysis of low-risk IBD patients undergoing CRC surveillance 
reported a low advanced neoplasia risk in patients who had consecutive technically 
adequate colonoscopies without neoplasia and no other endoscopic abnormalities.29, 30 
However, data regarding the impact of a neoplasia-free period in the high-risk category 
of IBD patients with LGD are not available. To date, only one small study reported that 6 
of 15 (40%) IBD patients with a negative follow-up colonoscopy after LGD still developed 
recurrent LGD thereafter 31, yet no study reported on the subsequent risk of advanced 
neoplasia. We found that a neoplasia-free period of 3 years after the index LGD was 
associated with a reduced subsequent incidence rate of advanced neoplasia of 8.5 
per 1,000 patient-years (CRC 5.2 per 1,000 patient-years). To put this into perspective, 
previous studies reported an average risk of advanced neoplasia in IBD patients with 
a history of LGD of 17-18 per 1,000 patient-years.6, 32
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In another high-risk category of IBD patients with concomitant primary sclerosing 
cholangitis (PSC), a higher incidence rate of advanced neoplasia of 13 per 1,000 patient-
years was reported.33 However, the incidence rate of CRC of 5.2 per 1,000 patient-years 
still exceeds the average risk in the general IBD population. A meta-analysis reported an 
incidence rate of CRC of 0.7 per 1,000 patient-years in the first decade and 4.2 per 1,000 
patient-years after more than 20 years disease duration in the general IBD population.34
Our results may impact current surveillance guidelines. The ASGE and AGA guidelines 
recommend an increased surveillance strategy after LGD detection, without specifically 
stating the duration and frequency of this intensified strategy.8, 9 The BSG recommends 
performing yearly colonoscopy for 5 years after LGD detection.3 Because dysplasia 
increased the advanced neoplasia risk in our study, our results underline the current 
intensified surveillance strategy after LGD detection including yearly surveillance. 
However, based on our data, 355 patients would have to undergo yearly surveillance 
after a neoplasia-free period of 3 years to detect 1 additional case of advanced neoplasia 
in the subsequent 2 years (ie, until 5 years after the index LGD). This risk was even lower 
in patients without previously identified risk factors and a subsequent neoplasia-free 
period of 3 years. This results in multiple negative endoscopies, associated with a high 
burden for the patients. Thus, our findings suggest that surveillance intervals may be 
extended if patients remain neoplasia-free for 3 years after LGD. In addition, patients 
with a baseline high-risk profile (eg, concomitant PSC) may benefit from a prolonged 
annual surveillance strategy.33 Future prospective studies are needed to further confirm 
these results and aid in risk stratification.
Strengths of our study include the nationwide study approach and the large size of 
our cohort with long-term follow-up. Our study also comes with some limitations. 
Inherent to the retrospective nature of our study, there were no standardized 
intervals between colonoscopies. This might have resulted in selection bias, because 
particularly patients who were considered at highest CRC risk might have received 
multiple follow-up colonoscopies. Second, although our results provide insight into 
the general advanced neoplasia risk in patients with LGD in a nationwide setting, 
no clinical and endoscopic data were available. Therefore, we could not correct for 
clinical confounders like endoscopic technique used, LGD location and morphology (ie, 
polypoid, non-polypoid, and endoscopically invisible), treatment of dysplastic lesions 
(biopsy sampling or endoscopic removal), concomitant diseases such as PSC, and the 




representative for the IBD population at large. Third, our cohort enrolled patients 
with LGD between 1991 and 2010, whereas current updated surveillance strategies, 
optimization of anti-inflammatory therapies, and new advanced endoscopic techniques 
may influence outcomes over time.35, 36 However, in our previous study we analyzed our 
data from two different cohorts based on time of LGD (1991-2000 and 2000-2010) and 
did not detect significant differences. Moreover, we verified in our cohort that recurrent 
LGD remained a risk factor after correction for year of LGD diagnosis.
In conclusion, in this nationwide study we found that patients with recurrent LGD 
are at increased risk of developing advanced neoplasia compared with patients 
without recurrent dysplasia (HR 1.66). In addition, a neoplasia-free period of 3 years 
after index LGD reduced the advanced colonic neoplasia risk. Our results support 
current surveillance guidelines recommending yearly surveillance colonoscopy after 
the detection of LGD in IBD patients. However, our findings suggest that subsequent 
lengthening of the surveillance intervals could be considered in selected low-risk 
patients who remain neoplasia-free in the subsequent 3 years after LGD.
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Supplementary Figure 1. 
Kaplan Meier plot showing the cumulative incidence of low-grade dysplasia and advanced 
neoplasia (combined) in the 2,383 IBD patients with a neoplasia-free period of 3 years 
after index LGD.
IBD=inflammatory bowel disease, LGD=low-grade dysplasia, HGD=high-grade dysplasia, 
CRC=colorectal cancer
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Patients with inflammatory bowel disease (IBD) who have postinflammatory polyps 
(PIPs) may have an increased risk of developing colorectal neoplasia. Current guidelines 
recommend an intensified surveillance strategy in these patients, although the evidence 
for this recommendation is conflicting. The aim of our study was to assess whether IBD 
patients with PIPs are at increased risk of colorectal neoplasia.
Methods
We established a retrospective cohort in a tertiary IBD center with IBD patients 
undergoing colorectal cancer (CRC) surveillance in the current era. We compared 
cumulative incidences of colorectal neoplasia since IBD diagnosis between patients 
with and without PIPs, and corrected for confounders. Second, we compared the risk 
of receiving a colectomy.
Results
In our cohort with >22 years of median follow-up, 154 of 519 patients had PIPs. PIPs 
were associated with extensive disease (odds ratio (OR) 2.76, 95% confidence interval 
(CI) 1.61-4.42, p<0.001) and with more severe inflammation at colonoscopy (OR 3.54, 
95%CI 2.28-5.50, p<0.001). After correction for confounders, the presence of PIPs was 
not associated with development of colorectal neoplasia (hazard ratio (HR) 1.28, 95%CI 
0.85-1.93, p=0.24) or with development of advanced neoplasia (HR 1.38, 95%CI 0.52-
3.68, p=0.52). There was a higher risk of colectomy in patients with PIPs (HR 3.41, 95%CI 
1.55-7.54, p=0.002).
Conclusion
In this cohort, PIPs were associated with disease extent, inflammation, and higher 
rates of colectomy. However, the presence of PIPs was not associated with the 
development of neoplasia. These findings suggest that patients with PIPs may not need 
an intensified surveillance strategy.
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INTRODUCTION
Patients with inflammatory bowel disease (IBD) bear an increased risk of colorectal 
cancer (CRC).1 Therefore, IBD patients undergo surveillance colonoscopies to detect and 
remove pre-malignant dysplastic lesions such as low-grade dysplasia (LGD) and high-
grade dysplasia (HGD). This may prevent progression to CRC and allow early detection 
of CRC, minimizing the morbidity and mortality associated with invasive cancer.1 The 
leading European surveillance guideline recommends surveillance intervals based on 
risk stratification, categorizing IBD patients into low-, medium-, and high-risk groups 
based on several risk factors.2 Likewise, the American Gastroenterological Association 
(AGA) recommends an increased surveillance frequency in patients with certain risk 
factors3. One of these risk factors includes the presence of postinflammatory polyps 
(PIPs), although evidence for PIPs as a risk factor for CRC in IBD patients is limited.
PIPs, commonly referred to as “pseudopolyps”, are non-neoplastic lesions that look 
like polyps or loose mucosal tags. The overall prevalence of PIPs in IBD patients is 
estimated at 20% to 40%. PIPs are the remnants of severe inflammation that are 
formed of stromal and epithelial components and inflammatory cells and they are 
associated with longstanding IBD.4-7 Patients with PIPs may be at increased risk 
of advanced neoplasia (ie, HGD or CRC), as PIPs may indicate longstanding severe 
inflammation which is associated with an increased CRC risk. In addition, PIPs may 
mask otherwise visible and resectable dysplasia. It is considered unlikely that PIPs have 
a direct malignant potential.5
Case-control studies from previous decades showed a 1.9 to 2.5-fold increased CRC risk in 
patients with PIPs.4, 6, 7 By contrast, a recent large retrospective cohort study did not find 
an increased advanced neoplasia risk in patients with PIPs, although the study did report 
an increased risk of undergoing a (sub)total colectomy.8 These conflicting data result 
in an ongoing debate regarding the necessity of an intensified surveillance strategy in 
patients with PIPs. Clarification of the risk of advanced neoplasia in patients with PIPs has 
important implications as safe extension of surveillance intervals could reduce the high 
burden associated with frequent colonoscopies and may reduce health care costs.
In the present study we aimed to (1) assess whether IBD patients with PIPs are at increased 
risk of colorectal neoplasia, (2) determine whether PIPs are associated with an increased risk 






We performed a retrospective single center cohort study to determine (1) the cumulative 
risk of developing advanced neoplasia (ie, HGD or CRC) and colorectal neoplasia (ie, LGD, 
HGD, or CRC), and (2) the risk of colectomy in IBD patients with PIPs compared with patients 
without PIPs. In addition, we identified factors associated with the development of PIPs.
Patient selection
We established a cohort including all IBD patients in the IBD surveillance program at 
the Radboud University Medical Center. Patients were identified with an electronic 
search in the local endoscopy database. This search included key terms for ‘surveillance’ 
and/or ‘colonoscopy’ in combination with key terms for IBD (‘ulcerative colitis’, ‘Crohn’s 
disease’, ‘inflammatory bowel disease’), or key terms for PIPs (postinflammatory 
polyp, pseudopolyp).
Ethical considerations
The study was approved by the medical ethical committee of the Radboud University 
Medical Center Nijmegen (2017-3645).
Inclusion and exclusion criteria
After initial patient identification, all medical data from the identified patients were 
reviewed from patient charts by two authors (V.G. and M.J.). Inclusion criteria were as 
follows: (1) confirmed IBD diagnosis (Crohn’s disease (CD), ulcerative colitis (UC), or IBD-
unclassified (IBD-U)); (2) colonic disease of at least 8 years, or of any duration when 
diagnosed with concomitant primary sclerosing cholangitis (PSC); (3) having at least left-
sided disease (UC) or involvement of >30% of the colonic surface (CD/IBD-U), or PSC with 
any disease extent; (4) receiving at least 1 surveillance colonoscopy between January 2012 
and December 2017. Exclusion criteria included disease activity limited to the ileum (CD), 
familial CRC syndromes such as Familial Adenomatous Polyposis or Lynch Syndrome, 
lack of any surveillance colonoscopy, and colorectal neoplasia before IBD diagnosis.
Data collection
The following baseline characteristics were extracted from the patients’ medical charts: 
age, gender, diagnosis of concomitant PSC, and family history of CRC. Regarding IBD we 
collected information on IBD type, age at IBD diagnosis, maximum disease extent and 
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IBD medication use including 5-aminosalicylic acid (5-ASA), thiopurines, methotrexate, 
and biologicals (anti-tumor necrosis factor, anti-α4β7 integrin monoclonal antibody or 
interleukin 12/interleukin 23 inhibitor). Extensive disease was defined as inflammation 
extending proximal to the splenic flexure in UC or colonic involvement of >50% in CD. Non-
extended disease included left-sided UC or segmental CD with <50% colonic involvement. 
In addition, dates and outcomes of IBD colonoscopies were extracted. As adapted from 
the study of Mahmoud et al.8, a mean inflammation score, reflecting the average extent 
of inflammation at colonoscopies, was calculated by averaging the inflammation scores 
of all colonoscopies (no inflammation=0, non-extensive inflammation=1, extensive 
inflammation=2). In view of our primary outcome, we extracted the date and type of 
colorectal neoplasia (indefinite for dysplasia, LGD, HGD, and CRC). Re-evaluation of 
dysplasia by a second pathologist is standard practice in our center, and therefore no 
histologic re-evaluation of the dysplasia diagnosis was performed for this study. For our 
secondary outcome, we extracted the date, type and indication of colectomy. A colectomy 
was defined as either a subtotal (ie, a colectomy only leaving the rectum in situ) or a total 
colectomy. To compare outcomes based on the presence of PIPs we reported the date 
and number of PIPs. Patients with a sporadic PIP (described as ‘a single’, or ‘one’ PIP) were 
considered as patients without PIPs due to the lack of consequences in clinical practice. 
Per the study of Mahmoud et al.8, patients with PIPs were subclassified as having ‘many’ 
PIPs if the colonoscopy reports described PIPs as ‘many ’, ‘fields’, ‘limiting visibility ’, ‘PIPs 
throughout the whole colon’, and/or if fields of PIPs were present on images and video 
recordings of colonoscopy procedures. In the absence of the abovementioned criteria 
for ‘many’ PIPs, patients were subclassified as having ‘few’ PIPs.
Statistical analysis
Descriptive statistics were used to describe the baseline characteristics. Continuous 
outcomes are presented as means and standard deviation (SD) if normally distributed 
and as medians with interquartile ranges (IQRs) if non-normally distributed. Baseline 
factors between patients with and without PIPs were compared using the chi-square test 
and independent t-test. Missing data were regarded as the absence of a characteristic 
for categorical parameters, there were no missing data on continuous outcomes.
To compare cumulative incidences of colorectal and advanced neoplasia between 
patients with and without PIPs, we used Kaplan Meier curves and log-rank analyses. Time 




Patients were censored at last follow-up surveillance colonoscopy, or if performed, at 
the moment of (sub)total colectomy given the low subsequent CRC risk.9
We performed an additional analysis comparing the cumulative incidence of colorectal 
neoplasia and advanced neoplasia in patients with ‘no’ PIPs versus ‘many’ PIPs.
Subsequently, we used a Cox-regression model to adjust for potential confounders 
impacting CRC risk. The following potential confounders were assessed: IBD type, 
gender, concomitant PSC, age at IBD diagnosis, maximum disease extent, medication 
use (categorized as 5-ASA, thiopurines, methotrexate, and biologicals), family history 
of CRC and mean inflammation score. A potential confounder was included in the final 
model when the beta coefficient of the variable of interest (PIP yes/no) changed by 
10% or more. Of note, PIP was included as a fixed factor in the multivariable model as 
our aim was to investigate whether this factor increases colorectal neoplasia risk.
Next, we performed a sensitivity analysis including all potential confounders as fixed 
covariates in our Cox regression model, as all variables are known risk factors for CRC 
development. 2, 10-15
Cumulative incidences of colectomy were compared using the log-rank test. Incidence 
rates were calculated as the number of cases per 1000 patient-years of follow-up. 
Logistic regression analysis was performed to identify factors associated with PIPs. 
Factors with a p-value <0.1 were included in the multivariable logistic regression model. 
A p-value of <0.05 was considered statistically significant. All analyses were performed 
using SPSS statistical software (version 22, IBM, Chicago, IL, USA).
RESULTS
Patient selection
A total of 519 IBD patients were eligible for inclusion (Figure 1). PIPs were present in 
154/519 (29.7%) patients (Table 1). A total of 80/519 (15%) patients had ‘many’ PIPs. The 
mean follow-up duration after IBD diagnosis was 21.6 (+10.7) years in patients with PIPs 
and 22.9 (+11.2) years in patients without PIPs. The total patient-years of follow-up was 
11,424 years (3,534 versus 7,890 years). The mean time between colonoscopies from 
first surveillance colonoscopy was 2.4 (+1.3) versus 2.3 (+1.1) years in patients with and 
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without PIPs, respectively (p=0.50). The cecum was reached in 96.9% of colonoscopies 
in patients with PIPs and 95% of colonoscopies in patients without PIPs.
Table 1. Baseline characteristics of included IBD patients with and without PIPs.
IBD = Inflammatory bowel disease, PIP=Postinflammatory polyp, CRC=Colorectal cancer, 
PSC=Primary sclerosing cholangitis, SD = Standard deviation, n=Number
Characteristic Patients with PIPs 
(n=154)
Patients without PIP 
(n=365 )
P-value
Male gender, n (%) 73 (47.4) 211 (57.8) 0.27
Disease
 Ulcerative colitis, n (%)









Age at IBD diagnosis,
mean (+ SD)
28.5 (+11.8) 28.9 (+12.4) 0.74
Family history CRC, n (%) 26 (16.9) 48 (13.2) 0.27
Concomitant PSC (%) 9 (5.8) 18 (4.9) 0.67
Extensive disease (%) 130 (84.4) 215 (58.9) <0.001
Follow-up after IBD diagnosis  
in years, mean (+ SD)
21.6 (+10.7) 22.9 (+11.2) 0.20
Mean inflammation score during 
follow-up
0.74 (+0.41) 0.39 (+0.47) <0.001
Cecal intubation rate (+ SD) 96.9 (+8.1) 95.0 (+14.4) 0.12
Figure 1. Flowchart of patient inclusion




Factors associated with the presence of PIPs
Baseline characteristics of patients with and without PIPs are shown in Table 1. 
Patients with PIPs more often had extensive disease (p<0.001) and had a higher mean 
inflammation score (p<0.001). Patients with ‘many’ PIPs, especially, more often had 
extensive disease (75/80, 94%) compared with patients with ‘few’ PIPs (55/74, 74%; 
p=0.001) and patients with no PIPs (215/365, 59%; p<0.001).
Multivariable logistic regression analyses identified extensive disease (odds ratio (OR) 
2.76, 95% confidence interval (CI) 1.61-4.42, p<0.001) and inflammation score (odds ratio 
3.54, 95% CI 2.28-5.50, p<0.001) as independent factors associated with PIPs (Table 2).
Table 2. Factors associated with the presence of PIPs
IBD= Inflammatory bowel disease; PSC= Primary sclerosing cholangitis; CI= Confidence 








Ulcerative colitis 1.41 0.96-2.06 0.08 1.25 0.83-1.88 0.29
Male gender 1.24 0.85-1.80 0.28
PSC 1.20 0.53-2.73 0.67
Extensive disease 3.78 2.33-6.12 <0.001 2.67 1.61-4.42 <0.001





4.53 2.97-6.93 <0.001 3.54 2.28-5.50 <0.001
Association between PIPs and colorectal neoplasia
Association of PIPs with development of colorectal neoplasia
Thirty-six of 154 (23.4%) patients with PIPs were diagnosed with colorectal neoplasia 
during follow-up (27 LGD, 3 HGD, 6 CRC), compared with 65/365 (17.8%) (55 LGD, 3 
HGD, 7 CRC) in the group without PIPs. This resulted in a cumulative incidence of 
colorectal neoplasia of 11.9% (PIPs) and 10.7% (no PIPs) after 20 years in both groups. 
The cumulative incidence of colorectal neoplasia was comparable between patients 
with and without PIPs (hazard ratio (HR) 1.28, 95%CI 0.85-1.93, p=0.24; Figure 2) and 
thus no association between PIPs and colorectal neoplasia development was found in 
univariable analysis. There was no association between PIPs and colorectal neoplasia in 
either UC (HR=1.21, 95% CI 0.73-2.00, p=0.46) or CD (HR=1.22, 95% CI 0.57-2.64, p=0.61). 
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Similarly, multivariable analyses with confounder correction did not show an association 
between PIPs and colorectal neoplasia development. In our multivariable model, there 
were no confounders changing the β of PIPs >10 percent, not allowing entry of additional 
confounders in our final model in addition to PIPs. Moreover, our multivariable 
sensitivity analysis including all confounders found no association between PIPs and 
colorectal neoplasia development (HR=1.08, 95% CI 0.66-1.75, p=0.76).
Subsequently, we performed an additional analysis classifying patients as having ‘no’, 
‘few’ or ‘many’ PIPs (Supplementary Figure 1). Univariable analysis showed a higher 
cumulative incidence in patients with ‘many’ PIPs compared with patients with ‘no’ PIPs 
(HR 1.68, 95%CI 1.05-2.70, p=0.03). However, after adjustment for all confounders, no 
association between ‘many’ PIPs and colorectal neoplasia was found (HR 1.46, 95%CI 
0.82-2.63, p=0.20).
Figure 2. Cumulative incidence of colorectal neoplasia in patients with PIPs versus patients 
without PIPs.




Association of PIPs with development of advanced neoplasia
The cumulative incidence of advanced neoplasia was 2.7% and 1.7% after 20 years in 
patients with and without PIPs, respectively. The cumulative incidence of advanced 
neoplasia was comparable between patients with and without PIPs (HR 1.93, 95% CI 
0.78-4.75, p=0.15) (Figure 3). This applied for both UC (HR=1.56, 95% CI 0.50-4.87, p=0.44) 
and CD (HR=2.38, 95% CI 0.53-10.69, p=0.26). In multivariable analysis, concomitant 
PSC and the mean inflammation score changed the β of PIPs more than 10%, and these 
factors were therefore included as confounders. This resulted in an adjusted HR of PIPs 
of 1.38 (95%CI 0.52-3.68, p=0.52). In our multivariable sensitivity analysis, with inclusion 
of all confounders, the presence of PIPs remained not associated with development of 
advanced neoplasia (HR=1.26, 95%CI 0.42-3.74, p=0.68).
Subsequently, in the analysis comparing patients with ‘no’, ‘few’ or ‘many’ PIPs 
(Supplementary Figure 2), the cumulative incidence of advanced neoplasia in patients 
with ‘many’ PIPs compared with patients with ‘no’ PIPs was comparable in both 
univariable (HR 2.49, 95% CI 0.90-6.87, p=0.08), and multivariable sensitivity analyses 
(HR=1.83, 95% CI 0.59-6.86, p=0.37). Likewise, there was no difference between ‘many’ 
and ‘few’ PIPs (HR 1.84, 95% CI 0.46-7.41, p=0.39).
Figure 3. Cumulative incidence of advanced neoplasia in patients with PIPs versus patients 
without PIPs.
IBD= Inflammatory bowel disease; PIP= Postinflammatory polyp
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Risk of colectomy
Of the patients with PIPs, 16/154 (10.4%) underwent a (sub)total colectomy versus 
10/365 (2.7%) in patients without PIPs. The cumulative incidence rate of colectomy was 
higher in patients with PIPs (HR 3.41, 95% CI 1.55-7.54, p=0.002. Figure 4). Reasons for 
(sub)total colectomy in patients with PIPs were as follows: inflammation (n=8), dysplasia 
(n=4), CRC (n=1), stenosis (n=2), perforation at colonoscopy (n=1); and in patients without 
PIPs: inflammation (n=4), dysplasia (n=3), CRC (n=1), stenosis (n=1), B-cell lymphoma 
(n=1) (Supplementary figure 3).
Of all patients with CRC (n=13), four patients received a (sub)total colectomy, two a 
hemi-colectomy, five a rectosigmoid resection, one an endoscopic removal of a T1 CRC 
and one patient received palliative treatment.
Figure 4. Cumulative incidence of colectomy in patients with PIPs versus patients without PIPs.
IBD= Inflammatory bowel disease; PIP= Postinflammatory polyp
DISCUSSION
In this cohort study including 519 patients with colonic IBD undergoing CRC surveillance, 
we found no association between PIPs and the development of colorectal and advanced 




scores at follow-up colonoscopies. Furthermore, we found that IBD patients with PIPs 
were more likely to undergo colectomy.
Current guidelines recommend an intensified surveillance strategy in patients with 
PIPs.2, 16 However, the evidence for this recommendation is limited, as it is based on a few 
studies from previous decades that reported on risk factors for CRC in general. Two case-
control studies reported that patients with UC and PIPs had 2.1-2.5 fold higher odds of 
developing colorectal neoplasia and advanced neoplasia, respectively. However, these 
results were not corrected for the presence of inflammation at follow-up colonoscopies. 
Furthermore, these results may not be representative for the current era with improved 
endoscopic vizualisation techniques and surveillance strategies. A case-control cohort 
study from 2011, including 565 CD and UC patients undergoing surveillance, reported a 
1.92-fold higher rate of CRC in patients with PIPs. 4, 6, 7 By contrast, a more recent, large 
retrospective multicenter study did not find an increased risk of advanced neoplasia 
compared with patients without PIPs.8 These findings are supported by another study 
not reporting PIPs as an independent risk factor for advanced neoplasia development 
in patients with UC and LGD.17
In line with the 2 most recent studies, we did not identify an association between PIPs 
and colorectal neoplasia or advanced neoplasia development. However, univariable 
analysis showed an increased cumulative colorectal neoplasia incidence in IBD patients 
with large fields of PIPs compared with patients without PIPs (HR 1.68, p=0.03). One 
can speculate that these large fields of PIPs indicate severe inflammation, resulting 
in an increased colorectal neoplasia risk. Indeed, we found that higher inflammation 
scores and extensive disease are associated with the presence of PIPs. In addition, 
inadequate visualization of the entire colonic mucosa may hamper detection of true 
neoplastic lesions among the fields of PIPs and consequently may lead to an increased 
advanced neoplasia risk as these neoplastic lesions may progress to CRC when not 
removed.5, 7 However, after adjustment for all confounders in multivariable analyses, 
no association was found between ‘many’ PIPs and colorectal neoplasia development 
(HR 1.46, p=0.20) or advanced neoplasia development (HR=1.83, p=0.37). The findings of 
our study suggest that the presence of PIPs alone is insufficient reason for an intensified 
surveillance strategy. Alternatively the severity of inflammation during the disease 
course may be more accurate for risk stratification. Indeed, previous studies reported 
a strong association between the severity of inflammation and the development of 
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neoplasia.8, 18 Prospective studies are needed to support our findings and aid in clinical 
decision-making on endoscopic surveillance intervals.
The strengths of our study include the rigorous collection of data of patients undergoing 
surveillance, and adjustment of our results for important confounders like inflammation 
during follow-up, concomitant PSC and the extent of disease. The setting of an 
IBD population undergoing CRC surveillance in the current era makes our cohort 
representative for clinical practice. Moreover, we established a relatively large cohort 
including over 500 IBD patients with >100 cases of neoplasia. However, there are also 
some limitations to this study that should be addressed. First, the retrospective study 
design brings some limitations, such as the absence of a standardized surveillance 
interval. However, there was no difference in mean time between subsequent 
colonoscopies between patients with and without PIPs. In addition, there was no 
standardized reporting of PIPs. Although unlikely, there might be misclassification 
of PIPs as other lesions might have been regarded as PIPs incorrectly. However, 
classification of PIPs by an endoscopist is often reliable, as demonstrated by the good 
inter-observer agreement between pathologists and endoscopists.19 To further reduce 
misclassification, we combined data from pathology reports, endoscopy reports, and 
endoscopy images/videos. Second, selection bias might be present, as this is a single-
center study in a tertiary referral center, with in general a trend towards more complex 
IBD phenotypes. Third, due to the lower incidence of advanced neoplasia, one can 
hypothesize that there is a lack of power to detect a significant difference for advanced 
neoplasia. However, our findings correspond with the results of recently published 
studies, that also found a higher colectomy rate but no association between PIPs 
and advanced neoplasia.8 We acknowledge that the higher colectomy rate in patients 
with PIPs may have resulted in a lower CRC risk. However, this finding reflects current 
clinical practice in which PIPs are outcomes of severe inflammation, thus resulting more 
frequently in a colectomy.
In conclusion, in a well-characterized cohort of IBD patients undergoing CRC surveillance 
in the current era, PIPs were not associated with development of colorectal neoplasia. 
These findings add to the growing body of evidence suggesting that IBD patients with 
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Supplementary Figure 1. Cumulative incidence of colorectal neoplasia in patients with 
respectively ‘no’, ‘few’ or ‘many’ PIPs.
IBD= Inflammatory bowel disease; PIP= Postinflammatory polyp
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Supplementary Figure 2. Cumulative incidence of advanced neoplasia in patients with 
respectively ‘no’, ‘few’ or ‘many’ PIPs.
IBD= inflammatory bowel disease; PIP= postinflammatory polyp
Supplementary Figure 3. Reasons for (sub)total colectomy
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Background and aims: The impact of serrated polyps on the advanced colorectal 
neoplasia (CRN) risk in inflammatory bowel disease (IBD) patients is unknown. 
Serrated polyps are histologically categorized as hyperplastic polyps (HPs), sessile 
serrated lesions (SSLs), and traditional serrated adenomas (TSAs). We aimed 1) to 
characterize the serrated polyps in IBD patients, 2) to identify factors associated with 
the presence of serrated lesions in IBD, and 3) to assess the CRN risk in IBD patients 
with serrated polyps.
Methods: We established a retrospective cohort of IBD patients with and without colonic 
serrated polyps. Cox-regression analysis with time-dependent variables was used to 
compare advanced CRN risk in IBD patients with and without serrated polyps.
Results: Of the 621 enrolled IBD patients, 198 had a serrated polyp (92 HPs, 88 SSLs 
without dysplasia, 13 SSLs with dysplasia, and 5 TSAs). Independent factors associated 
with serrated polyps were ulcerative colitis (UC) (odds ratio (OR) 1.77, 95% confidence 
interval (CI) 1.19-2.62, p=0.005), male gender (OR 1.63, 95% CI 1.11-2.40, p=0.013), and 
older age (per year increase, OR 1.06, 95%CI 1.05-1.08, p<0.001). TSAs and SSLs with 
dysplasia were risk factors for subsequent advanced CRN (HR 13.51, 95% CI 3.11 – 58.68, 
p<0.001), while HPs (HR 1.98, 95% CI 0.46-8.60, p=0.36) and SSLs without dysplasia (HR 
0.87, 95% CI 0.11-6.88, p-0.89) did not impact the subsequent advanced CRN risk.
Conclusion: UC, male gender and older age were associated with the presence of 
serrated polyps. TSAs and SSLs with dysplasia were associated with subsequent 
advanced CRN, while HPs and SSL without dysplasia were not.
Keywords
Serrated polyp, Colorectal cancer, Ulcerative colitis, Crohn’s disease, surveillance
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INTRODUCTION
Colorectal cancer (CRC) is one of the most detrimental complications of colonic 
inflammatory bowel disease (IBD), with an incidence that is estimated 1.5 – 2-fold 
higher compared to the general population.1 Therefore, IBD patients undergo regular 
surveillance colonoscopies to remove precancerous lesions and prevent CRC. According 
to international guidelines, the interval between surveillance colonoscopies depends 
on the individual risk profile.2, 3 One of the most important risk factors for CRC is the 
presence of colitis-associated low-grade dysplasia (LGD) or high-grade dysplasia (HGD).4 
However, it is unknown if the presence of colorectal serrated polyps in IBD impacts the 
colorectal neoplasia (CRN) risk and how it should impact surveillance guidelines.
In the general population, approximately 25% of sporadic CRCs arise via serrated 
precursor lesions.5 Serrated polyps include hyperplastic polyps (HPs), sessile serrated 
lesions (SSLs) and traditional serrated adenomas (TSAs). They develop through a 
distinct molecular pathway and have a distinct endoscopic appearance compared 
to conventional adenomas. Before 2010 serrated polyps were poorly recognized by 
endoscopists and most serrated polyps were regarded as harmless HPs.5 Since then, 
several studies reported that patients with serrated polyps have a 2- to 4- fold increased 
risk of synchronous and metachronous advanced CRN (including HGD and CRC).6, 7
To date, only few small retrospective studies described the risk of CRN in IBD patients 
with serrated polyps.8-13 These studies did not show an increased CRN risk in patients 
with HPs, while one study including 78 patients reported that IBD patients with serrated 
polyps with dysplasia had a higher risk of advanced CRN.8 However, these studies 
were published before the renewed World Health Organisation (WHO) criteria from 
2019 were adopted for subclassification of serrated polyps.14 Moreover, since most 
studies included mainly HPs, the CRN risk of other types of serrated polyps in IBD 
patients remains unclear.
To fill this knowledge gap, we established a large retrospective IBD cohort undergoing 
endoscopic surveillance. We aimed 1) to characterize serrated polyps in IBD patients, 
2) to identify factors associated with the presence of serrated polyps in IBD, and 3) to 





Study design and outcomes
We adopted a retrospective cohort study design to characterize IBD patients with 
serrated polyps, and to assess the (advanced) CRN risk in patients with and without 
serrated polyps. Primary endpoints were CRN defined as either LGD, HGD or CRC; and 
advanced CRN including HGD and CRC.
Study population
We established a cohort of IBD patients undergoing standardized CRC surveillance 
according to the British Society of Gastroenterology guidelines2 at the Radboud 
University Medical Center, Nijmegen, The Netherlands. Patients were identified using 
an electronic search in the local endoscopy and histopathology databases. This search 
included key terms for ‘surveillance’ and/or ‘colonoscopy’ in combination with key terms 
for IBD (‘ulcerative colitis’, ‘Crohn’s disease’, ‘inflammatory bowel disease’). Subsequently, 
IBD diagnoses were verified in the individual patients’ medical charts.
Next, we identified all serrated polyps in the established cohort (including 
histopathology slides for histopathological review). To this end, we performed a 
search in the local histopathology database from January 1996 to December 2017 using 
different terms for serrated polyps (metaplastic polyp, hyperplastic polyp, sessile serrated 
lesion, traditional serrated adenoma).
Finally, we selected a control group of IBD patients who developed LGD but no serrated 
polyps from the established cohort. Only patients with colitis-associated LGD, defined 
as LGD located in a colonic area with (prior) inflammation, and at least one follow-up 
colonoscopy were included in this group.
Inclusion and exclusion criteria
All patients with a diagnosis of IBD (ulcerative colitis (UC), Crohn’s disease (CD) and 
IBD-unclassified (IBD-U)) who received at least 1 complete surveillance colonoscopy 
were eligible for inclusion. Exclusion criteria were defined as follows: HGD and/or CRC 
diagnosis before IBD development, serrated polyps before IBD diagnosis, serrated 
polyps that could not be confirmed after histopathology review, serrated polyps before 
1996 (histopathology slides are available since 1996), patients with hereditary CRC 
syndromes such as Lynch syndrome and familial adenomatous polyposis, patients 
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with an IBD duration of less than 8 years or patients with proctitis only (since these 
patients are not eligible for surveillance2, 15), objection against the use of data, and 
insufficient clinical data.
Data collection
The following baseline characteristics were extracted from the patients’ medical 
charts: gender, age, family history of CRC, diagnosis of concomitant primary sclerosing 
cholangitis (PSC), and smoking status. Regarding IBD, we collected information on 
IBD type, age at IBD diagnosis, and disease extent. Extensive disease was defined 
as inflammation extending proximal of the splenic flexure in UC or an estimated 
colonic involvement of >50% in CD. Non-extended disease included left-sided 
UC or segmental CD with 30-50% colonic involvement. To study the association of 
inflammation and serrated polyps, a mean inflammation score was calculated by 
averaging the inflammation scores of all colonoscopies (no inflammation=0, non-
extensive inflammation=1, extensive inflammation=2), reflecting the average extent of 
inflammation at colonoscopies.16, 17 Date and outcomes of all IBD colonoscopies were 
extracted including the development of serrated polyps and CRN. Synchronous CRN was 
defined as neoplasia that was detected during the same colonoscopy as the serrated 
polyp. Metachronous CRN was defined as neoplasia that was detected at any follow-
up colonoscopy or at subsequent colectomy. Furthermore, we extracted the date and 
type of colectomy. A colectomy was defined as either a subtotal (i.e. a colectomy only 
leaving the rectum in situ) or a total colectomy. Follow-up data were collected until 
August 1st, 2019.
Histopathology review
Histopathology slides from all serrated polyps and lesions with CRN were reviewed 
by an expert IBD pathologist (I.N., S.V., R.P.). This was performed in a blinded fashion. 
In case of doubt, slides were discussed and re-assessed by the other pathologists in 
order to obtain consensus. Slides with serrated polyps were reviewed according to the 
renewed WHO criteria.14 Serrated lesions were classified into HP, SSL without dysplasia, 
SSL with dysplasia, or TSA (always with dysplasia).14 HPs are polyps with a normal 
architecture with crypts that are evenly spaced, but the superficial epithelium shows 
serration up to two-thirds of the crypts. According to the updated WHO criteria, the 
presence of a single unequivocally distorted crypt is considered diagnostic for an SSL. 
TSAs are the least common serrated polyps. The cells of these villous polyps contain 




Grade of CRN was classified into LGD, HGD, or CRC.18 Revised results were used 
for further analyses.
Statistics
Descriptive statistics were used to describe the baseline characteristics. Continuous 
outcomes are reported as means including standard deviation (SD) if normally 
distributed, and as medians with interquartile range (IQR) if non-normally distributed. 
Logistic regression analysis was used to compare baseline factors between patients 
with and without serrated polyps. Factors with a p-value <0.1 in univariable analysis 
were included in multivariable logistic regression analysis.
Kaplan Meier curve and log-rank analysis were used to compare cumulative incidences 
of CRN between HPs, SSLs with dysplasia, SSLs without dysplasia, and TSAs. Time to 
event was calculated from the date of the first serrated polyp until (advanced) CRN 
or censoring. The first serrated polyp was regarded as the index polyp. Only CRN 
identified after index serrated polyp detection was regarded as an event. Patients who 
had synchronous HGD or CRC were excluded from all log-rank analyses. In addition, 
patients who had synchronous LGD were excluded as well in a sensitivity analysis. 
Patients were censored at last follow-up colonoscopy, or if performed, at the moment 
of (sub)total colectomy given the impact on the subsequent CRC risk.19
Finally, we compared the risk of metachronous CRN between IBD patients with serrated 
polyps and IBD patients with colitis associated LGD (without serrated polyps).
Cox regression analysis was used to compare the risk of advanced CRN between IBD 
patients with and without serrated polyps. Here, time to event was calculated from 
the moment of IBD diagnosis until advanced CRN or censoring. To limit the risk of 
immortal time bias, serrated polyps were included in the Cox regression models as 
a time-changing covariate. We subsequently corrected for the confounders gender, 
concomitant diagnosis of PSC, history of smoking, IBD type, family history of CRC and 
the mean inflammation score.
A 2-tailed p-value of <0.05 was considered to be statistically significant. Data analysis 
was performed using the SPSS statistical software (version 22, IBM, Chicago ILL).
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Ethical considerations
The study was approved by the medical ethical committee at the Radboud university 
medical center, Nijmegen (2017-3645).
RESULTS
Patient selection
A total of 621 patients were eligible for inclusion, including 198 patients who had at least 
one serrated polyp after revision (Figure 1). A total of 47 patients had LGD without a 
serrated polyp. Baseline characteristics of patients with and without serrated polyps 
are shown in Table 1. The index serrated polyp was an HP in 91 patients, an SSL in 102 
patients, and a TSA in five patients. The mean follow-up after IBD diagnosis was 22.2 
(±13.6) and 21.3 (±10.6) years in patients with and without a serrated polyp, respectively. 
The median follow-up time after the index serrated polyp was 3.0 years. During follow-
up 14/92 patients (15%) with an HP developed an SSL and 25/101 patients (25%) with 
an SSL developed a second SSL.
Figure 1. Flowchart of inclusion of patients.




Table 1. Baseline characteristics of included patients with low-grade dysplasia.
IBD = inflammatory bowel disease, CRC = colorectal cancer, SD = standard deviation, 
IQR = interquartile range.
Characteristic IBD patients with 
serrated polyp 
(n=198)
IBD patients without 
serrated polyp
(n=423)
Male, n (%) 102 (51.5%) 177 (41.8)
Disease
 Ulcerative colitis, n (%)








Age at IBD diagnosis in years (+ SD) 37.0 (14.5) 26.9 (10.4)
Follow-up after IBD diagnosis in years, mean (+ SD) 22.2 (13.6) 21.3 (10.6)
Years between consecutive colonoscopies, mean (+ SD) 3.0 (1.7) 3.3 (2.0)
Mean inflammation score (+ SD) 0.56 (0.47) 0.50 (0.49)
Family history of CRC (%) 28 (14) 60 (14)
Serrated polyps
 Hyperplastic polyp
 Sessile serrated lesion with dysplasia







Age at serrated polyp, mean (+SD) 54.8 (12.0) -
Follow-up after index serrated lesion in years, 
median (IQR)
3.0 (0-5.8) -
Table 2. Location of the serrated polyps.












Not specified 8 7 0 0
Location specified n=83 n=82 n=13 n=5
n % n % n % n %
Rectum 44 53 28 34 3 23 1 20
Left colon 31 37 28 34 5 38 1 20
Transverse colon 5 6 8 10 2 15 1 20
Ascending colon 3 4 18 22 3 23 2 40
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Characteristics of serrated polyps in IBD
Table 2 illustrates the location of the detected serrated polyps. Index HPs were located in 
the distal colon in 90% (53% rectum and 37% left-sided colon), and rarely in the transverse 
colon (6.0%) or ascending colon (4%). SSLs without dysplasia and SSLs with dysplasia were 
located in the proximal (transverse or ascending) colon in 32% and 38%, respectively. In 
addition, 60% of TSAs were located in the proximal colon. The mean size of the serrated 
polyp was 5.3 millimeters in lesions with dysplasia versus 3.5 millimeters in serrated 
polyps without dysplasia (p=0.06). The mean size of TSAs was 7.3 millimeters.
Factors associated with the presence of serrated polyps in IBD
A diagnosis of UC, male gender, and age (per year increase) were associated with the 
presence of serrated polyps in IBD in the univariable logistic regression analysis (Table 
3). There was no difference in mean inflammation score, smoking history, family history 
of CRC or PSC diagnosis. In line, multivariable logistic regression analysis identified UC 
(odds ratio (OR) 1.77, 95% confidence interval (CI) 1.19-2.62, p=0.005), male gender (OR 
1.63, 95% CI 1.11-2.40, p=0.013), and age (1.06, 95%CI 1.05-1.08, p<0.001) as independent 
factors associated with the presence of serrated polyps. Excluding HPs from this 
analysis, only UC (OR 2.31, 95% CI 1.35-3.95, p=0.002) and older age (OR 1.08, 95% CI 
1.06-1.10, p<0.001) were associated with the presence of serrated polyps, as shown in 
Supplementary Table 1. Male gender was included in the multivariable analysis but did 
not reach statistical significance (p=0.051).
Table 3. Factors associated with the presence of serrated polyps
IBD= Inflammatory bowel disease; PSC= Primary sclerosing cholangitis; CI= Confidence 
interval, OR= Odds ratio, CRC=colorectal cancer
In bold factors with a p-value <0.05
Baseline OR
Uni-variable




Ulcerative colitis 1.95 1.37-2.78 <0.001 1.77 1.19-2.62 0.005
Male 1.51 1.07-2.12 0.02 1.63 1.11-2.40 0.013
PSC 1.68 0.72-3.90 0.23 - - -
Age at IBD diagnosis 
(per year increase)
1.07 1.05-1.08 <0.001 1.06 1.05-1.08 <0.001
Mean inflammation 
score
1.25 0.87-1.81 0.23 - - -
Smoking 1.01 0.72-1.43 0.94 - - -





Risk of metachronous and synchronous (advanced) CRN in IBD patients with  
serrated polyps
Figure 2 illustrates the risk of synchronous and metachronous neoplasia. Synchronous 
CRN was present in 13.0%, 14.6%, 7.7%, and 40% of patients with an HP, SSL without 
dysplasia, SSL with dysplasia, and TSA with dysplasia, respectively. At follow-up, 
6/18 patients (33.3%) with serrated polyps with dysplasia (TSA and SSL) developed 
metachronous CRN in the same colonic segment, while only 10/180 (5.5%) of patients 
with serrated polyps without dysplasia developed CRN in the same segment (p<0.001).
Figure 2. Serrated polyps and risk of synchronous and metachronous neoplasia
HP=hyperplastic polyp, SSL=sessile serrated lesion, TSA=traditional serrated adenoma, LG-
D=low-grade dysplasia, HGD=high-grade dysplasia
Figure 3 illustrates the cumulative incidence of CRN after the index polyp. The 2-year 
cumulative incidence of CRN was 7.4%, 6.8%, 44%, and 50% after the detection of an HP, 
an SSL without dysplasia, an SSL with dysplasia, and a TSA, respectively. Patients with a 
TSA or SSL with dysplasia had an increased incidence of metachronous CRN compared 
with patients with HPs and an SSL without dysplasia (log-rank test, p<0.001). This 
difference remained if patients with synchronous colitis associated LGD were excluded 
from the analysis (sensitivity analysis, p<0.001). Patients with an SSL without dysplasia 
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had a similar CRN risk as patients with HPs (p=0.78). Of note, 6/72 patients with one SSL 
without dysplasia developed metachronous CRN (8.3%; 5 LGD and 1 advanced CRN) 
versus 2/17 patients who had an SSL without dysplasia more than once (11.8%; 2 LGD; 
p=0.65). Patients with a serrated polyp without dysplasia with synchronous LGD had a 
higher cumulative advanced CRN risk than those without synchronous LGD (p<0.001).
Figure 3. Kaplan-Meier plot illustrating the risk of metachronous colorectal neoplasia in IBD 
patients with serrated polyps or colitis associated LGD. Patients with synchronous advanced 
colorectal neoplasia at index colonoscopy were excluded from this analysis.
HP=hyperplastic polyp, SSL=sessile serrated lesion, TSA=traditional serrated adenoma, LG-
D=low-grade dysplasia, CRN=colorectal neoplasia
Cumulative risk of metachronous CRN in IBD patients with serrated polyps versus 
colitis associated LGD
We compared the metachronous CRN risk between IBD patients with serrated polyps 
and IBD patients with colitis-associated LGD without serrated polyps (n=47). The mean 
size of the colitis-associated LGD was 4.2 mm. Baseline characteristics of this control 
cohort are described in Supplementary Table 2 Patients with LGD were younger at 
IBD diagnosis, and had a lower mean inflammation score than patients with serrated 
polyps. Patients with a TSA or an SSL with dysplasia had a higher cumulative incidence of 
metachronous CRN compared with patients with colitis associated LGD (p<0.001, Figure 




had a lower cumulative incidence of metachronous CRN compared with patients with 
colitis associated LGD.
We did not observe a higher cumulative CRN risk in serrated polyps that developed 
within an area of (prior) inflammation (p=0.19), and similarly not after excluding HPs 
from the analysis (p=0.60).
Risk of advanced CRN in IBD patients with versus without serrated polyps
In the Cox-regression analysis with the presence of serrated polyps as a time-changing 
factor, serrated polyps with dysplasia (TSA and SSL) were associated with an increased 
subsequent advanced CRN risk (HR 13.51, 95% CI 3.11 – 58.68, p<0.001) compared 
with IBD patients without a serrated polyp. This association remained after correcting 
for the confounders gender, concomitant diagnosis of PSC, (history of) smoking, IBD 
type, family history of CRC and mean inflammation score (adjusted HR 6.02, 95% CI 
1.06-34.32). Specifically assessing patients with SSLs with dysplasia resulted in an HR 
of 7.96 (95% CI 1.45-43.62, p=0.017). In contrast, neither HPs (HR 1.98, 95% CI 0.46-
8.60, p=0.36) nor SSLs without dysplasia (HR 0.87, 95% CI 0.11-6.88, p-0.89) were 
associated with an increased risk of advanced CRN compared with IBD patients without 
a serrated polyp.
DISCUSSION
In this cohort study including 621 patients with colonic IBD undergoing CRC surveillance, 
we observed that TSAs and SSLs with dysplasia were associated with an increased risk 
of advanced CRN (HR 13.51) compared with IBD patients without a serrated polyp. 
By contrast, HPs and SSLs without dysplasia were not associated with an increased 
advanced CRN risk. UC, male gender, and older age were associated with the presence 
of serrated polyps.
We found an increased CRN and advanced CRN risk in patients with serrated polyps 
with dysplasia. This is in line with previous literature, although previous studies were 
performed before the latest classification system for serrated polyps was adopted.14 
One previous study (n=78 patients) reported a shorter advanced CRN-free survival 
time in IBD patients with an index SSL with dysplasia compared with serrated polyps 
without dysplasia (p=0.002).8 A recent study reported that 4/30 IBD patients with a 
TSA developed advanced CRN12, while another study including 25 IBD patients with 
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an SSL reported a high rate of synchronous CRN (36%) and metachronous CRN (8 of 
13 patients who had follow-up), although this study did not distinguish between SSLs 
with and without dysplasia.9 In contrast, a retrospective cohort including 115 patients 
(of whom 112 with an HP) reported a low metachronous CRN risk in IBD patients with 
HPs.11 In line, we observed that IBD patients with serrated polyps without dysplasia 
had no increased risk of advanced CRN, and a lower risk of metachronous CRN than 
patients with colitis-associated LGD.
We observed a higher CRN risk of serrated polyps with dysplasia than colitis-associated 
LGD, although this result may be biased by the higher mean inflammation score. 
Several studies conducted in the general population demonstrated that the CRC 
risk of serrated polyps is equally great or even greater than that of conventional 
adenomas.7, 20, 21 This high risk has been attributed to the fact that serrated polyps are 
easily missed or incompletely removed endoscopically because of their subtle and 
flat endoscopic appearance.
In our cohort, HPs were rarely located in the proximal (transverse or ascending) colon 
(9.6%), while SSLs were located more frequently in the proximal colon (32% SSL without 
dysplasia; 38% SSL with dysplasia). Likewise, a previous study in IBD patients reported 
that serrated polyps with dysplasia were proximally located in 20%.8 In contrast, in the 
general population 70-80% of all SSLs are detected in the proximal colon5, 9, although 
SSLs with dysplasia might be located more throughout the colon.22 We observed that 
serrated polyps with dysplasia (including TSAs and SSLs) were generally larger than 
serrated polyps without dysplasia, although this did not reach statistical significance 
(mean size 5.3 vs 3.5 mm, p=0.06). In line, previous studies reported that TSAs and SSLs 
are generally larger than HPs.23 24 25
Serrated polyps were detected more often in UC than in CD, which is in line with 
previous studies.8, 9 However, we found no association between colonic inflammation 
and the development of serrated polyps. Previous studies reported that molecular 
alterations of serrated polyps are similar between IBD and non-IBD patients and the 
impact of inflammation on serrated polyps remains unclear.8, 26 Furthermore, serrated 
polyps in IBD patients were found more often with increasing age, similar to the general 
population.5 In addition, we found male gender to be associated with the presence of 
serrated polyps. Although several other studies reported a higher risk in men as well, 




Our findings may impact current surveillance guidelines. Given the increased advanced 
CRN risk in IBD patients with serrated polyps with dysplasia, we propose an intensified 
surveillance strategy for these IBD patients similar to that of IBD patients with colitis 
associated LGD conform current European guidelines.2, 15 This would result in a 
yearly surveillance colonoscopy for five years following removal of a serrated polyp 
with dysplasia. The high risk of metachronous CRN in the same colonic segment that 
harbored the serrated polyp with dysplasia indicates that this colonic segment should 
be monitored closely. Since we did not identify serrated polyps without dysplasia 
as a risk factor for advanced CRN in IBD, we argue that these lesions should not 
impact surveillance intervals.
Our study has several strengths, including the rigorous collection of data, the 
histopathology review by expert pathologists according to the renewed [2019] WHO 
criteria, and the control group of IBD patients without serrated polyps. The setting of an 
IBD population undergoing CRC surveillance makes our cohort representative for clinical 
practice. However, there are also some limitations. It is known that serrated polyps 
may be difficult to detect, especially in the past before high-definition colonoscopes 
were used. This may have resulted in an underdiagnosis of serrated polyps. Moreover, 
although the mean interval between surveillance colonoscopies was similar between 
patients with and without serrated polyps, the individual differences in surveillance 
intervals may have resulted in different adenoma detection rates. Second, although we 
established the largest cohort of patients with serrated polyps to date, the relatively 
small proportion of index serrated polyps with dysplasia might have resulted in a lack of 
power to detect other significant differences such as the size of the dysplastic and non-
dysplastic serrated polyps. Third, since this cohort was established in a single-center 
retrospective setting, our results should be confirmed in future studies.
In conclusion, in a relatively large cohort of IBD patients undergoing surveillance, we 
observed that TSAs and SSLs with dysplasia are associated with an increased risk of 
advanced CRN while HPs and SSLs without dysplasia were not. These findings suggest 
that the detection of serrated polyps with dysplasia may warrant a similar surveillance 
strategy to that of IBD patients with colitis associated LGD.
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SUPPLEMENTARY TABLES
Supplementary Table 1. Factors associated with the presence of sessile serrated lesions and 
traditional serrated adenomas
IBD= Inflammatory bowel disease; PSC= Primary sclerosing cholangitis; CI= Confidence 
interval, OR= Odds ratio. CRC=colorectal cancer
* factors with a p-value <0.05
Baseline OR
Uni-variable




Ulcerative colitis 2.83 1.76-4.56 <0.001* 2.31 1.35-3.95 0.002*
Male 1.50 0.98-2.30 0.06 1.65 0.99-2.73 0.051
PSC 1.23 0.39-3.84 0.73 - - -
Age at IBD diagnosis 
(per year increase)
1.08 1.06-1.11 <0.001* 1.08 1.06-1.10 <0.001*
Mean inflammation 
score
1.16 0.73-1.84 0.54 - - -
Smoking 0.82 0.53-1.27 0.37 - - -
Family history of CRC 0.97 0.54-1.82 0.99 - - -
Supplementary Table 2. Characteristics of control group of IBD patients with colitis 
associated low-grade dysplasia.
IBD= Inflammatory bowel disease; LGD= Low-grade dysplasia
In bold factors with a p-value <0.05




to serrated polyp 
cohort)
Male, n (%) 26 (55.3%) 0.45
Disease
 Ulcerative colitis, n (%)








Age at IBD diagnosis in years (+ SD) 30.1 (13.5) <0.001
Follow-up after IBD diagnosis in years,
mean (+ SD)
29.3 (11.6) <0.001
Years between consecutive colonoscopies,
mean (+ SD)
2.1 (1.3) 0.41
Mean inflammation score (+ SD) 0.39 (0.37) 0.008




Supplementary Table 2. (continued)
















Age at LGD, mean (+SD) 53.4 (13.9) N/A
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Background and aims: Patients with inflammatory bowel disease (IBD) have an 
increased risk of colorectal cancer (CRC). We performed a systematic review and meta-
analysis to provide a comprehensive overview of all prognostic factors for advanced 
colorectal neoplasia (aCRN, high-grade dysplasia or CRC) in patients with IBD.
Methods: A systematic literature search was conducted according to the PRISMA 
guidelines. Odds ratios and hazard ratios were separately analyzed for different study 
designs using random-effect models. An additional analysis was performed including 
only studies with a low risk of bias according to the Quality in Prognostic Studies tool. 
The evidence for all prognostic factors was categorized as ‘weak’, ‘moderate’, or ‘strong’, 
based on the strength of the prognostic factor, the heterogeneity between studies, 
and the risk of bias.
Results: A total of 164 studies were included allowing pooled analysis of 31 potential 
prognostic factors. Among all putative risk factors, the evidence for extensive disease 
was classified as strong, while evidence for low-grade dysplasia, strictures, primary 
sclerosing cholangitis, post-inflammatory polyps, family history of CRC, and ulcerative 
colitis versus Crohn’s disease was considered moderate. Evidence for any dysplasia, 
colon segment resection, aneuploidy, male sex, age, and histologic inflammation was 
classified as weak. The evidence for the protective factors colonoscopic surveillance, 
5-ASA, thiopurines, and smoking was moderate.
Conclusion: In this systematic review and meta-analysis we identified 13 risk factors and 
5 protective factors for aCRN in IBD patients. These findings might lay the groundwork 
for an improved CRC risk stratification-based surveillance in IBD.
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INTRODUCTION
Patients with colonic inflammatory bowel disease (IBD) have a 1.7 fold increased risk 
of colorectal cancer (CRC).1 Therefore, international guidelines recommend enrollment 
of patients with ulcerative or Crohn’s colitis in surveillance programs to detect and 
remove dysplastic lesions before progression to advanced colorectal neoplasia 
(aCRN, high-grade dysplasia (HGD) and CRC) occurs.2-5 Indirect evidence indicates that 
endoscopic surveillance is effective in terms of a reduced CRC incidence and CRC-
associated mortality.6 However, the optimal surveillance strategy is presently unclear 
and guidelines vary considerably.
American guidelines recommend surveillance colonoscopies every 1-3 years, without 
stratifying the individual surveillance interval except for concomitant primary sclerosing 
cholangitis (PSC).4, 5 In contrast, European guidelines assign patients to a low, moderate, 
or high-risk category based on the presence of a number of clinical and histological 
risk factors2, 3 including concomitant PSC,7 a history of low-grade dysplasia (LGD),8 and 
extensive disease.9 However, most recommendations in current guidelines are based 
on studies of diverse quality.
To provide an up-to-date overview of literature that may guide risk stratification in 
future surveillance guidelines, we performed a systematic review and meta-analysis 
of all available studies regarding prognostic factors for aCRN in IBD.
METHODS
This study followed the Preferred Reporting Items for Systematic Reviews and 
Meta-analyses (PRISMA) reporting guideline and was registered on PROSPERO 
(CRD42019141345) prior to the literature search.10
Search strategy
A comprehensive literature search using broad search criteria was conducted in the 
PubMed and EMBASE databases (date: July 10th, 2019). In short, the search terms 
included all key terms for IBD in combination with all terms for (a)CRN and terms 
for location in the colon. There were no language restrictions. Animal studies were 




reference lists of included studies and previous meta-analyses on prognostic factors 
were screened for additional eligible articles.
Study selection
First, all titles and abstracts of identified studies were independently screened by two 
researchers (M.J. and A.W.) to exclude studies irrelevant for our aim. Discrepancies 
were resolved through a consensus discussion with the senior authors (F.H., M.L., B.O.). 
Case reports, conference abstracts, letters, and review articles were excluded. Next, 
we assessed the full-text of all potentially relevant studies for the following inclusion 
criteria: 1) cohort study or case-control study; 2) data on prognostic factors for aCRN 
in IBD (ulcerative colitis (UC), Crohn’s disease (CD) or IBD-unclassified), with at least 
one event of aCRN; 3) reporting an odds ratio (OR) or a hazard ratio (HR) (with a 95% 
confidence interval (CI)) or providing data (number of events and patients in exposed 
and non-exposed group) that allowed for calculation of an OR and its standard error. 
Studies that reported prognostic factors for LGD and aCRN combined in a composite 
outcome or that only enrolled patients who had undergone a proctocolectomy were 
excluded. If more than one article assessed the impact of the same prognostic factor 
in identical or overlapping cohorts, we included the study that particularly focused on 
this prognostic factor (if not applicable, the most recent study was selected).
Data extraction and quality assessment
The following data were collected from all eligible studies using an electronic data-entry 
sheet: first author, publication year, country, study design, inclusion and exclusion criteria, 
cohort size, duration of follow-up, IBD type, duration of IBD, number of patients with aCRN 
per prognostic factor, and univariable and multivariable estimates of effect (OR or HR). If 
relative risks (RR) were reported and additional data were provided we calculated the OR 
because only 6 studies reported a RR for our outcome. Adjusted estimates of effect were 
documented as multivariable results. Details of all included studies are provided in S2. The 
set of covariates that was adjusted for in each study is specified in S3. Data from all studies 
were extracted separately by M.J. and A.W. and discrepancies were resolved through 
discussion. The quality of included studies was assessed using the Quality In Prognosis 
Studies (QUIPS) tool (S4).11 The criteria of the QUIPS tool were expanded to enable grading of 
all included studies (S5). The overall quality of included studies was graded according to the 
methods previously described by Grooten et al.12 If all QUIPS domains were rated as low risk 
of bias (RoB), or if all domains were rated as low RoB with one scoring moderate RoB, studies 
were categorized as low RoB. Studies were graded as high RoB if one or more domains were 
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scored as high RoB or if ≥3 domains were scored as moderate RoB. Remaining studies were 
graded as moderate RoB. Domain five, ‘study confounding’, was not considered in grading 
the overall quality since few studies reported multivariable models.
Prognostic factors
All potential prognostic factors reported in literature were included without any pre-
selection. All prognostic factors that were reported in ≥1 study are discussed in the 
results section while related forest plots are shown in S6-S38. In addition, the factors 
endoscopic inflammation and p53 mutations were included since they were reported 
in several studies, even though pooled analysis was not possible. The remaining factors 
are reported in S39.
To assess extent of disease we included studies that provided data on patients with 
left-sided UC versus extensive disease (inflammation extending at least proximal of the 
splenic flexure). In CD, an estimated involvement of >50% of the colon was regarded 
as extensive disease. Studies not clearly defining disease extent were excluded.
To compare the risk of UC versus CD we only included studies that reported the 
risk of aCRN in IBD patients with colonic involvement. Studies were excluded if the 
provided data did not allow for calculation of the OR after exclusion of patients 
without colonic involvement.
The definitions of the other identified prognostic factors are specified in the 
supplementary files of each prognostic factor.
Statistical analysis
A random-effects model based was applied to pool the overall effect of a potential 
prognostic factor. We performed separate analyses to calculate the pooled univariable 
and multivariable ORs and HRs of potential prognostic factors. In addition, we 
performed secondary analyses by study design (cohort and case-control studies 
separately). The I2 statistic was used to assess the heterogeneity among studies. An 
I2 ≥ 50% indicates substantial to considerable heterogeneity.13 These analyses were 
provided in the supplementary files of the prognostic factor. Meta-analyses were 
performed using Review Manager, version 5.3 (Cochrane Collaboration, Copenhagen, 
Denmark). R statistical software, version 3.5.1 (Metafor package), was used to create 




plots were visually assessed for asymmetry and in addition the Eggers’ regression test 
was performed if ≥10 studies were included13. A p-value < .05 indicates substantial 
asymmetry of funnel plots and thereby implies publication bias.15
Good quality synthesis
A separate pooled analysis was performed with inclusion of only the studies that were 
regarded as ‘good quality studies’. Studies of good quality had to meet the following 
criteria: 1) the overall quality of study was graded as ‘low RoB’ using the QUIPS tool 
(excluding domain five ‘study confounding), 2) exclusively UC patients with at least left-
sided disease or CD patients with colonic involvement were included in the study.
Summary of all identified prognostic factors
The quality of evidence for all identified prognostic factors was graded separately for 
univariable analysis and multivariable analysis based on the following criteria:
• Strong evidence: OR/HR ≥2 (risk factor) or ≤0.50 (protective factor) and P-value < .05 
and heterogeneity ≤50% and ≥5 studies in pooled analysis and P-value < .05 in pooled 
good quality synthesis
• Moderate evidence: OR/HR ≥1.5 (risk factor) or ≤0.67 (protective factor) and P-value < 
.05 and ≥5 studies in pooled analysis
• Weak evidence: OR/HR >1 (risk factor) or <1 (protective factor) and P-value < .05 in 
pooled analysis
Prognostic factors were only included in the summary table if ≥2 studies were included 
in the pooled analysis. The pooled subgroup analysis (univariable HR or OR and 
multivariable OR or HR) including the largest number of studies was selected. If the 
number of included studies within both sub-analyses was equal, grading of the level of 
evidence was based on the sub-analysis with the lowest heterogeneity.
RESULTS
Search results
The initial search identified 10,674 unique articles from PubMed and Embase libraries. 
An additional 6 articles were identified through manual screening of references. A total 
of 10,291 articles were excluded after screening of titles and abstracts. After full-text 
screening of the remaining 393 articles, 164 articles remained eligible for inclusion. The 
main reasons for exclusion were: no evaluation of prognostic factors for aCRN (number 
(n) =76), not reporting the exact number of aCRN (n=38), and lack of a control group 
107
RIsk factors for advanced colorectal neoplasia: a systematic review and meta-analysis
(n=31). In addition, 12 studies were excluded based on overlapping cohorts. The flow 
diagram of the inclusion process is shown in figure 1.
Figure 1: Flow diagram of the selection process (derived from PRISMA)
N=number, OR=odds ratio, HR=hazard ratio.
Study characteristics and quality assessment
A total of 164 studies were included (121 cohort studies, 43 case-control studies). 
The characteristics of all included studies are shown in S2. A total of 83 studies were 
conducted in Europe, 44 in North America, 29 in Asia, 4 in Australia or New Zealand, 2 
in Africa and 2 in South America.
The overall quality of the included studies, as assessed using the QUIPS tool, was graded 
as ‘low RoB’ in 83 studies, ‘moderate RoB’ in 32 studies and ‘high RoB’ in 49 studies (S5).
Prognostic factors
Figure 2 and figure 3 depict the pooled results from the univariable and the multivariable 




Figure 2: Univariable (A) and multivariable (B) odds ratios of all potential prognostic factors
Prognostic factor (number of studies), right column: odds ratio (OR) and confidence interval 
(CI) from pooled analysis (pooled data if ≥2 studies included in analysis).
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Figure 3: Univariable (A) and multivariable (B) hazard ratios of all potential prognostic factors
Prognostic factor (number of studies), right column: hazard ratio (HR) and confidence interval 






The pooled univariable OR comparing extensive UC with left-sided UC was 2.42 (95%CI 
2.00-2.92, I2=0%), based on 41 studies. The pooled HR from 3 studies in UC was 3.48 
(95%CI 1.58-7.65, I²=2%). No study assessed the risk of >50% colonic involvement in 
patients with CD, but in one study, extensive CD, defined as involvement of >2/3rd of 
the colon was not associated with a higher risk as compared to partial CD, defined as 
involvement of less than 1/3rd of the colon (calculated OR 0.35, 95%CI 0.01-11.08).16 All 
forest plots are shown in S6A-F.
IBD type
The pooled univariable OR from 7 cohort studies comparing UC versus CD (ileocolonic or 
colonic disease) was 1.50 (95%CI 1.09-2.06, I²=11%). No difference in aCRN risk between 
UC versus CD was found if UC patients who only had proctitis were included in the 
analysis (OR 1.14 (95%CI 0.79-1.64, I²=26%) (S7A-E).
History of LGD
All analyses showed an increased risk of aCRN in IBD patients with a history of LGD 
(S8A-D). The pooled univariable OR from 8 studies was 10.85 (95%CI 5.13-22.97, I²=69%). 
Although all studies reported an increased risk, the magnitude of this risk ranged widely 
with ORs varying from 1.25 to 86.0. The multivariable HR of 4 studies was 3.67 (95%CI 
2.23-6.06, I²=17%).
History of indefinite for dysplasia
Four studies reported on the risk of aCRN in patients with a history of indefinite for 
dysplasia (IND) lesions (S9A-C). The pooled univariable OR from 3 studies did not show 
a significantly increased risk (OR 2.42, 95%CI 0.75-7.81, I2=52%), but one cohort study 
with a multivariable model found a HR of 6.85 (95%CI 1.78-26.36).17
Any dysplasia (not specified)
Four studies assessed the impact of any dysplasia (not further specified) on the risk of 
aCRN (S10A-D). Pooled univariable data of 2 cohort studies resulted in an OR of 10.70 
(95%CI 4.60-24.87, I²=28%).
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Post-inflammatory polyps
The aCRN risk in patients with post-inflammatory polyps (PIPs) was reported in 8 studies 
(S11A-D). The pooled univariable OR indicated that patients with PIPs were at higher risk 
(OR 3.29, 95%CI 2.41-4.48, I²=0%) but this association was not confirmed in the pooled 
HR analyses (univariable HR 1.67, 95%CI 0.99-2.82, I²=0%; multivariable HR 1.73, 95%CI 
0.88-3.40, I²=56%).
Endoscopic inflammation
Two studies evaluated the association of endoscopic inflammation with aCRN (S12A-
D). One large cohort study reported a univariable HR of 2.14 (95%CI 1.48-3.09) and a 
multivariable HR of 2.39 (95%CI 1.63-3.50).7 One case-control study calculated the mean 
score of endoscopic inflammation and found a higher risk of aCRN in patients with a 
higher score (OR 2.62, 95%CI 0.84-8.17 per 1-unit increase in score), although this did 
not reach statistical significance.18
Histologic inflammation
Six studies assessed the impact of histologic inflammation on aCRN using different 
definitions (described in S13D). Three case-control studies provided data for calculation 
of a pooled univariable OR (1.98, 95%CI 0.68-5.73, I²=40%). The pooled multivariable 
HR of 2 cohort studies and one case-control study was 2.51 (95%CI 1.75-3.61, I²=0%) 
(S13A-D).
Strictures
Four studies were identified in which the impact of colonic strictures on development 
of aCRN was evaluated. One of these studies provided data for analyzing UC and CD 
separately (UC: univariable OR 12.74, 95%CI 5.81-27.94; CD: univariable OR 4.14, 95%CI 
1.49-11.51).19 Pooled analysis of all data on strictures in UC patients resulted in a pooled 
OR of 4.68 (95%CI 0.45-48.25, I²=77%). Combining all data on strictures in CD patients 
resulted in a pooled OR of 8.03 (95%CI 3.50-18.45, I²=30%). The pooled univariable 
analysis combining data from CD and UC patients resulted in an OR of 7.78 (95%CI 
3.74-16.18, I²=46%, shown in figure 2). One study provided data on strictures and risk of 
CRC in IBD patients in a multivariable model (OR 8.42, 95%CI 3.85-18.42) (S14A-C).19
Perianal disease
Five studies provided risk estimates of rectal aCRN in patients with perianal disease 




data was 2.57 (95%CI 0.92-7.15, I²=64%) (S15A-B). The multivariable OR based on one 
study was 3.86 (95%CI 1.87-7.97).24
Disease duration
Four studies evaluated the association of disease duration on the development of 
aCRN in predefined groups using different definitions (S16A-B). Both univariable and 
multivariable pooled analyses did not show a statistically significant difference.
Aneuploidy
Five studies evaluated the potential of DNA aneuploidy as a premalignant marker 
(S17A-C). The pooled univariable OR of 4 studies was 5.17 (95%CI 2.28-11.71, I²=0%). 
Multivariable analysis showed a HR of 4.30 (95%CI 2.50-7.40) in one case-control 
study.25
P53 mutation
Two studies examined whether p53 mutations can serve as biomarkers for development 
of aCRN (S18A-C). In a cohort of 95 patients with longstanding UC, p53 mutations 
were not predictive for aCRN (OR 2.47, 95%CI 0.72-8.48).26 In a case-control study, the 
presence of p53 mutations in random surveillance biopsies was not associated with the 
development of CRC (multivariable HR of 1.70, 95%CI 0.93-3.10).25
Baseline characteristics
Primary sclerosing cholangitis
A concomitant diagnosis of PSC in IBD patients was associated with an increased aCRN 
risk, with a pooled univariable OR of 4.12 (95%CI 2.85-5.96, I²=58%) based on 34 studies. 
There was substantial heterogeneity due to the wide range in ORs, yet almost all studies 
showed (a trend towards) an increased risk. The multivariable HR of 4 studies was 
2.77 (95%CI 1.76-4.38, I²=0%) (S19A-D). Almost all separate analyses per study type 
demonstrated an increased risk in IBD patients with PSC (S19A-D).
Sex
Pooled results from 60 studies showed that the aCRN risk was higher in male patients 
(OR 1.27, 95%CI 1.12-1.44, I² 30%). Male sex remained a significant risk factor for aCRN 
in the pooled multivariable HR and OR analyses (S20A-D).
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Age
Age as a risk factor for aCRN was evaluated in 8 studies, using different definitions 
(S21A-D). Four studies used the definition ‘age per year increase’ resulting in a pooled 
univariable HR of 1.031 per year (95%CI 1.017-1.046, I²=71%). Three studies provided 
multivariable data, yielding a pooled multivariable HR of 1.036 per year (95%CI 1.012-
1.061, I²=51%).
Family history of colorectal carcinoma
Data from 15 studies showed that a positive family history of CRC was associated with 
a higher aCRN risk (OR 2.62, 95%CI 1.93-3.57, I²=0%) (S22A-E). Six studies restricted 
family history of CRC to first-degree relatives (pooled OR 2.48, 95%CI 1.49-4.14, I²=0%). 
Combination of the remaining 9 studies using different definitions (‘any relative’, 
‘second-degree relative’) or not providing one, resulted in a pooled OR of 2.59 (95%CI 
1.59-4.21, I²=19%).
Family history of IBD
Four studies evaluating the impact of a positive family history of IBD on the aCRN 
risk did not report a significant association (univariable OR 1.13, 95%CI 0.53-2.39, 
I²=0%, S23A).
Smoking
Patients with a history of smoking had a lower risk of developing aCRN in univariable, 
but not in multivariable analysis. The pooled univariable OR in 14 studies was 0.66 
(95%CI 0.49-0.88, I2=28%). All studies but two27, 28 included only UC patients. The pooled 
multivariable OR of 3 studies was 1.27 (95%CI 0.75-2.13, I²=70%), based on one study 
providing data from a UC cohort29 and 2 studies from IBD cohorts (S24A-C).
Appendectomy
Seven studies evaluated the impact of appendectomy on the aCRN risk (S25A-B). The 
pooled univariable OR was 1.57 (95%CI 0.72-3.41, I2=34%). All data were derived from 
UC cohorts except for one study consisting of a CD cohort.27 One study reporting a 
multivariable OR did show a higher risk of aCRN in patients with an appendectomy 




Age at IBD diagnosis
Studies that compared the impact of young versus old age at IBD diagnosis (n=12) on 
aCRN development used a wide range of cut-off ages, ranging from 25 to 60 years 
(S26A-G). Therefore, only a few studies could be pooled. The pooled univariable OR 
from 3 cohort studies comparing age <30 years versus ≥30 years was 1.00 (95%CI 0.59-
1.70, I²=0%). The pooled univariable HR of 2 studies was 1.69 (95%CI 0.83-3.45, I²=0%), 
while data from 2 studies in a multivariable model reported a pooled HR of 0.76 (95%CI 
0.23-2.55, I²=71%).
Colon segment resection
Four studies evaluated the impact of colon segment resection on the development of 
aCRN. Three of these studies did not specify the indication for resection (S14D). The 
pooled univariable HR of 2 cohort studies (one study including IBD patients and one 
study including UC and IBD-U patients) showed an increased risk of aCRN in patients 
with a history of a colon segment resection 6.46 (95%CI 1.32-31.61, I²=51%). In contrast, 
one case-control study in CD patients did not find an association (univariable OR 0.63, 
95%CI 0.16-2.48).31 The pooled multivariable analysis of two studies including IBD 
patients did not find an association as well (HR 0.81, 95%CI 0.06-10.71, I²=77%). One of 
these studies, in which patients were excluded who received colon segment resection 
because of a diagnosis of neoplasia, reported a lower risk of aCRN (HR 0.25, 95%CI 
0.07-0.89) (S27A-D).32
Surveillance colonoscopies
The definition of ‘surveillance colonoscopies’ varied widely between studies. Pooling 
of studies in which overlapping definitions were used (as specified in S28E and S28F) 
yielded a lower risk of aCRN in patients enrolled in surveillance programs (univariable 
OR 0.39 (95%CI 0.23-0.66, I²=64%); multivariable OR 0.43 (95%CI 0.26-0.70, I²=43%)). 
However, in the pooled univariable and multivariable HR analyses no significant 
association between surveillance colonoscopies and aCRN was found, both analyses 
with considerable heterogeneity between studies.
Race
Three studies evaluated the role of race as a risk factor for aCRN (S29A-D). No differences 
were found in studies comparing Caucasian race versus ‘other race’ or ‘African-American 
race’ in all sub-analyses (univariable OR of two studies 1.11, 95%CI 0.85-1.45, I²=0%).
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Medication
Thiopurines
Thiopurine use was associated with a lower aCRN risk (pooled univariable OR 0.55, 95%CI 
0.37-0.82, I²=66%). This pooled analysis included 19 studies. The pooled univariable HR 
from 5 studies was 0.55 (95%CI 0.33-0.90, I²=25%). In contrast, the pooled multivariable 
OR and HR did not show a statistically significant protective effect (S30A-E).
5-Aminosalicylic acid
Patients who ever received 5-Aminosalicylic acid (5-ASA) had a lower risk of aCRN, 
with a pooled univariable OR of 0.53 (95%CI 0.39-0.72, I²=67%). Six studies that 
provided multivariable ORs showed a lower risk as well (pooled OR 0.51, 95%CI 
0.39-0.66, I²=0%) (S31A-E).
Tumor necrosis factor (TNF)-alpha inhibitors
Six studies evaluated the use of TNF-alpha inhibitors in relation to aCRN. Our pooled 
univariable analysis of 4 studies did not show a protective effect (OR 0.71, 95%CI 0.14-3.67, 
I²=86%). One cohort study did not report a protective effect of anti-TNF in a multivariable 
model (OR 1.01, 95%CI 0.62-1.65).33 One case-control study showed a protective effect 
of anti-TNF in a multivariable hazard model (HR 0.22, 95%CI 0.10-0.50) (S32A-E).34
Non-Steroidal Anti-Inflammatory Drugs
No significant effect of the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on 
aCRN risk was found in 3 case-control studies. The pooled OR was 0.70 (95%CI 0.22-2.22, 
I²=90%) (S33A-C). In contrast, the only study reporting on NSAID use in a multivariable 
model did report a lower risk (OR 0.10, 95%CI 0.03-0.33).35
Folic acid
Of 9 studies reporting on the effect of folic acid use, only one found a significant 
protective effect (S34A-D).36 The pooled univariable OR of 6 studies was 0.86 (95%CI 
0.57-1.29, I²=0%). The pooled multivariable HR from 2 cohort studies was 0.44 (95%CI 
0.02-7.93, I²=92%).
Corticosteroids
The impact of corticosteroids on the risk of aCRN was studied in 10 studies. The 





Figure 4: Univariable odds ratio good quality synthesis
Prognostic factor (number of studies), right column: odds ratio (OR) and confidence interval 
(CI) from pooled analysis (pooled data if ≥2 studies included in analysis).
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Figure 5: Univariable (A) and multivariable (B) hazard ratios good quality synthesis
Prognostic factor (number of studies), right column: hazard ratio (HR) and confidence interval 





One cohort study found no lower risk in patients who used statins in a univariable 
model (HR 1.09, 95%CI 0.25-4.74).37 In contrast, the pooled multivariable OR from 2 
studies was 0.39 (95%CI 0.22-0.70, I²=6%, S36A-E).
Calcium supplements
Use of calcium supplements was associated with a non-significant decreased risk of 
aCRN in 2 studies (OR 0.43, 95%CI 0.18-1.02, I²=61%) (S37A-D).
Acetylsalicylic acid
There was no association between the use of acetylsalicylic acid and aCRN. The pooled 
univariable OR from 3 studies was 0.62 (95%CI 0.15-2.59, I²=82%). A multivariable 
analysis suggested a protective effect of acetylsalicylic acid in one other study (OR 
0.30, 95%CI 0.10-0.90) (S38A-C).29
Other factors
Potential prognostic factors reported in only one study are shown in S39A-L.
Good quality synthesis
Forty studies fulfilled the criteria for ‘good quality’ using the previously defined terms. 
The results of (pooled) analysis of these studies are shown in figure 4 and 5. Extensive 
disease, LGD, UC (versus CD), aneuploidy, PSC and male sex remained risk factors for 
aCRN in this analysis. Thiopurine use remained a protective factor for aCRN (S40A-F).
Summary
Figure 6 summarizes the quality of evidence of the identified prognostic factors, 
categorized as ‘strong’, ‘moderate’ or ‘weak’.
Publication bias
The Eggers’ regression test did not show statistically significant funnel plot asymmetry 
for any prognostic factor (S41). However, visual inspection of funnel plots suggests 
asymmetry and thus potential publication bias for male sex, family history of CRC, 
5-ASA and thiopurine use (S42).
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Figure 6: Summary of all identified risk and protective factors for aCRN
• Prognostic factors were included in the summary table if pooled analysis was possible ( ≥2 
studies in pooled analysis)
• Categorization based on the sub-analysis (OR or HR) including most studies, if equal, the 
sub-analysis with the lowest heterogeneity was selected.
• Level of evidence:
• Strong evidence: OR/HR ≥2 (risk factor) or ≤0.50 (protective factor) and P-value < .05 & 
heterogeneity ≤50% and ≥5 studies in pooled analysis and P-value < .05 in pooled good 
quality synthesis
• Moderate evidence: OR/HR ≥1.5 (risk factor) or ≤0.67 (protective factor) and P-value < 
.05 and ≥5 studies in pooled analysis
• Weak evidence: OR/HR >1 (risk factor) or <1 (protective factor) and P-value < .05 in 
pooled analysis
*: significant prognostic factor in good quality synthesis.
#: equal number of studies and heterogeneity, estimate of effect is based on the smallest CI.
DISCUSSION
Main findings
This is the first systematic review and meta-analysis of all factors that potentially impact 
the risk of aCRN in IBD patients. Based on 164 studies we identified 31 prognostic 
factors for which pooled analysis was possible. Using stringent criteria to summarize 
the level of evidence for all identified prognostic factors (figure 6), there was strong 
evidence for the risk factor extensive disease; moderate evidence for LGD, strictures, 
PSC, PIPs, family history CRC, IBD type; and weak evidence for any dysplasia, colon 




analysis, PSC was the only identified risk factor with moderate evidence. Protective 
factors with moderate evidence in univariable analysis were surveillance colonoscopies, 
5-ASA, thiopurines, and smoking. In multivariable analysis there was moderate evidence 
for use of 5-ASA as a protective factor.
Summary of identified risk factors for aCRN
Several established pre-malignant markers were identified as risk factors for aCRN, 
including LGD, any dysplasia, and aneuploidy. IBD patients with LGD had an increased 
risk in both univariable and multivariable analyses, although the magnitude of the 
impact of LGD varied widely between studies (I² 69%). The latter can at least partially 
be ascribed to inter-observer variability between pathologists38, 39, the heterogeneous 
morphology of the lesions, differences in quality of endoscopic visualization techniques, 
and treatment variation (e.g. biopsy, polypectomy, or surgery). Of note, the inter-
observer variance might even be greater for IND.38 Aneuploidy seems to be a promising 
predictor of aCRN as well (pooled univariable OR of four studies 5.17, 95%CI 2.28-11.71). 
These results are in line with a previous meta-analysis that reported a high risk of 
CRC in patients with aneuploidy,40 although this meta-analysis included patients with 
aneuploidy who already had developed dysplasia. The impact of p53 mutations was only 
assessed in a few studies and did not reach statistical significance in pooled analyses. 
The increased aCRN risk in IBD patients with premalignant lesions has been attributed 
to the concept of ‘field cancerization’. This concept implies that clonal molecular 
abnormalities in otherwise histologically normal-appearing mucosa throughout the 
colon causes colitis-associated cancer susceptibility.41, 42 Identification of these pre-
neoplastic fields seems a promising and rational approach for surveillance of patients 
with long-standing colitis.
Although we identified colon segment resection as a risk factor for aCRN, the true 
impact of this factor remains uncertain. It is conceivable that segment resection was 
indicated for neoplastic lesions or therapy-refractory disease, which might have led to 
divergent effects on the risk of aCRN. Since most studies did not specify the indication 
for surgery a clear answer whether resection protects against aCRN or is associated 
with a higher risk cannot be provided.
Several (surrogate) markers for chronic inflammation were found to be robust predictors 
of aCRN, ranging from histological inflammation scores to disease extent, strictures, 
and possibly the presence of PIPs. Since studies reported different estimates of effects 
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on endoscopic inflammation scores, a pooled analysis was not possible, although all 
studies showed promising results. Notable is the fact that one cohort study reported 
endoscopic inflammation scored during surveillance colonoscopies to remain a risk 
factor for aCRN in a multivariable model (HR 2.39, 95%CI 1.63-3.50).7 To our knowledge, 
no previous meta-analysis evaluated these markers for inflammation as risk factors for 
aCRN. The observed negative association of thiopurine use, 5-ASA-use, and smoking 
(in UC) with aCRN probably results from their anti-inflammatory effects. The protective 
effect of treatment with 5-ASA and thiopurines might be confounded by patient profile 
or additional excipients, therefore the protective effect should not just be interpreted 
as a causal effect. Current guidelines use surrogate markers for inflammation such as 
PIPs and strictures to stratify patients in risk categories.2-5 It has been hypothesized that 
cumulative inflammatory burden scores are more direct and reliable predictors for the 
risk of (a)CRN. Indeed, recent studies support this concept,43-45 although it is currently 
not clear how to construct the optimal cumulative inflammatory burden score. It can be 
questioned whether surrogate markers for inflammation should still be used to stratify 
patients. For example, we observed that PIPs were not an independent risk factor for 
aCRN risk if outcomes were adjusted for the mean inflammation score.46, 47
A concomitant diagnosis of PSC is an established risk factor for aCRN (univariable OR 
4.12, 95%CI 2.85-5.96; multivariable OR 3.53, 95%CI 1.83-6.79). This increased risk is 
in line with the result of a previous meta-analysis that reported a pooled univariable 
OR for CRC of 3.41 (95%CI 2.13-5.48).48 In our study, several relevant new studies were 
included and aCRN, instead of CRC only, was used as an outcome parameter. The 
mechanisms underlying the increased risk of CRC in IBD patients with PSC have yet to 
be clarified. Several studies suggested a role for the altered colonic bile composition in 
PSC, but intestinal dysbiosis49 or a distinct genotype might also play a role.50
Genetic predisposition contributes importantly to CRC development in the general 
population51, but its role in IBD is less well-defined. We observed an increased risk of 
aCRN in IBD patients with a family history of CRC (OR 2.62 (95%CI 1.93-3.57) based on 15 
studies. No other meta-analysis is available for comparison. The increased risk in male 
patients (OR 1.27, 95%CI 1.12-1.44, 60 studies) is in line with the male preponderance of 
CRC in the general population. In the general population, the cause of this increased risk 
is believed to be multifactorial.52 We identified increasing age as a risk factor for aCRN 
in IBD patients, which is in line with data from the general population53. The remaining 





Our study has several strengths. This meta-analysis was performed in accordance 
with the PRISMA guidelines for systematic reviews and meta-analysis.10 An important 
contribution of this study is that we attempted to determine the level of evidence for all 
prognostic factors and to quantify the magnitude of impact of all published prognostic 
factors. The use of broad search terms and the lack of restrictions on country of origin 
ensured the identification of all prognostic factors for aCRN in IBD. We also included 
studies that did not report effect estimates but provided sufficient data to calculate the 
ORs. Moreover, the scale of our endeavor enabled us to perform subgroup analyses 
based on study design (case-control or cohort study) and type of outcome (univariable/
multivariable and OR/HR). Last, we performed a separate synthesis, including only 
those studies that fulfilled criteria of good quality.
Our study has several limitations worth noting. First, considerable heterogeneity 
between studies for several risk factors was found, possibly due to regional differences 
and changes over time with respect to screening and therapeutic strategies. By 
performing subgroup analyses per estimate of effect and per study design we aimed 
to reduce heterogeneity caused by methodology. Moreover, multivariable data on 
prognostic factors was derived from studies using different techniques of model 
building and taking into account a varying set of covariates (specified in S45). Second, 
the majority of included studies had a retrospective study design, introducing inherent 
biases such as selection, missing data, and lack of predefined endpoints. Of note, 
prospective studies are often not performed in this field, given the large number 
of patients and the long-term follow-up that is needed. Third, some of the included 
studies assessed the aCRN risk in patients with only proctitis (UC) or ileal disease (CD), 
which must have influenced the effect sizes of the prognostic factors. To overcome 
this problem we adjusted the study selection criteria for the analysis of disease extent 
and IBD type as a risk factor, and additional selection criteria were applied for the 
good quality synthesis.
The findings of this comprehensive study can be used for the development of an 
improved colitis-associated CRC risk stratification model. We feel that a reliable and 
easy-to-use model should be based on a combination of clinical or endoscopic risk 
factors accounting for the number of risk factors present and the associated effect size 
of these factors, rather than the presence of just one risk factor. The addition of (a set 
of) biomarkers can be expected to considerably improve the predictive power of a new 
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model. We identified several biomarkers for which the evidence is still incomplete, such 
as IND, aneuploidy, and p53 mutations. Future studies should clarify the impact of these 
factors. In addition, whereas univariable data are abundant, there is a lack of evidence 
on prognostic factors for aCRN from multivariable models (only 37 of the 164 included 
studies reported multivariable data). This demonstrates the need for large surveillance 
cohorts with long-term follow-up that correct for important confounders.
Conclusion
In this systematic review and meta-analysis we provided more precise risk estimates 
of all known prognostic factors for aCRN in IBD patients. In summary, there was strong 
evidence for extensive disease; moderate evidence for LGD, strictures, PSC, PIPs, family 
history of CRC, and UC (versus CD); and weak evidence for any dysplasia, colon segment 
resection, aneuploidy, male sex, age (per year increase), and histologic inflammation. 
Protective factors with moderate evidence included surveillance colonoscopies, 5-ASA, 
thiopurines, smoking and weak evidence for statin use. These findings may aid in the 
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Approximately 30% of ulcerative colitis patients require a colectomy during their disease 
course. This substantially reduces colorectal cancer risk, although it is still possible to 
develop colorectal neoplasia in the remaining rectum. Although clear and well-accepted 
surveillance guidelines exist for inflammatory bowel disease patients with an intact 
colon, specific surveillance recommendations following colectomy are less clear.
Here, we aim to summarize the prevalence, incidence and risk factors for developing 
colorectal cancer in inflammatory bowel disease patients who underwent subtotal 
colectomy with a permanent end ileostomy and rectal stump, or with ileorectal 
anastomosis. Subsequently, gained insights are integrated into a proposed endoscopic 
surveillance strategy of the residual rectum.
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Surveillance for rectal CRC after subtotal colectomy
CLINICAL VIGNETTES
Case 1
A 10 year-old boy was diagnosed with ulcerative pancolitis in 1976. The disease remained 
well-controlled for 12 years with intermittent use of sulfasalazine. In 1988 and 1994 
he was hospitalized due to exacerbations necessitating treatment with intravenous 
corticosteroids. Since then he continued treatment with 5-aminosalicylic acids (5-
ASA). Following an IBD duration of 25 years, at the age of 35, the patient developed 
colorectal cancer (CRC) at the hepatic flexure with lymph node metastasis (pT3 pN2). 
At his own request, he underwent right hemicolectomy and subsequently received 
adjuvant 5-fluorouracil / leucovorin chemotherapy. Two years later, in 2003, carcinoma 
in situ was diagnosed in the remaining colon resulting in an additional subtotal 
colectomy and construction of an ileorectal anastomosis (IRA). Other than diabetes 
mellitus type 1, the patient did not have any co-morbidities. The CRC family history 
revealed an uncle and aunt with CRC at the age of 63 and 42 years, respectively. Genetic 
counseling did not reveal a hereditary CRC syndrome. What rectal surveillance strategy 
should be recommended?
Case 2
A 32-year old patient was diagnosed with left-sided ulcerative colitis in 1999. His disease 
progressed in 2000 to a fulminant pancolitis and treatment consisted of topical and 
systemic 5-ASA with high dose corticosteroids. Despite optimal medical treatment in 
the pre-anti-TNF era, severe inflammation persisted and a rectal stricture developed 
resulting in a subtotal colectomy in 2003 with construction of an end ileostomy 
and remaining rectal stump. The resection specimen revealed a severe ulcerative 
pancolitis without features that indicate a diagnosis of Crohn’s disease, and without 
dysplastic lesions. Post-operatively, the disease course was complicated by a rectal 
abscess requiring surgical incision and drainage. The patient developed no other 
complications and except steroid-induced diabetes, co-morbidities were absent. In 






Patients with inflammatory bowel disease (IBD) who underwent colectomy have 
a substantially reduced risk to develop colorectal cancer (CRC) in the remaining 
bowel. Consequently, endoscopic surveillance guidelines recommend a different 
surveillance strategy post-colectomy compared with IBD patients with an intact colon. 
These recommendations are tailored towards IBD patients with an ileal pouch-anal 
anastomosis (IPAA), but the majority of IBD patients who undergo colectomy never 
receive IPAA construction and continue with a permanent end ileostomy and rectal 
stump or alternatively, with an ileorectal anastomosis (IRA).
All current international surveillance guidelines lack a specific surveillance strategy for 
IBD patients with a residual rectum after colectomy (Table 1) [1-4]. Irrespective of the 
surgical procedure, the British surveillance guidelines (BSG) distinguish low (no high 
risk factors) and high risk groups (primary sclerosing cholangitis (PSC), prior colorectal 
neoplasia, atrophic mucosa) following colectomy, and recommend surveillance intervals 
of 5 and 1 year, respectively [3]. Nevertheless, CRC risk significantly differs between 
IBD patients with IPAA and those with a rectal stump or IRA [5, 6]. Guidelines of the 
American Gastroenterology Association (AGA), American Society for Gastrointestinal 
Endoscopy (ASGE), and European Crohn’s and Colitis Organisation (ECCO) do not 
incorporate specific post-colectomy surveillance recommendations for IBD patients 
with a residual rectum [1, 2, 4].
Lack of clear and consistent guidelines for rectal surveillance after colectomy in patients 
with IBD may result in a wide variation in clinical practice. A surveillance interval that 
is too short may result in an unnecessary burden for patients, whereas a surveillance 
frequency that is too low may lead to delayed detection of dysplasia or even CRC. 
Therefore careful interpretation of the recently updated evidence for surveillance of 
the rectal stump and IRA is needed. Here, we aim to discuss and interpret the available 
evidence regarding endoscopic surveillance of the residual rectum in IBD patients who 
underwent colectomy with a permanent end ileostomy and rectal stump or with IRA. 
Subsequently, we suggest an evidence-based surveillance approach for this category 
of IBD patients.
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Table 1. Overview of surveillance guidelines for IBD patients with a residual rectum 







AGA 2010 n/a n/a → No recommendations
BSG 2010 Yes • High risk:
• Previous rectal dysplasia
• Dysplasia/cancer at the 
time of pouch surgery
• Primary sclerosing 
cholangitis
• Type C pouch mucosa*
• Low risk:
• Absence of high risk factors
→ Yearly
→ 5-Yearly
ASGE 2015 n/a n/a → No recommendations
ECCO 2015 n/a n/a → No recommendations
AGA, American Gastroenterology Association; BSG, British Society of Gastroenterology; 
ASGE, American Society for Gastrointestinal Endoscopy; ECCO, European Crohn’s and Colitis 
Organisation
* Type C pouch mucosa is defined as mucosa exhibiting permanent persistent atrophy and 
severe inflammation
COLORECTAL CANCER RISK AFTER ILEORECTAL  
ANASTOMOSIS
Prevalence and incidence
A meta-analysis, incorporating 2762 IBD patients with IRA, estimated a pooled rectal 
carcinoma prevalence of 2.4% during a variable follow up between 1 and 35 years [5]. 
However, this prevalence might be slightly overestimated since mainly single center 
studies rather than population-based cohorts were available for inclusion. Indeed, a more 
recently published population-based Swedish cohort study reported a rectal carcinoma 
prevalence of 1.8% (20/1112 patients) after a mean follow up of 8.6 years [7].
The cumulative rectal carcinoma incidence in this latter population-based cohort study 
was 1.6% at 10 years and 5.6% at 20 years follow up after IRA [7]. This equals the CRC 
life time incidence of approximately 5% in the general population [8]. Slightly higher 
cumulative rectal carcinoma incidences were reported in hospital-based studies. As 
such, cumulative rectal carcinoma incidences of 1.4%, 3.2% and 7.3% after 5, 10 and 




from 13 French centers [9, 10]. Another single center study including 86 IBD patients 
with IRA showed a cumulative rectal carcinoma incidence of 0%, 2%, 5% and 14% after 
5, 10, 15 and 20 years, respectively [11].
Risk factors
The major determinant for rectal carcinoma development in IBD patients following 
IRA is a prior history of CRC. Based on 3 studies, one meta-analysis reported a pooled 
odds ratio of 12.8 favoring prior CRC as risk factor to develop rectal carcinoma [5]. In 
line, a recent multicenter study showed prior CRC as an independent risk factor for 
rectal carcinoma development with a hazard ratio of 5.9 [9]. Those with prior CRC had a 
cumulative rectal carcinoma incidence of 50.5% (95% confidence interval 3.5% - 86.9%) 
after 10 years compared with 2.1% (95% confidence interval 0.8% - 4.6%) in the group 
without prior colorectal neoplasia. Although prior colonic dysplasia was not identified as 
an independent risk factor (hazard ratio 0.6), the cumulative rectal carcinoma incidence 
was 25% (95% confidence interval 0.4% - 57.4%) after 10 years in this patient group [9]. 
This might be in part the result of small patient groups and large confident intervals.
PSC also predisposes for rectal carcinoma development after colectomy and IRA 
construction, with reported hazard ratios of 6.1 and 8.2 [7, 9]. In addition, longer IBD 
duration may increase rectal carcinoma risk as well [5, 7, 9]. In the literature none of 
the rectal carcinomas developed before 9.7 years of IBD duration [5, 9]. Higher rectal 
carcinoma incidences were reported in patients with longer IBD duration; 1 in 185 
patient-years between 10 and 20 years of IBD duration and 1 in 117 patient-years in 
patients with IBD history of more than 20 years [12]. Moreover, in a multicenter cohort 
study, every 10-year increase in IBD duration at the time of IRA resulted in a 1.6-fold 
increase in risk to develop rectal carcinoma [9]. Finally, a meta-analysis reported 
an increased CRC risk with an odds ratio of 10.3 in IRA patients with a diagnosis of 
ulcerative colitis rather than Crohn’s disease [5].
COLORECTAL CANCER RISK IN THE RECTAL STUMP
Prevalence and incidence
A recent population-based cohort study including 4358 IBD patients with ileostomy and 
a rectal stump reported a rectal carcinoma prevalence of 0.6% during a mean follow up 
of 5.7 years [7]. The cumulative risk to develop rectal carcinoma was 0.5% at 10 years 
and 2.2% at 20 years after colectomy. By contrast, one meta-analysis (1011 patients) 
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estimated a pooled rectal carcinoma prevalence of 2.1% in a variable duration of follow 
up between 0.25 and 40 years [5]. The higher reported prevalence might be explained 
by selection bias as mainly single center studies were included in the meta-analysis.
Risk factors
Similar to IBD patients with IRA or IPAA, prior colorectal neoplasia is the main risk 
factor for rectal carcinoma development in patients with ileostomy and rectal stump. 
A population based study (4358 patients) showed a hazard ratio of 3.7 for patients with 
a history of “severe” colorectal dysplasia or carcinoma to develop rectal carcinoma 
[7]. In addition, PSC and IBD duration emerged as risk factors in a case control study 
comparing 12 rectal stump carcinomas and 18 IBD control patients without rectal stump 
neoplasia [13]. The study design of this latter study was not sufficient to identify a 
history of colorectal neoplasia as risk factor because these patients were excluded 
from the control group.
SURVEILLANCE STRATEGY
Current guidelines lack specific surveillance recommendations tailored to IBD patients 
who underwent colectomy and IRA or construction of an end ileostomy with rectal 
stump. Indeed, direct evidence evaluating endoscopic surveillance of a residual 
rectum in a prospective manner is not available. As such, studies assessing prevalence 
and risk factors for CRC development in the residual rectum may assist surveillance 
recommendations. However, most of these studies were of low quality with insufficient 
sample sizes, short duration of follow up and selection bias given the retrospective 
single-center study design. In the light of recently updated evidence, we propose a 
surveillance strategy for IBD patients with a residual rectum.
Similar to surveillance strategies for IBD patients with an intact colon, we propose a 
strategy based on evidence-based risk stratification (Figure 1). Based on the impact of 
risk factors we categorized patients into a low, intermediate or high CRC risk category. 
Evidence regarding the optimal surveillance intervals for each category is lacking. As 
a consequence, intervals were adopted from BSG guidelines and from a previously 
published proposal for pouch surveillance [3, 14].
Risk stratification is mainly based on a previous history of CRC since this is the major 




as a remaining rectal stump [5, 7, 9]. In the absence of risk factors (Figure 1), including a 
previous history of CRC, we recommend to forgo endoscopic surveillance given the low 
rectal carcinoma incidence, especially in those without previous CRC [9]. By contrast, 
we propose yearly surveillance for patients with previous CRC as this raises rectal 
carcinoma risk significantly (hazard ratio between 3.7 and 12.8). Given the assumed 
inflammation – dysplasia – carcinoma pathway and the increased cumulative CRC 
incidence in IBD patients with previous colorectal dysplasia (25% after 10 years following 
IRA construction) we recommend surveillance in the subgroup with previous dysplasia 
as well, although less frequent (suggested interval of 2-3 years) [15]. Moreover, PSC was 
elucidated as risk factor to develop rectal carcinoma in IBD patients with IRA or rectal 
stump [7, 9, 13]. However, cumulative rectal carcinoma incidences were low in patients 
without previous CRC, regardless of the presence of PSC. This allows us to propose 
surveillance in patients with PSC with a suggested interval of 2-3 years (Figure 1). Finally, 
longer IBD durations were associated with higher CRC incidences. As a consequence 
we suggest surveillance intervals of 5 years in the low risk group with an IBD duration 
of more than 20 years.
Figure 1
Proposed post-colectomy surveillance strategy for IBD patients with an ileostomy and rectal 
stump, or ileorectal anastomosis.
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FUTURE PERSPECTIVES
A first step towards optimized post-colectomy surveillance in IBD is to widely adapt 
one uniform surveillance strategy enabling prospective and systematic evaluation. 
The yield and the number of interval carcinomas could be assessed, further refining 
post-colectomy surveillance.
Nevertheless, several questions remain currently unknown as for example the optimal 
endoscopy technique (chromo-endoscopy or white light) and biopsy protocol (random 
or targeted). Evidence regarding this topic is absent in IBD patients with a residual 
rectum. Furthermore, it could be questioned whether rectal carcinoma risk is reduced 
following multiple negative endoscopies and whether stop criteria are of additional 
value. Moreover, what is the appropriate management of low-grade dysplasia and high-
grade dysplasia in the residual rectum? And does the use of biomarkers, such as p53 
and K-ras mutations, predict rectal carcinoma development? Finally, the management 
of rectal stump stenosis, not allowing adequate endoscopic surveillance, remains 
challenging. Parallel to the adaptation of a widely accepted surveillance strategy more 
data regarding these topics for both IBD patients with and without colectomy are 
essential to further improve a post-colectomy surveillance strategy.
CLINICAL VIGNETTES CONTINUED
Case 1
Due to a history of CRC, this patient would be categorized into the high risk category, 
requiring yearly endoscopic surveillance of the rectum. In real-life, rectal endoscopy 
was performed in 2003, 2005, 2008, 2009, and since 2012 yearly. However, multiple 
endoscopies were performed for reasons of disease activity, not including surveillance 
biopsies. Moreover, surveillance gaps occurred between 2005 and 2008, and between 
2009 and 2012.
In 2013, at the age of 47, 10 years after his second CRC, surveillance endoscopy showed 
indefinite for dysplasia in the IRA. One year later, a new CRC (pT1 pN1) was diagnosed in 
the IRA during surveillance endoscopy, 14 centimeters from the anal verge. Proctectomy 
with IPAA construction was performed. Subsequently, the patient underwent yearly 





The absence of colorectal neoplasia and PSC categorizes this patient into the low risk 
group for CRC development of the rectal stump. According to our surveillance proposal, 
no surveillance endoscopic surveillance is recommended in the first 20 years following 
IBD diagnosis given the low cumulative CRC risk (2.2% at 20 years).
Based on the available medical history, this patient underwent in total three surveillance 
endoscopies of the rectal stump during 14 years of follow up. In 2008, 2014, and 2017 
mild inflammation with pseudopolyps were found. Biopsies were taken in all three 
surveillance endoscopies and none of them showed dysplasia. We recommend no 
additional surveillance endoscopies until 2019 given the absence of CRC risk factors 
and low cumulative CRC risk. From 2019 we recommend surveillance intervals of 5 years 
given the IBD duration of more than 20 years, according to our surveillance proposal.
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Although all major international inflammatory bowel disease (IBD) guidelines 
recommend surveillance colonoscopies to prevent advanced colorectal neoplasia 
(aCRN, including high-grade dysplasia and colorectal cancer) in patients with colonic 
IBD, the optimal surveillance strategy remains unclear.1-3 Given the large differences 
in the aCRN risk between subgroups of IBD patients, a one size fits all strategy seems 
not appropriate. Establishing an individual risk profile based on the IBD patients’ 
characteristics may aid in determining the most appropriate surveillance strategy. 
Although European guidelines already propose an individualized surveillance strategy 
based on several baseline- and disease characteristics, the evidence for these 
recommendations is still limited and conflicting.
The aim of this thesis was to study the aCRN risk in IBD patients stratified by risk profile 
and to translate our findings into evidence-based surveillance guidelines. Here, in the 
general discussion, I will discuss the results and implications of the separate studies. 
In addition, I will propose research questions that still need to be addressed in future 
studies. To guide this discussion, Table 1 provides an overview of the main findings, 
implications, and limitations of the individual studies.
PART I THE RISK OF ADVANCED NEOPLASIA AFTER LOW-
GRADE DYSPLASIA IN IBD
Current guidelines recommend annual surveillance colonoscopies for a period of five 
years after detection of low-grade dysplasia (LGD). However, the need for this aggressive 
surveillance strategy is uncertain since the aCRN rates after LGD varied widely between 
previous studies. The aims in part I of my thesis were: (1) to establish the cumulative 
incidence of aCRN after LGD in patients with IBD; (2) to identify factors associated 
with an increased aCRN risk following LGD; (3) to determine whether recurrent LGD 
impacts the aCRN risk; and (4) to assess the prognostic impact of a neoplasia-free 
period after LGD.
Findings
In chapter 2 we found in a large nationwide histopathology-based cohort including 
4284 IBD patients with LGD that the risk of aCRN after LGD is 17.4 per 1000 patient-
years. The cumulative incidence of aCRN after 1, 5-, 10-, and 15- year was 3.6%, 8.5%, 
14.4%, and 21.7%, respectively. This high risk is in line with a meta-analysis including 
671 ulcerative colitis (UC) patients that reported a pooled incidence rate of aCRN of 18 
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per 1000 patient-years.4 There were no differences between UC and Crohn’s disease 
(CD) in our cohort. Our findings showed that IBD patients in academic centers, who 
are more likely to have a more severe disease course with ongoing inflammation, are 
the patients with the highest aCRN risk. In addition, male gender and age > 55 years 
at moment of LGD detection were significant risk factors for aCRN development.
In chapter 3 we observed that the risk of aCRN was higher in IBD patients with 
recurrent/persistent LGD within 3 years after the index LGD. As a corollary, we 
observed that a longer neoplasia-free period after index LGD was a good predictor 
for a decreased subsequent aCRN risk. A neoplasia-free period of 3 years after index 
LGD was associated with a reduced aCRN risk. In addition, if patients with a neoplasia 
free period of 3 years had none of the previously reported risk factors (ie, male gender, 
age ≥55 years at moment of index LGD, and treatment in academic centers), the risk of 
aCRN was even further reduced.
Strengths and limitations
The strengths of these studies include the unique setting of a nationwide, population-
based cohort including a large number of patients with a relatively long follow-up period 
of mean 6.4 years. We confirmed that we were able to reliably identify IBD patients 
using this database (> 95% accuracy). As such, this cohort allowed us to establish point-
estimates of the aCRN incidence and to identify risk factors for aCRN development for 
the IBD population with LGD at large. Our data may be more representative than data 
from previous studies performed in tertiary referral centers. Moreover, we performed 
the first study that investigated the impact of a neoplasia-free period after LGD in IBD 
patients. However, there are some limitations inherent to the design of our studies. 
The setting of a histopathology-based cohort did not allow us to collect data on 
several important confounders, most notably the morphology of the lesion containing 
LGD (visible/not visible, size, flat/raised) and the treatment of the lesion (biopsy or 
polypectomy). In addition, histopathology results were not always re-assessed by a 
second pathologist in the past although this is currently recommended in clinical care. 
Inter-observer variability in grading dysplasia between pathologists is not uncommon 
and these limitations should be considered when interpreting our results.
Clinical implications
The high aCRN risk after LGD supports an intensified surveillance strategy after 




IBD patients with LGD varies. This implicates that some IBD patients with LGD need 
intensified surveillance (male, age > 55 years at moment of LGD, and patients in 
academic centers), while other patients without these factors may benefit from a less 
intensified strategy. However, clinical risk factors, such as the morphology of the lesion, 
completeness of resection, and primary sclerosing cholangitis should be considered as 
well when determining the appropriate surveillance interval in IBD patients with LGD.
The findings of chapter 3 suggest that the surveillance strategy in IBD patients with 
LGD also depends on the neoplasia-free time after LGD. There is no solid evidence for 
the current recommendation to perform annual surveillance for 5 consecutive years 
after detection of LGD. We propose that the surveillance interval may be extended to 
2-3 years if patients remain 3 years neoplasia-free after detection of LGD. This applies 
particularly for patients without the previously reported risk factors (male, age > 55 
years at moment of LGD, and patients in academic centers). However, studies with 
clinical data are needed to confirm our data and to identify IBD patients with LGD who 
need annual surveillance for longer than 3 years before extending the surveillance 
interval. The surveillance interval should not be extended in IBD patients who have 
recurrent/persistent LGD, since we observed that these patients have an even further 
elevated aCRN risk.
Future studies
Results of this thesis may be used as a starting point for future studies. We showed that 
the individual risk of aCRN in patients with LGD varies. Therefore, future studies should 
assess potential risk factors. Ideally, these studies would meet the following conditions: 
1) collection of all relevant clinical data in a large cohort, ideally in a prospective 
fashion. 2) have a substantial follow-up period of at least 5 years, 3) surveillance 
colonoscopies are systematically conducted with high-definition colonoscopy or 
chromoendoscopy, according to current guidelines, and 4) the morphology and 
treatment of polyps containing dysplasia is well-characterized and LGD diagnosis is 
re-assessed by a second pathologist. In addition, similar studies are needed to identify 
the IBD patients who still need annual surveillance even after a neoplasia-free period 
of 3 years after LGD. However, apart from identification of high-risk patients with 




In addition to studies that determine the impact of LGD, studies focusing on outcomes 
after detection of HGD in patients with IBD are needed as well. Currently, most patients 
with HGD receive a (sub)total colectomy. However, with the emergence of improved 
endoscopic techniques and new anti-inflammatory medication, a (sub)total colectomy 
may not always be appropriate or required any more. It can be speculated that, in case 
of a complete polypectomy, an intensive surveillance strategy may be sufficient in some 
patients with HGD. Another alternative treatment strategy may be a surgical resection 
of just the colonic segment that harbors the dysplastic lesion, especially in patients 
without extensive colitis. Currently, we are performing a retrospective multicenter 
study to assess the outcomes of different treatments in IBD patients with HGD. A 
future standardized algorithm for treatment of HGD combined with a multi-center 
prospective registry would provide valuable data to further optimize recommendations 
for surveillance and treatment.
PART II RISK FACTORS FOR ADVANCED NEOPLASIA IN IBD
Whilst dysplasia is the strongest predictor of aCRN development in IBD patients, 
several other factors that may augment this aCRN risk should be considered as well. 
One of these potential risk factors is the presence of post-inflammatory polyps (PIPs). 
In chapter 4 we used a retrospective cohort of 519 IBD patients undergoing CRC 
surveillance to demonstrate that there is no association between the presence of PIPs 
and development of (a)CRN. This is in line with results from another large retrospective 
study that reported that PIPs are associated with prior inflammation, but are no reliable 
predictor for aCRN.5 However, it should be noted that patients with large fields of PIPs 
(estimated >100) did have a higher risk of CRN in univariable analysis in our cohort. It can 
be hypothesized that these large fields of PIPs are a result of more severe inflammation 
and that it might be difficult to detect and remove true (pre)carcinogenic lesions that are 
present in these fields of PIPs. However, this association did not remain after correction 
for the cumulative inflammation score.
In chapter 5 the impact of serrated polyps was studied. Serrated polyps include 
hyperplastic polyps, sessile serrated lesions (with or without dysplasia), and traditional 
serrated adenomas (that always contain dysplasia). Serrated polyps develop through 
a different molecular pathway than adenomas but some are also associated with an 
increased risk of aCRN in the general population.6, 7 Nevertheless, current IBD guidelines 




adenomas but not for serrated polyps. We established a retrospective cohort of 650 
IBD patients undergoing surveillance and found that traditional serrated adenomas 
and sessile serrated lesions with dysplasia are associated with an increased risk of 
aCRN (hazard rate 13.5). In contrast, hyperplastic polyps and sessile serrated lesions 
without dysplasia did not impact this risk We did not observe an association between 
inflammation scores and presence of serrated polyps, nor was there a higher CRN risk 
in serrated polyps that developed within an inflamed colonic segment. This suggests 
that serrated polyps can develop in IBD patients regardless of inflammation. In line, 
a small study reported that molecular alterations of hyperplastic polyps are similar 
between UC and non-UC patients.8
In chapter 6 we provided a comprehensive overview of all available literature on 
potential risk factors for aCRN development in a systematic review and meta-analysis. 
We identified several risk factors for aCRN that are (surrogate) markers for inflammation, 
including histologic and endoscopic inflammation scores, extensive disease, strictures, 
PIPs, and the need for a colon segment resection. In addition, some premalignant 
lesions (LGD, any dysplasia, and aneuploidy) and several baseline characteristics (PSC, 
male sex, age, a family history of CRC, UC) are risk factors for the development of aCRN 
in IBD patients, with varying grades of evidence. Factors associated with a lower risk of 
aCRN included thiopurines, 5-ASA, surveillance colonoscopies, smoking, and younger 
IBD age. In chapter 7 we focused on IBD patients who received a subtotal colectomy. 
Here, we proposed a surveillance strategy in IBD patients with an ileal pouch-anal 
anastomosis. Based on the results of our literature search, we stratified these IBD 
patients in a high-risk category (patients with prior CRC), intermediate risk category 
(patients with prior dysplasia or with concomitant primary sclerosing cholangitis), and 
low risk category (patients without risk factors).
Strengths and limitations
The cohorts from chapters 4 and 5 in this thesis are representative for current clinical 
practice since we included IBD patients undergoing CRC surveillance in the current era, 
according to recent guidelines. The extensive data collection including the outcomes of 
surveillance colonoscopies was important to assess the impact of individual risk factors 
while correcting for several other known confounders like inflammation. Limitation 
of our cohorts included the single-center retrospective setting and the potential 
surveillance bias, since high-risk patients may have received surveillance colonoscopies 
more often throughout the follow-up period. This could have resulted in a lower aCRN 
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risk in high-risk patients because precancerous lesions may have been removed before 
progressing to aCRN. However, a randomized setting, with random selection of patients 
who receive surveillance, is not possible for ethical considerations.
Chapter 6 is the first systematic review and meta-analysis to provide a complete 
overview of all risk factors in IBD patients. The literature search with the broad 
search terms resulted in a complete overview of risk factors in all studies worldwide. 
Furthermore, by conducting this literature search, we identified several knowledge 
gaps that remain to be addressed in future studies. For example, data on the aCRN 
risk in IBD patients with strictures, aneuploidy, or indefinite for dysplasia is scarce. We 
additionally performed a best-evidence synthesis, including only high-quality studies. 
However, a limitation was the substantial heterogeneity between studies for some risk 
factors due to the different design and setting of studies. This limits the value of pooling 
the data for these factors.
Implications
Our findings in chapter 4 imply that the presence of PIPs alone does not warrant 
an intensified surveillance strategy. In contrast, the pooled results from the meta-
analysis (chapter 6) still identified PIPs as a risk factor. However, most studies that were 
included in this analysis did not correct their results for the (cumulative) inflammation 
scores. Studies that did correct for inflammation did not show a higher aCRN risk in 
patients with PIPs. Rather than using indirect markers for inflammation like PIPs to 
stratify patients in high-risk categories, a cumulative inflammation score could be a 
more reliable marker. Previous studies have proposed different equations to calculate 
this score using endoscopic and/or histologic inflammation scores at surveillance 
colonoscopies.9-11 The best method for clinical purposes has yet to be determined.
The findings of chapter 5 suggest that patients with serrated polyps that contain 
dysplasia may need an intensified surveillance strategy similar to that of IBD patients 
with regular LGD. The size of the serrated polyp may be a marker of its malignant 
potential, although this factor did not reach statistical significance in our cohort 






Ideally, studies should be conducted in a prospective, multicenter setting to limit 
biases and prevent missing data. However, given the large number of patients and 
resources needed for this design, well-conducted retrospective studies are of great 
value until prospective studies can provide long-term longitudinal data. Some large 
prospective cohorts are already in place, like the Dutch IBD registry IBDREAM, the 
Swiss IBD cohort, the IBD South-Limburg cohort, and a CRC surveillance cohort in Kings 
College. Uniform prospective data collection including data on baseline characteristics, 
disease characteristics, cumulative inflammation and anti-inflammatory treatment, and 
outcomes of surveillance colonoscopies would allow for multinational collaboration and 
benchmarking. Recent studies from a Dutch - American collaboration proved already 
that such pooling of data can provide valuable insights with direct clinical implications.12 
If more of such cohorts were to be combined, the large number of patients would 
allow for the development of a risk-stratification model to calculate a personalized risk 
score, like the models that already have been developed in cardiovascular diseases.13 
This risk score should be based not only on the presence of a single risk factor, but 
on the total score of all risk factors combined. The results of the meta-analysis in this 
thesis may guide the choice of factors that should be included in such models. Another 
future direction is the incorporation of the patients’ preferences in the decision of the 
surveillance interval. To this end, we are conducting a study to assess the patients’ 
viewpoint on the interval between surveillance colonoscopies.
SUMMARY
Figure 1 shows the current surveillance strategy in IBD patients in the Netherlands14 
including the suggested changes based on the findings of this thesis. It should be 
noted that the strength of evidence for our suggested changes varies and this figure 
serves the purpose of a starting point for discussion. Naturally, we acknowledge that 
































































































This thesis described the impact of several potential risk factors on the risk of aCRN in 
IBD patients. We found that LGD is associated with a high risk of aCRN. This implicates 
that an annual surveillance strategy is warranted in these patients. However, if patients 
remain neoplasia-free for 3 years after LGD the risk was substantially lower. Second, 
we found that PIPs are no independent risk factor for aCRN. In contrast, serrated 
polyps with dysplasia did increase the aCRN risk. Third, we performed a literature 
search to identify all risk factors for aCRN that have been described, allowing for a 
more comprehensive individual risk stratification. In future, this may substantiate 
the development of a cumulative risk score guiding endoscopic surveillance intervals. 
Finally, we proposed a surveillance strategy in patients with an ileal pouch-anal 
anastomosis, based on current literature.
Table 1. Summary of the individual studies in this thesis.
IBD= inflammatory bowel disease; aCRN = advanced colorectal neoplasia (high-grade 
dysplasia & colorectal cancer) ; LGD = low-grade dysplasia ; PIPs = post-inflammatory polyps ;
CRC = colorectal cancer
PART I THE RISK OF ADVANCED NEOPLASIA AFTER LOW-GRADE DYSPLASIA IN IBD
Chapter Aim(s) Main findings and conclusion Limitations and 
comments
2. • To determine the long-
term risk of aCRN after 
detection of LGD
• To establish risk 
factors for aCRN in 
patients with LGD
• The cumulative incidence of aCRN 
after 1, 5-, 10-, and 15- years was 
3.6%, 8.5%, 14.4%, and 21.7%, 
respectively
• LGD age >55 years, male
• sex and academic center are risk 
factors for aCRN





biases such as 
surveillance bias
• Lack of clinical data
3. • To determine the 
impact of recurrent 
LGD on the risk of aCRN
• To establish the 
prognostic impact of a 
neoplasia-free period 
after LGD
• To determine the 
duration of annual 
surveillance after LGD
• Recurrent LGD at follow-up 
colonoscopy after initial LGD was 
a risk factor for aCRN (hazard 
rate 1.66)
• A neoplasia-free period can be 
considered a fair predictor for risk 
of aCRN development (area under 
the receiver operater curve 0.76)
• A neoplasia-free period of 3 years 
after initial LGD was associated 





biases such as 
surveillance bias
• Lack of clinical data
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PART II RISK FACTORS FOR ADVANCED NEOPLASIA IN IBD
Chapter Aim(s) Main findings and conclusion Limitations and 
comments
4. • To determine if PIPs 
are a risk factor for the 
development of aCRN
• To determine the 
characteristics of IBD 
patients with PIPs
• To establish whether 
patients with PIPs 
receive a colectomy 
more often?
• There was no association 
between PIPs and the 
development of aCRN (p=0.68).
• PIPs were associated with more 
extensive disease and higher 
inflammation scores at follow-up 
colonoscopies.
• IBD patients with PIPs were more 
likely to undergo colectomy
• Retrospective 
cohort
• The exact number 
of PIPs was an 
estimation
5. • To study the impact of 
serrated polyps on the 
risk of aCRN
• Sessile serrated lesions with 
dysplasia and traditional serrated 
adenoma are a risk factor for 
aCRN
• Hyperplastic polyps and sessile 
serrated lesion without dysplasia 








6. • To identify all risk 
factors for aCRN in IBD 
patients from current 
literature
• Identified risk factors: Histologic 
and endoscopic inflammation 
score, extensive disease, 
strictures, PIPs, low-grade 
dysplasia, aneuploidy, primary 
sclerosing cholangitis, male sex, 
age, a family history of CRC, UC
• Protective factors: thiopurines, 
5-aminosalicylic acid, surveillance 
colonoscopies, smoking, younger 
IBD age
• High heterogeneity 
between studies 
for some risk 
factors
• Too many risk 
factors to provide 
subgroup analysis 
for all risk factors
7. • To propose a 
surveillance strategy 
for IBD patients with 
an ileal pouch-anal 
anastomosis?
• We propose the following 
surveillance interval based on 
available literature:
• No surveillance: no prior 
dysplasia or CRC
• 2-3 years: prior dysplasia
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Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the 
gastrointestinal tract that includes Crohn’s disease and ulcerative colitis. The disease 
follows a relapsing course, characterized by a variety of symptoms such as abdominal 
pain, (hemorrhagic) diarrhea, weight loss, and anemia. The goal of treatment is to 
limit colonic inflammation to improve symptoms and to prevent development of 
complications. One of the most detrimental complications is colorectal cancer.
Colorectal cancer develops through an inflammation – low-grade dysplasia  – high-grade 
dysplasia pathway to carcinoma. Patients undergo surveillance colonoscopies to identify 
and to remove precancerous lesions before advanced colorectal neoplasia (aCRN, 
including high-grade dysplasia and colorectal cancer) develops. Although different 
IBD guidelines state that a subgroup of IBD patients should undergo surveillance 
colonoscopies, the proposed surveillance strategy varies widely between guidelines. 
Some guidelines use a risk stratification model that stratifies IBD patients into a high- 
or low risk category based on the presence of potential risk factors. Based on the 
assigned risk category, the interval between consecutive surveillance colonoscopies is 
determined. However, there are several gaps in knowledge regarding the risk factors 
in these models. The aim of this thesis was to establish the impact of several potential 
risk factors on the risk of aCRN, and to translate these findings into recommendations 
for an improved surveillance strategy in IBD patients.
Part I of this thesis describes the prognostic impact of LGD, recurrence of LGD, and a 
neoplasia-free period after LGD in IBD patients. 
In chapter 2 the long-term risk of developing aCRN after LGD was studied. Therefore, 
we established a nationwide cohort using the Dutch national histo-and cytopathology 
database (PALGA). We identified all patients with a concomitant diagnosis of IBD and 
LGD, and found that the cumulative incidence of aCRN after 1, 5-, 10-, and 15- year after 
LGD was 3.6%, 8.5%, 14.4%, and 21.7%, respectively. We observed that male gender, 
academic center, and age > 55 years at moment of LGD detection were associated with 
the highest risk in this patient category. These findings support a surveillance strategy 
with annual surveillance colonoscopies after detection of LGD. 
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In chapter 3 we observed that the risk of aCRN was higher in IBD patients with 
recurrent/persistent LGD within 3 years after the first LGD (‘index LGD’). As a corollary, 
we observed that a longer neoplasia-free period after index LGD was a good predictor 
for a decreased subsequent aCRN risk. A neoplasia-free period of 3 years after index 
LGD was associated with a relatively low risk of aCRN. In addition, if patients with 
a neoplasia-free period of 3 years had none of the previously reported risk factors 
(ie, male gender, age ≥55 years at moment of index LGD, and treatment in academic 
center), the risk of aCRN was even further reduced. These findings suggest that the 
surveillance interval after LGD may be extended in some IBD patients if they remain 3 
years neoplasia-free. In contrast, the surveillance interval should not be extended in 
IBD patients who have recurrent/persistent LGD.
In Part II, several other potential risk factors for aCRN were studied. One of these 
potential factors is the presence of postinflammatory polyps. These polyps are non-
neoplastic lesions that look like polyps or loose mucosal tags. They are the remnants 
of severe inflammation and they are associated with longstanding IBD. In chapter 4 we 
demonstrated that the presence of postinflammatory polyps was not associated with 
the development of aCRN. However, whether this also applies for patients with large 
fields of postinflammatory polyps needs further studies. Based on previous literature, 
we propose that cumulative inflammation scores (thus, a score that represents the 
severity and the extent of colonic inflammation of the past years) are a more reliable 
marker to predict the individual patients’ risk rather than surrogate markers for 
inflammation like the presence of postinflammatory polyps.
In chapter 5 we investigated the risk of serrated polyps. Serrated polyps are distinct 
polyps that are characterized by their sawtooth appearance when examined by 
microscopy. While the increased risk of developing colorectal cancer after serrated polyps 
in the non-IBD population has been widely demonstrated, data in IBD patients remain 
scarce. Consequently, current IBD guidelines do not report on serrated polyps as a risk 
factor. We retrospectively analyzed a relatively large IBD cohort undergoing surveillance, 
and found that serrated polyps harboring dysplasia (ie, sessile serrated lesions with 
dysplasia and traditional serrated adenomas) were associated with an increased risk of 
aCRN. In contrast, this risk was not increased with serrated polyps without dysplasia (ie, 
hyperplastic polyps and sessile serrated lesions without dysplasia). 
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In chapter 6 we performed a systematic review and meta-analysis of all prognostic 
factors for aCRN development. We identified several risk factors with various grades of 
evidence, including extensive disease, LGD, strictures, primary sclerosing cholangitis, 
postinflammatory polyps, family history of CRC, ulcerative colitis, the need for 
receiving a colon segment resection, aneuploidy, male sex, and age. Protective factors 
included surveillance colonoscopies, medication use (5-ASA, thiopurines, statins), and 
smoking. The results of this large meta-analysis will be used to develop an individual 
risk stratification model. 
In chapter 7 we proposed a surveillance strategy in IBD patients who received a subtotal 
colectomy. Based on the results of our literature search, we stratified these IBD patients 
in a high risk category (patients with prior colorectal cancer), intermediate risk category 
(patients with prior dysplasia or with concomitant primary sclerosing cholangitis), and 
low risk category (patients without risk factors). 
In conclusion, this thesis focuses on the impact of several prognostic factors for aCRN 
in IBD patients. We demonstrated a relatively high long-term risk of aCRN after LGD 
and recurrent LGD. Additionally, we showed that the finding of serrated polyps with 
dysplasia is associated with a high subsequent aCRN risk and thus may warrant an 
intensified surveillance strategy. In contrast, we did not find evidence for the need 
of intensified surveillance after the finding of serrated polyps without dysplasia and 
postinflammatory polyps. The results of the literature studies in this thesis may be used 
to guide risk stratification in regular IBD patients, as well as IBD patients who received 
a subtotal colectomy. Future studies will hopefully provide additional evidence towards 




Inflammatoire darmziektes (IBD) zijn chronische inflammatoire aandoeningen van 
het maagdarmkanaal en omvatten de ziekte van Crohn en colitis ulcerosa. De ziektes 
hebben een recidiverend beloop en worden gekenmerkt door een verscheidenheid aan 
symptomen zoals buikpijn, (bloederige) diarree, gewichtsverlies en bloedarmoede. Het 
doel van de behandeling is om de ontsteking van de dikke darm te beperken zodat de 
symptomen verbeteren en zodat het ontstaan van complicaties wordt voorkomen. Een 
van de meest ernstige complicaties is het colorectaal carcinoom.
Een colorectaal carcinoom ontwikkelt zich via een darmontsteking – laaggradige dysplasie – 
hooggradige dysplasie uiteindelijk tot carcinoom. Patiënten met IBD ondergaan surveillance 
colonoscopieën om premaligne laesies te identificeren en te verwijderen voordat 
gevorderde colorectale dysplasie ontwikkelt (zogenaamde advanced colorectal neoplasia 
(aCRN) ). Advanced colorectal neoplasia omvat hooggradige dysplasie en colorectaal 
carcinoom. Hoewel de verschillende IBD richtlijnen aanbevelen dat een subgroep van IBD 
patiënten surveillance colonoscopieën moet ondergaan, bestaan er aanzienlijke verschillen 
in de voorgestelde surveillance strategie. Enkele richtlijnen gebruiken een risicostratificatie 
model waarbij het individuele risico wordt ingeschat op basis van de aanwezigheid van 
potentiële risicofactoren. Op basis van de bijbehorende risico categorie wordt het interval 
tussen surveillance colonoscopieën voor de patiënt bepaalt. Er bestaan echter hiaten in 
de kennis over de risicofactoren die gebruikt worden in deze modellen. Het doel van deze 
thesis is om van verschillende potentiële risicofactoren vast te stellen wat de impact is op 
het risico op de ontwikkeling van aCRN. Vervolgens willen we deze bevindingen gebruiken 
om suggesties te doen voor een verbeterde surveillance strategie bij IBD patiënten.
Deel I van dit proefschrift beschrijft de prognostische impact van laaggradige dysplasie 
(LGD), recidiverende LGD en een periode zonder recidief na LGD bij patiënten met IBD.
In hoofdstuk 2 wordt het lange termijn risico op het ontwikkelen van aCRN na LGD 
bestudeerd. Hiervoor werd een landelijk cohort opgezet met behulp van de Nederlandse 
nationale histo- en cytopathologische database (PALGA). We identificeerden alle 
patiënten met een gelijktijdige diagnose van IBD en LGD en vonden dat de cumulatieve 
incidentie van aCRN na 1, 5, 10 en 15 jaar na LGD respectievelijk 3,6%, 8,5%, 14,4% en 
21,7% was. We stelden vast dat mannelijk geslacht, academisch centrum en leeftijd> 55 
jaar op het moment van detectie van LGD geassocieerd waren met het hoogste risico 
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in deze patiëntencategorie. Deze bevindingen ondersteunen een surveillancestrategie 
met jaarlijkse surveillance colonoscopieën na detectie van LGD.
In hoofdstuk 3 beschrijven we dat het risico op aCRN hoger is bij patiënten met IBD en 
recidiverende / persisterende LGD binnen 3 jaar na het moment van de eerste LGD (‘index 
LGD’). Een langere periode zonder nieuwe dysplasie (na index LGD) is een betrouwbare 
voorspeller voor een verminderd toekomstig risico op aCRN. Een dysplasie-vrije periode 
van 3 jaar na index LGD was geassocieerd met een relatief laag risico om alsnog aCRN 
te ontwikkelen. Bovendien, als patiënten met een dysplasie-vrije periode van 3 jaar 
geen van de eerder gerapporteerde risicofactoren hadden (dat wil zeggen: mannelijk 
geslacht, leeftijd ≥55 jaar op het moment van index LGD en behandeling in academisch 
centrum), bleek het risico op aCRN nog evident lager. Deze bevindingen suggereren 
dat het surveillance interval na index LGD bij sommige patiënten met IBD kan worden 
verlengd wanneer ze 3 jaar dysplasie-vrij blijven na index LGD. Dit geldt echter niet voor 
het surveillance interval van patiënten met een IBD en een recidief LGD.
In deel II van deze thesis worden de verschillende andere potentiële risicofactoren 
voor aCRN bestudeerd. Een van deze mogelijke risicofactoren is de aanwezigheid van 
postinflammatoire poliepen. Dit zijn onschuldige laesies die er uitzien als poliepen. 
Ze zijn de restanten van ernstige ontstekingen en worden in verband gebracht met 
langdurige IBD.  In hoofdstuk 4 toonden we dat de aanwezigheid van postinflammatoire 
poliepen niet geassocieerd was met de ontwikkeling van aCRN, hoewel dit wel in huidige 
richtlijnen wel als dusdanig wordt beschreven. Of dit ook geldt voor patiënten die grote 
velden met postinflammatoire poliepen hebben, behoeft echter nog nader onderzoek. 
Op basis van eerdere literatuur menen we dat een cumulatieve ontstekingscore 
een betrouwbaardere en meer directe marker is om het risico van individuele 
patiënten te voorspellen in vergelijking met surrogaatmarkers voor ontsteking zoals 
postinflammatoire poliepen. Deze cumulatieve inflammatie score kan worden berekend 
uit de ernst en uitbreiding van inflammatie van de darm van de afgelopen jaren.
In hoofdstuk 5 onderzochten we het risico op aCRN na de detectie van zogenaamde 
‘serrated poliepen’. Serrated poliepen zijn poliepen die worden gekenmerkt door hun 
zaagtand uiterlijk wanneer bekeken onder de microscoop. Hoewel het verhoogde risico 
op het ontwikkelen van colorectaal carcinoom na serrated poliepen in de normale ‘niet-
IBD’ populatie reeds meermaals is aangetoond, zijn de gegevens bij patiënten met IBD 
nog schaars. Om die reden benoemen de huidige IBD-richtlijnen het risico op aCRN en 
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het surveillance interval na serrated poliepen niet. We analyseerden een relatief groot 
retrospectief cohort van patiënten met IBD die surveillance hebben ondergaan. Daarbij 
ontdekten we dat serrated poliepen die dysplasie bevatten (sessiel serrated laesies met 
dysplasie en traditioneel serrated adenomen) geassocieerd waren met een verhoogd 
risico op aCRN. Dit risico was echter niet verhoogd bij serrated poliepen zonder dysplasie 
(dus hyperplastische poliepen en sessiel serrated laesies zonder dysplasie).
In hoofdstuk 6 hebben we een systematische review en meta-analyse uitgevoerd naar alle 
prognostische factoren voor het ontwikkelen van aCRN. We identificeerden verschillende 
risicofactoren met verschillende gradaties van bewijs waaronder het hebben van 
uitgebreide ziekte, LGD, stricturen, primaire scleroserende cholangitis, postinflammatoire 
poliepen, familieleden met CRC, colitis ulcerosa, het moeten ondergaan van een resectie 
van het colon, aneuploïdie, mannelijk geslacht en oudere leeftijd. Beschermende factoren 
waren onder meer het ondergaan van surveillance colonoscopieën, medicatiegebruik (5-
ASA, thiopurines, statines) en roken. De resultaten van deze grote meta-analyse zullen 
worden gebruikt om een individueel risicostratificatie model te ontwikkelen.
In hoofdstuk 7 stellen we een surveillance strategie voor bij patiënten met IBD die 
een subtotale colectomie hebben ondergaan. Op basis van de resultaten van ons 
literatuuronderzoek stratificeerden we deze IBD patiënten in een categorie met een 
hoog risico (patiënten met eerder een colorectaal carcinoom), een categorie met 
gemiddeld risico (patiënten met eerdere dysplasie of met primaire scleroserende 
cholangitis) en een categorie met een laag risico (patiënten zonder risicofactoren).
Concluderend focuste deze thesis zich op de impact van verschillende prognostische 
factoren op de ontwikkeling van aCRN bij patiënten met IBD. We toonden aan dat het  lange 
termijn risico op aCRN na LGD relatief hoog was, en nog hoger in geval van recidiverende 
LGD. Ook beschreven we dat de detectie van serrated poliepen met dysplasie geassocieerd 
was met een hoog daaropvolgend risico op aCRN en dat daarom een intensieve surveillance 
strategie gerechtvaardigd lijkt. Daarentegen vonden we geen bewijs voor de noodzaak van 
intensievere surveillance bij serrated poliepen zonder dysplasie en bij postinflammatoire 
poliepen. De resultaten van de literatuurstudies uit deze thesis kunnen worden gebruikt 
als leidraad voor risicostratificatie bij zowel de reguliere patiënt met IBD als bij patiënten 
met IBD die een subtotale colectomie hebben ondergaan. Toekomstige studies zullen 
hopelijk aanvullende inzichten geven, hetgeen zal kunnen leiden tot verdere optimalisatie 




Een van de dingen wat een promotietraject zo leuk maakt, is de kans om met zo veel 
verschillende mensen samen te mogen werken. Nu dit proefschrift is afgerond, grijp 
ik hierbij de kans om mijn dank uit te drukken voor alle fantastische mensen die een 
belangrijke bijdrage hebben geleverd.
Dr. F. Hoentjen, beste Frank, bedankt voor de goede begeleiding die je me hebt gegeven 
tijdens het promotietraject. Dankzij jouw begeleiding werd ik gestimuleerd om kritisch maar 
ook pragmatisch te zijn in het onderzoek. Door de terugkomende vraag wat mijn suggestie 
zou zijn, heb ik de onderzoeken steeds zelfstandiger kunnen verrichten. Je wist altijd tijd vrij 
te maken om mee te denken over de oplossing van grote vraagstukken. En niet onbelangrijk, 
naast de serieuze zaken zorgde je ervoor dat de afgelopen jaren onvergetelijk waren 
door de goede sfeer in het team, mede dankzij de terugkerende IB-Dinervergaderingen, 
gezamenlijke brainstormsessies (al dan niet in café Jos) en barbecues in de achtertuin.
Prof. Dr. J.P.H. Drenth, beste Joost, het begon allemaal met een onderzoeksstage naar 
polycysteuze leverziektes. Daarna kreeg ik van jou de kans om verder onderzoek te doen als 
promovendus naar dit andere mooie onderwerp, en met trots toon ik hier het eindresultaat! 
Je kent het onderzoeksveld als geen ander en deelde je expertise graag met mij en de 
andere arts-onderzoekers. Met jouw goede suggesties en scherpe opmerkingen wist je de 
manuscripten steeds naar een hoger niveau te tillen. De ruimte voor persoonlijke ontwikkeling 
die werd geboden, heeft de promotietijd tot een enorm leerzame periode gemaakt. 
Dr. L.A.A.P. Derikx, beste Lauranne, jouw enthousiasme voor alle nieuwe onderzoek 
ideeën werkte altijd weer enorm aanstekelijk. We hebben veel bijeenkomsten gehad 
om de onderzoeksresultaten te bespreken, en samen de oplossing voor elk probleem 
te weten vinden. De wijze waarop jij altijd weer 5 zinnen wist te verkorten tot één enkele 
zin verbaast mij nog steeds. Ik heb veel van je geleerd en waardeer jouw betrokkenheid 
en waardevolle input die je hebt geleverd. 
Leden van de manuscriptcommissie, Prof. Dr. Van Laarhoven, Prof. Dr. Dekker en Prof. Dr. Ver- 
heul, hartelijk bedankt voor de genomen tijd voor het beoordelen van mijn proefschrift. 
Dr. W. Kievit, als ik door alle poliepen het bos niet meer kon zien, wist jij me te vertellen 
hoe ik de statistische analyse het beste kon aanpakken. Dat je daarna het vertrouwen 
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dat ik in je had misbruikte door me op de skireis wijs te maken dat je ooit het Nederlands 
kampioenschap ‘hakken’ had gewonnen, zal ik je daarom graag vergeven.
Alle medewerkers van PALGA, hartelijk bedankt voor de fijne samenwerking en de 
spoedige levering van alle pathologie data. Deze gegevens vormden de basis voor 
hoofdstukken 2 en 3 uit dit proefschrift.
Prof. Dr. Nagtegaal, dr. Vos en dr. Post, jullie wisten in jullie drukke rooster steeds ruimte 
vrij te maken voor brainstormsessies over een nieuwe studie en om daarnaast uren 
aan (soms verstofte) pathologiecoupes te reviseren. Beyhan, bedankt voor de hulp bij 
het uitzoeken van al deze coupes.
Alle medewerkers van het Jeroen Bosch ziekenhuis en het Rijnstate waren enorm 
behulpzaam bij het verzamelen van de benodigde data. Speciale dank aan Carmen 
Horjus en Tessa Römkens voor hun bijdrages aan het verzamelen en leveren van data.
Harma, bedankt voor de mooie omslag van het proefschrift!
Alle arts-onderzoekers, jullie hebben de promotiejaren tot een onvergetelijke tijd gemaakt. 
Het hoogtepunt van de dag was altijd de lunchtijd, waar we onze vaste plek bij de rode 
bankjes mochten betreden. Ik zie het als een voorrecht dat ik de promotietijd met zo’n 
grote en gezellige groep heb kunnen doorlopen. Iedereen staat altijd klaar om elkaar te 
helpen, wat het leven van een promovendus een stuk makkelijker maakt. Daarvoor hartelijk 
bedankt Marleen, Ayla, Christa, Edo, Elsa, Fenna, Kelly, Lisa, Lucas, Maarten, Menso, Nathan, 
Pepijn, Thijs, Veerle, Yonne, Ali, Lia, Bram, Vince, Isabelle, René, Simon, Angelique, Dorian, 
Judith, Liyanne, Michelle, Vera, Xavier, Yannick, Karina en alle nieuwe onderzoekers!
Lisa, Vince, Maarten, Edo, Pepijn, Nathan, Fenna, wat een mooie tijd was het met jullie in 
het exponentieel groeiende IBD-team. Ik heb veel geleerd en genoten van de gezamenlijke 
overleggen en congressen. Hopelijk blijft het humorniveau op hetzelfde (bedenkelijke) peil 
door de alom gedeelde voorliefde voor slechte woordgrappen. Simon, Lucas, en Elsa, gelukkig 
zijn we blijven doorgaan met onze periodieke borrels en leipe lijstjes. Hopelijk kunnen we 
elkaar volgende jaren weer treffen bij Down The Rabbit Hole en bij de andere gezamenlijke 
festiviteiten. Marleen, zelden heb ik met zo’n fanatiekeling gekeken naar voetbal- 
wedstrijden (al was jij dan voor de verkeerde club). Het waren verder mooie tijden in de 
kamer met de spannende verhalen van Kelly, de zelfde voorkeur voor sterke koffie (zonder 
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extra water!) als Ali, de after-aesculaaf pizzasessies met Ayla en natuurlijk de gezelligheid 
van Judith, Christa en Dorian. Als student kon ik al lachen om de humor van René en heb 
daar vervolgens als collega nog iets langer om kunnen lachen. Yonne, je hebt dan wel de 
neiging om zo nu en dan disproportioneel grote hoeveelheden water naar anderen te 
gooien, het was altijd gezellig tijdens de vrijdagmiddag festiviteiten. Pepijn en Maarten, 
betere (en gezelligere) opvolgers kan ik me niet bedenken! Vince, het waren mooie tijden bij 
alle congressen, als ik je tenminste niet kwijt was omdat je uren gefascineerd naar dezelfde 
mierenburcht aan het kijken was. Isabelle, leuk om jou nu weer als collega tegen te komen 
in het Rijnstate! Ook waren de adviezen van Sonja, Chantal, Cynthia en Marlon van grote 
waarde om mij op gang te helpen tijdens het begin van mijn promotietraject.
IBDREAM-team; Maurice Russel, Tessa Römkens, Rachel West, Frank Hoentjen, Jeroen 
Jansen en alle betrokken verpleegkundigen; het was een fantastische uitdaging om 
samen het patiënten register IBDREAM op te zetten. Het is een mooi project dat van 
grote toegevoegde waarde is voor de patiëntenzorg en voor de wetenschap. Hopelijk 
zet de groei van dit project door en zal het tot nog vele mooie publicaties leiden!
Anouk, wat een gigantische klus hebben we verricht en wat een mooi resultaat. Ik kijk 
uit naar het moment dat we dit kunnen gaan vieren! Bas Oldenburg en Joren, mede 
door de gedeelde interesse in het onderwerp van dit proefschrift was het erg leuk om 
samen aan projecten te werken.
Met veel plezier heb ik enkele studenten mogen begeleiden bij hun onderzoeksstage. 
Jullie hebben ontzettend hard gewerkt en zijn van grote hulp geweest bij enkele 
projecten. Daarvoor veel dank Britt, Rowi, Heleen en Veerle!
Mijn dank gaat ook uit naar alle stafleden en arts-assistenten voor de leerzame lessen 
tijdens alle onderwijs- en overdracht momenten.
Nieuwe collega’s in het Rijnstate, dankzij de goede sfeer op de afdeling MDL ga 
ik nu elke dag met veel plezier naar Arnhem. De collegialiteit en aandacht voor 
onderwijs maken dat het werk als arts nog leuker is dan dat ik had durven hopen. 
Naast alle serieuze zaken was er natuurlijk ook voldoende tijd voor ontspanning. Alle leuke 
uitstapjes met als hoogtepunt de wintersport en het jaarlijkse kerstdiner in maart blijven 
een genot Tijko, Jan, Manon, Marit, Diederik, Sabrina, Carine en Eefke! Wouter, ik hoop nog 
165
Dankwoord
vaak terug te keren naar Eindhoven voor ouderwetse Brabantse gezelligheid. Lennart, 
hoewel een nieuwe 3-maandelijkse trip naar de andere kant van de wereld er wellicht 
voorlopig niet meer in zit, blijft dit plan toch nog zeker hoog op de bucket list staan.
Tim en Tom, bedankt dat jullie de belangrijke taak als  ‘paranimf’ op jullie willen nemen. 
Hoewel ik vrees dat jullie vragen over de tractus digestivus tijdens de plechtigheid 
niet geheel correct kunnen beantwoorden, ken ik jullie lang genoeg om te weten dat 
er ongetwijfeld een bijdehand antwoord zal volgen waarmee de corona ook tevreden 
gestemd zal worden. Alle zin en onzin die wij afgelopen jaren beleefd hebben, is eigenlijk 
een aaneenschakeling van hoogtepunten (behalve misschien de vakantie in Rusland 
dan, Tom). Hopelijk zullen wij elkaar tot in de verre toekomst blijven lastigvallen met 
slappe woordgrappen en andere onzin.
Ook iedereen van “In principe” (oud) Heren 1/2/6, het blijft een heerlijk tijdverdrijf 
om met jullie elke zondag op het hockeyveld te staan. Hoewel in de loop der jaren 
het beste gedeelte van de wedstrijd steeds iets meer van de 1e naar de 3e helft is 
verschoven, geniet ik er nog steeds evenveel van als in de tijd dat wij nog als zogenaamde 
‘Godenzonen’ het veld betraden.
Pap en mam, het is voor jullie niet meer dan vanzelfsprekend om op elk moment van 
dag voor mij klaar te staan. Weet dat dit ontzettend gewaardeerd wordt. Ik ben jullie 
dankbaar voor alle support en blij dat ik de totstandkoming van dit boekwerk met 
jullie kan gaan vieren! Nienke, een betere zus kon ik me niet wensen. We hebben het 
geluk gehad een paar jaar in dezelfde stad te studeren waardoor we elkaar regelmatig 
konden bezoeken. Ik bewonder je om je sterke wil om te gaan voor wat jij wilt, om 
hier dan vervolgens ook altijd in te slagen. Alle familieleden, leuk dat jullie altijd 
zo geïnteresseerd waren.
En tot slot, lieve Jadeena, jij zorgde altijd weer voor de welkome afleiding als ik weer 
eens in de avond uren achter mijn laptop door moest werken. Er is niets leukers om 
vervolgens de overgebleven vrije tijd samen met jou door te mogen brengen. Je denkt 
mee over oplossingen, spoort me aan als het nodig is, je lacht om mijn grapjes (goede 
eigenschap!), en ik lach nog harder om die van jou. Ik ben dan ook blij dat je jouw 
reuze appartement in de lichtstad hebt verlaten om samen met mij onze huidige 55 
m2 in Nijmegen te betrekken. Er ligt ons nog heel wat moois in het verschiet, en dit 
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